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7CHAPTER 1
GENERAL INTRODUCTION 
AND OUTLINE OF THE THESIS
8GENERAL INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most common cardiomyopathy 
with a prevalence of 1:500 in the general population.1, 2 Donald Teare was the 
first to describe this disease in 1958, and ever since, this disease has intrigued 
clinicians and investigators.3 
HCM is defined by left ventricular (LV) hypertrophy that cannot solely 
be explained by abnormal loading conditions, such as hypertension or an 
aortic stenosis.1, 2 HCM is caused by a mutation in genes encoding for sarco-
mere proteins with detrimental effects on sarcomere function. Currently, the 
link between sarcomere dysfunction and the development of the hypertro-
phic phenotype remains largely unknown. Clinically, HCM is characterized by a 
very heterogeneous disease presentation, even within families with the same 
genetic background. Patients with HCM may remain asymptomatic throughout 
their lives, but HCM is also the most common cause of sudden cardiac death 
(SCD) among young athletes and may lead to overt heart failure.4
The variety in clinical expression and prognosis has made HCM a complex 
cardiac disease causing dilemma and controversy among clinicians with regard 
to diagnostic criteria and management.1, 2 Despite known risk factors discrimi-
nation between low and high risk patients with HCM remains inadequate, which 
is probably due to an incomplete understanding of the pathophysiology of the 
disease. It is generally considered that an imbalance between an increased 
myocardial oxygen demand due to hypertrophy and a reduced myocardial 
oxygen supply due to microvascular disease results in ischemia and myocyte 
injury, which ultimately determines the clinical presentation of HCM. 
Appreciating the pivotal role of ischemia in HCM,5-9 it is surprising that the role 
of cardiac troponin in patients with HCM has not been extensively studied.10-15 
Whereas in the general population large studies have been performed on the 
prevalence and determinants of (elevated) troponin concentrations, data in 
HCM remain scarce.16-18 In light of the above, to increase insight in myocyte 
injury in HCM and how markers of myocyte injury may impact clinical manage-
ment, we designed a study integrating the use of cardiac troponin, exercise 
stress testing and cardiovascular magnetic resonance (CMR) imaging: the BE 
STRONG HCM study (Biomarkers, Exercise Stress Testing, and MRI to Obtain 
New insiGhts in Hypertrophic CardioMyopathy). This study sought to assess 
the prevalence of both detectable and elevated troponin concentrations in 
relation to demographic and clinical variables and phenotypic characteristics 
on CMR imaging. In addition, troponin concentrations were studied in relation 
to a short bout of exercise in HCM. In this thesis the results of the BE STRONG 
HCM study will be reported. As a further introduction, the definition of HCM 
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will be described to appreciate our study population. In addition, a concise 
overview will be presented of the current literature on the HCM geno- and 
phenotype. Furthermore, the current role of troponin and CMR imaging in HCM 
will be discussed. Lastly, the study procedures of the BE STRONG HCM study 
and outline of this thesis will be presented.
THE DEFINITION OF HYPERTROPHIC CARDIOMYOPATHY
Since its first description, it has been challenging for the scientific and clin-
ical community to define HCM.19, 20 Even today, the definition of HCM differs 
between the European and Northern American guidelines. It is, however, 
generally agreed that HCM is characterised by LV hypertrophy (LVH) in the 
absence of increased loading conditions. The definition of LVH in the setting 
of HCM is met in case of a myocardial wall thickness of ≥15mm, assessed with 
echocardiography, CMR imaging or CT. In case of an identified HCM related 
genetic mutation or a HCM family history a myocardial wall thickness of ≥13mm 
is sufficient for the diagnosis of HCM.1, 2
Among patients with LVH in the absence of increased loading conditions a 
distinction can be made between 3 types of individuals:  1) Patients with LVH in 
whom a mutation in a gene encoding for a sarcomere protein is identified; and 
2) Patients with LVH due to other more rare causes of LVH, such as amyloidosis, 
Anderson-Fabry and Friedreich’s ataxia; and 3) Patients with LVH in whom 
no extracardiac, metabolic or genetic findings are identified. According to 
the European guidelines, these patients are, respectively referred to as sarco-
meric HCM, non-sarcomeric HCM and HCM patients with an unknown cause of 
disease. Alternatively, the Northern American guidelines do not consider the 
second group as HCM patients, but as patients with LVH secondary to another 
(systemic) disease. The present thesis addresses a HCM population comprising 
patients from group 1 and 3. 
Lastly, a distinction must be made between clinical HCM patients on the 
one hand and subclinical HCM mutation carriers on the other. The former are 
patients with LVH, i.e. with the hypertrophic phenotype. The latter are individ-
uals with an identified genetic mutation without the hypertrophic phenotype.
10
GENOTYPE AND SARCOMERE DYSFUNCTION
HCM is the most common genetic cardiac disorder and the disease is inherited 
as a Mendelian autosomal dominant trait.21 More than a 1000 different muta-
tions in over 10 different genes encoding for cardiac sarcomeric proteins have 
been described in HCM. The β-myosin-heavy-chain and myosin-binding-pro-
tein-C genes are the most common locations for these mutations. In about 
50% of all HCM patients worldwide and in 65% of HCM patients in The Nether-
lands a mutation can be found in those 2 genes.22, 23 Specifically in The Nether-
lands, three founder mutations account for 35% of HCM cases.24
Although much remains to be investigated, it is generally perceived that 
gene mutations detrimentally affect sarcomere function (Figure 1).25-28 Various 
studies have been performed on the function of the contractile apparatus of 
diseased cardiomyocytes surgically obtained from HCM patients with a severe 
phenotype. In these samples, reduced length-dependent sarcomere activation, 
responsible for the Frank-Starling effect, has been demonstrated.29 In addi-
tion, reduced force generating capacity and a rise in energetic cost of tension 
generation in HCM patients have been observed.26, 27, 30, 31 Although some of 
these observations may be gene-specific, these experiments also demon-
strated that increased calcium sensitivity is a common characteristic of HCM.25, 
28, 32-34 Whereas for some mutations increased calcium sensitivity seems to be 
a secondary phenomenon due to sarcomere dysfunction, for others a direct 
effect on calcium sensitivity has been suggested.25, 34 Regardless of its cause, 
it has been postulated that an increased calcium sensitivity may contribute to 
diastolic dysfunction and energy deficits of the cardiomyocyte.28, 32-39 
Importantly, this intrinsic cellular failure may already be present prior to the 
development of the hypertrophic phenotype. Especially in case of increased 
myocardial stretch and workload, such as during exercise, sarcomere dysfunc-
tion may lead to oxidative stress of the cardiomyocyte. It has been hypothe-
sized that this may trigger signalling pathways (via currently unknown medi-
ators) for the development of interstitial fibrosis. In that regard, a profibrotic 
state has been suggested in subclinical mutation carriers using serum markers 
of collagen turnover and sophisticated CMR imaging techniques.40, 41 Moreover, 
myocyte stress due to sarcomere dysfunction may be the trigger for the devel-
opment of the hypertrophic phenotype with concurring microvascular disease 
and myocyte disarray, which may contribute to more myocyte injury, ultimately 
in the form of fibrosis.28, 32-34, 40, 42-45 Hypothetically, the release of troponin may 
be an early marker of disease in subclinical HCM mutation carriers and a marker 
of disease progression in clinical HCM patients. In light of this, we sought to 
investigate the well-known marker of myocardial injury cardiac troponin in 
11
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subclinical HCM mutation carriers and clinical HCM patients both at rest and 
after exercise (Chapters 3, 4 and 5). 
PHENOTYPE AND CLINICAL PRESENTATION
The HCM phenotype is characterised by asymmetrical LVH, which can typi-
cally be observed in about 70% of HCM patients at the interventricular septum 
and anterior wall.46-49 Specific but not obligatory findings in HCM patients are 
dynamic left ventricular outflow tract obstruction and systolic anterior motion 
of the mitral valve.50, 51 Histological features of HCM found at autopsy include 
myocyte hypertrophy and disarray, small vessel disease, interstitial fibrosis and 
myocardial scarring.9, 42, 43, 52-57 Interestingly, in areas of fibrosis viable cardio-
myocytes may be present.58 Importantly, the cardiomyopathic process is not 
confined to areas with gross wall thickening, but also occurs in non-hypertro-
phied regions.59, 60 Imaging studies using thallium perfusion, positron emission 
tomography and CMR imaging have repeatedly shown myocardial perfusion 
abnormalities in HCM patients.7, 61-67 
The combination of hypertrophy, microvascular disease and intrinsic cellular 
failure is likely to promote mismatch between myocardial oxygen demand 
and supply, leading to ischemic injury. Ischemia may, on the one hand, lead to 
myocardial cell death resulting in replacement fibrosis, i.e. myocardial scar, and 
FIGURE 1. Hypertrophic cardiomyopathy from genotype to 
 clinical presentation
Mutation Sarcomere
 dysfunction
Force generation ↓
Frank-Starling ↓
Calcium sensitivity ↑
Tension cost ↑
Energy 
depletion
Hypertrophy
Small vessel disease
Myocardial disarray
Ischemia
Myocyte injury
Fibrosis
Arrhythmias
Heart failure
Risk 
stratification
Troponin
CMR imaging
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on the other hand, may lead to the activation of collagen synthesis resulting 
in diffuse myocardial fibrosis.5, 43, 54, 57, 66, 68-70 Eventually, these processes may 
lead to the clinical presentation of HCM, characterised by heart failure and 
(life-threatening) arrhythmias.5-9, 50
Concerning the clinical presentation of HCM, variation in natural history and 
prognosis of patients with HCM is substantial. In previous studies with patients 
from tertiary referral centres, an annual mortality rate of 6% was found in chil-
dren and adolescents, and 2-4% in adult patients.71, 72 However, selection bias 
overestimated the risk of HCM.73 Reports in the 1990s from more representative 
less selected patient cohorts, adjusted expected HCM mortality rates to about 
1.5%/year.74 However, by utilizing contemporary and aggressive treatment inter-
ventions (particularly the ICD and heart transplantation), it has been reported 
that mortality in adult patients has further decreased to about 0.5% per year.75
Globally, three distinctive patterns of clinical course can be differentiated. 
First, a group of HCM patients exists with a relative mild and benign course. 
A second group consists of HCM patients who develop atrial fibrillation and 
congestive heart failure which progresses towards end-stage heart failure and 
finally results in death. The most devastating presentation in HCM, seen in a 
third group, is SCD in relatively young patients with or without prior symptoms 
due to malignant ventricular tachyarrhythmias.76, 77
An important but complex issue has been identification of patients with 
HCM at high risk of SCD. There is general consensus that implantable cardio-
verter defibrillator (ICD) implantation is indicated after a prior cardiac arrest, 
but the indication for an ICD implantation in the setting of primary prevention is 
(a lot) less clear.1, 2 Currently, large differences exist between the European and 
Northern American guidelines on SCD risk stratification. In the Northern Amer-
ican guidelines a strategy is advised, that is based on five conventional clinical 
variables, associated with SCD: family history of premature HCM related death, 
syncope, non-sustained ventricular tachycardia on ambulatory (holter) ECG 
recordings, abnormal blood pressure response to exercise, and extreme LVH 
(>30mm).2, 72, 76-80 However, the positive predictive value of each of these vari-
ables is quite low.50, 81 Moreover, even among patients with no conventional risk 
factors SCD still occurs.82 The European guidelines have put forward the HCM 
Risk-SCD score as an alternative preferential approach.1, 83 This score integrates 
7 different variables and produces an estimated 5-year SCD risk. In case the 
risk exceeds 6%, an ICD implantation should be considered according to the 
guidelines.1 For European HCM patients this risk score has been externally vali-
dated, whereas for Northern American patients its validation has been ques-
tioned.84, 85 Consequently, there remains a clinical imperative for improvement 
of SCD risk stratification in HCM.
13
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Assessment of myocyte injury using serum biomarkers, such as troponin, 
and CMR imaging may play an important role for identification of those who 
are likely to have progressive disease and are at risk of SCD. Therefore, this 
thesis aims to provide additional insight into the prevalence and determi-
nants of myocyte injury in HCM, as assessed with troponin and CMR imaging 
(Chapters 3, 4 and 5). Moreover, the potential of these markers as risk strati-
fiers for patient management will be discussed in Chapters 6 and 7.
CURRENT DATA ON CARDIAC TROPONIN IN HCM
In general, troponin is a very sensitive and specific marker for myocardial injury. 
In addition, elevated serum troponin levels indicate increased risk of adverse 
outcome in many different clinical situations, for example in patients with acute 
chest pain and myocardial infarction.86-88 Appreciating that ischemia has long 
been incriminated in HCM as a pivotal determinant of the disease course of 
HCM patients, cardiac troponin deserves further investigation in HCM.89
In this thesis, the biomarker of primary concern is cardiac troponin T assessed 
with a highly sensitive assay (hs-cTnT). This assay was clinically introduced in 
2009 and is now integrated in daily clinical practice of many non-US hospitals.90 
Importantly at the time of study design, data on troponin in HCM were limited 
to only two reports comprising in total 37 HCM patients, with troponin concen-
trations assessed with “non-high-sensitivity” assays.10, 11 With the introduction of 
the hs-cTnT assay, we now have the possibility to assess hs-cTnT concentrations 
between the limit of blank at 3ng/l and the 99th percentile at 14ng/l.
Based on the few reports available now in HCM, the prevalence of an elevated 
hs-cTnT concentration (≥14ng/l) at rest in HCM can be estimated at about 
25-50%.14, 91-94 An elevated hs-cTnT concentration has been associated with 
various disease characteristics assessed with echocardiography, such as 
maximal wall thickness, LV outflow tract gradient and diastolic function.14, 91-93, 
95 In addition, elevated hs-cTnT has been associated with the presence of late 
gadolinium enhancement (LGE).14, 91, 95 Lastly, a relation with adverse clinical 
outcome has been suggested.91, 93 
In the general population, it has been demonstrated in a large registry that 
hs-cTnT concentration is related to LV mass.16 In large community-based regis-
tries hs-cTnT was also related to cardiovascular risk profile and future cardio-
vascular events.16-18 In HCM patients who are characterised by LVH, little data 
exist on this topic.95 Further research is warranted whether observations in the 
general population can be translated to the HCM population. Insight in both 
common and distinct pathways for hs-cTnT release may be valuable for inter-
pretation of hs-cTnT concentrations in HCM. In Chapter 3 the association of 
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hs-cTnT with LV mass and the risk of future cardiovascular events is described 
in HCM patients. We also address for the first time hs-cTnT concentrations 
between the limit of blank at 3ng/l and the 99th percentile at 14ng/l.
As stated, elevated hs-cTnT has been associated with the presence of 
myocardial injury, indicated by LGE CMR imaging.14, 91, 95 Among HCM patients 
with LGE, a subgroup also demonstrates high signal intensity on T2-weighted 
CMR imaging (HighT2) occurring within areas of LGE. The presence of HighT2 
in patients with HCM is assumed to be evidence of oedema due to recently 
sustained ischemic injury and it has been hypothesized that HighT2 is indicative 
of a more active disease state.96, 97 In that regard, we were the first who sought 
assess the association between HighT2 and an elevated hs-cTnT concentra-
tion, independent of LV mass. This issue will be described in Chapter 4. 
Only one small pilot study at the time of study design described the pres-
ence of troponin in sera of patients with HCM in rest and after exercise.10 As 
previously stated, exercise may induce additional stress to HCM patients with 
intrinsic cellular failure, microvascular disease and hypertrophy. Clinically, it 
has been suggested that exercise acutely increases the risk of SCD in HCM.98, 
99 In that regard, we sought to investigate whether a short bout of exercise 
can induce troponin release in HCM. Further investigation of which pheno-
typic characteristics are associated with exercise-induced troponin release 
may provide insight in mechanisms that are pivotal for myocardial injury 
in HCM. Finally, ischemia might take place in subclinical mutation carriers 
without hypertrophy. Whether troponin release at rest or after exercise can be 
demonstrated in these patients has not yet been assessed. In that regard, we 
have assessed hs-cTnT concentrations before and after exercise in both clin-
ical HCM patients and subclinical mutation carriers. In clinical HCM patients, 
we have assessed the association between exercise-induced troponin release 
and phenotype characteristics using CMR imaging. This will be addressed in 
Chapter 5. 
THE CURRENT ROLE OF CMR IMAGING IN HCM
Over the past few years, the use of CMR imaging has steadily increased in 
patients with HCM. CMR imaging offers a number of unique features which 
makes it particularly well-suited to assess the HCM phenotype.1, 48, 100, 101 In this 
thesis hs-cTnT concentrations will be described in relation to phenotypic char-
acteristics, as assessed with cine, LGE and T2-weighted CMR imaging. On the 
one hand, cine CMR imaging allows detailed assessment of myocardial geom-
etry and function, while on the other hand LGE and T2-weighted CMR imaging 
provide in vivo myocardial tissue characterisation. 
15
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Cine CMR imaging - Cine CMR imaging is considered the gold standard 
for quantification of LV geometry and function, which carry diagnostic and 
possibly prognostic information.102 Traditionally, the diagnosis was made by 
echocardiography, but the latest guidelines also endorse CMR imaging for the 
diagnosis of HCM.1 In addition to assessment of maximal wall thickness, cine 
CMR imaging can be used for quantification of LV mass. Although LV mass is 
often increased in HCM patients, it should be appreciated that in a substan-
tial portion of HCM patients LV mass is normal, which can be consistent with a 
clinical diagnosis of HCM based on increased maximal wall thickness.103 Lastly, 
cine CMR imaging allows assessment of LV ejection fraction (EF), which is in 
general normal or increased in HCM patients. 
With regard to prognosis, cine CMR imaging is not yet part of the current risk 
stratification schemes,1 but it was demonstrated that LV EF and LV mass might 
be used to identify HCM patients at high risk of adverse cardiac events.69, 103-105 
Despite recommendations in the current CMR guidelines, uniformity in CMR 
image analysis for LV EF and mass is lacking in daily practice regarding the 
measurements of the papillary muscles. The guidelines state that LV volumes 
and LV mass should be quantified according to the same protocol as used for 
the reference ranges.106, 107 In general, studies on normal values of LV parame-
ters used to include the papillary muscles in the LV mass.108-110 Surprisingly, in 
most general hospitals exclusion of the papillary muscles has become the stan-
dard.111 Given the observation that in HCM patients the papillary muscle mass is 
higher than in normal healthy volunteers, the impact of the papillary muscles 
on quantification of LV parameters might be substantial, especially in the HCM 
population.112 This issue is addressed in Chapter 2.
LGE CMR imaging - In addition to cine CMR imaging, the possibility of tissue 
characterisation using LGE CMR imaging has received much interest. Although 
the precise mechanisms that lead to LGE in HCM are unknown, LGE is generally 
considered to be the result of repetitive bouts of ischemia, which may ultimately 
lead to myocyte death and replacement fibrosis with concurrent increased 
interstitial space.48 Histological evidence, however, is limited to a small number 
of case reports of end-stage HCM patients, in whom LGE indeed correlates to 
areas of fibrosis.58, 67, 113
In general, areas of LGE are demonstrated in about 60-70% of clinical HCM 
patients.105, 114-118 In these patients, LGE is most often demonstrated as diffuse and 
patchy regions in the myocardial segments with the highest degree of hyper-
trophy and at the insertion points of the right ventricle (Figure 2). This charac-
teristic pattern may be used clinically to differentiate between LVH due to HCM 
or another cause of LVH such as hypertension or Anderson Fabry’s disease.119
16
Furthermore, the extent of LGE can be quantified as a percentage of LV mass 
that is filled with LGE. However, there is no consensus on the preferred method 
of LGE quantification in HCM. On the one hand, investigators relied on visual 
assessment, whereas others used a signal-intensity-based cut-off.120 The lack 
of consensus on LGE quantification limits comparison between studies and 
different results have been reported regarding the average LGE extent in 
general HCM populations. Although dependent on the image analysis tech-
nique that is used, the average extent of LGE in HCM patients can be estimated 
to be about 5-10% of the LV mass.105, 114-118
At the time of the design of the study, we chose to use a semi-quantitative 
score, previously validated in HCM against a method of manual delineation 
after visual assessment.116, 121 For this semi-quantitative score, each individual 
segment of  the AHA-17-segment model needs to be assessed for the rela-
tive percentage of the segmental area that is filled with LGE.122 Then, each 
segment needs to be scored according to this percentage (0=no LGE, 1=1-25%, 
2=26-50%, 3=51-75%, 4=76-100%). Lastly, the individual segmental scores are 
summed and converted to a percentage of the maximum possible score of 68 
to estimate the extent of LGE relative to LV mass.
Myocardial fibrosis is a well-known substrate for arrhythmias and in that 
regard various studies in HCM addressed the role of LGE for SCD risk stratifi-
FIGURE 2. Late gadolinium enhancement CMR imaging in a clinical 
 HCM patient 
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cation.120, 123 At first, an association with the number of SCD risk factors and in 
particular, a history of non-sustained ventricular tachycardia on Holter moni-
toring was demonstrated.64, 124 Following these observations, medium-sized 
cohort studies demonstrated an association between the presence of LGE with 
prognosis, heart failure and SCD.117, 118, 125 Although the mere presence of LGE has 
been associated with SCD, it is not useful as a predictor of SCD. This is due to 
the fact that the majority of the HCM population (60-70%) demonstrates LGE, 
whereas SCD only occurs in a small minority.123 To differentiate among HCM 
patients with LGE, the extent of LGE has been investigated.105, 114 A meta-anal-
ysis revealed a strong association with SCD and it has been suggested that the 
extent of LGE improved prediction of SCD.114, 120 Currently, the extent of LGE is 
not established as a risk factor for SCD in the latest European and Northern 
American guidelines.1, 2 But the role of LGE CMR imaging is now a matter of 
debate and Northern American experts in the field advocate to perform LGE 
CMR imaging in patients with low-intermediate SCD risk, to assess whether 
extensive LGE is present, which would imply an approximately two-fold higher 
risk of SCD and the consideration of ICD implantation.126 With regard to this 
approach, it should be taken into account that the majority of HCM patients 
is at low-intermediate SCD risk. Given the low prevalence of extensive LGE 
( ̴10%), implementation of LGE CMR imaging in this category of HCM patients 
would result in a lot of additional LGE CMR imaging, with a positive finding in 
only one out of ten patients.114 In view of this, in order to improve risk strati-
fication with CMR imaging in a cost-effective way, a strategy based on easily 
obtainable characteristics that would alter the pre-test threshold seems a 
promising approach.89, 127 Chapter 7 describes our study in which we sought 
to identify predictors of extensive LGE among both routinely assessed clinical 
variables and a broad panel of biomarkers in a cohort of low-intermediate risk 
HCM patients.
T2-weighted CMR imaging - While much interest has gone into LGE CMR 
imaging, the potential of T2-weighted CMR imaging has largely been overlooked 
in HCM. T2-weighted CMR imaging allows tissue characterisation based on 
prolongation of T2 relaxation times due to increased myocardial water content. 
In analogy to findings of HighT2 in patients that suffered from acute myocardial 
infarction (AMI), the presence of HighT2 in patients with HCM is assumed to be 
evidence of oedema.96 Although confirmed in patients with AMI, histopatho-
logical data in HCM are lacking.128-131 Furthermore, the number of HCM cohorts 
in which HighT2 has been investigated in relation to other imaging and clinical 
characteristics is limited. There are, however, a few important consistent obser-
vations that have shed light on the potential relevance of HighT2 in HCM. 
18
In general, the prevalence of HighT2 varies highly between reports ranging 
from 17 and 55%, against a background prevalence of LGE of over 75%.66, 96, 
97, 132-135 With regard to myocardial distribution, HighT2 occurs primarily in the 
hypertrophic mid-wall regions.66, 96, 97, 134 In addition, myocardial perfusion was 
reduced in patients with HighT2 compared to those without HighT2.66, 97, 132 
Most strikingly, however, is the consistent reporting of the co-localization of 
HighT2 and LGE.66, 96, 97, 132-136 In all the reports that were available, the coinci-
dence of a clear HighT2 signal without LGE hardly ever occurred. Interestingly, 
these areas of HighT2 were almost exclusively located within the boundaries 
of LGE. In light of the above, it is tempting to conclude that HighT2 is a reflec-
tion of ischemic injury, most likely in the form of oedema. Although ischemic 
injury is considered the final common pathway, the pathophysiology of isch-
emia in HCM distinctly differs from AMI. It has been postulated for patients 
with HCM that areas with HighT2 might be indicative of a more active disease 
state.96, 97 This requires additional research on CMR imaging and the interpreta-
tion of HighT2 in HCM. In the abovementioned context, we aimed in Chapter 4 
to explore the association between HighT2 and an elevated hs-cTnT concentra-
tion in a well-defined cohort of patients with a clinical HCM.
Importantly, studies with clinical follow-up on HighT2 are lacking. Intrigu-
ingly, in addition to the association with LGE, the presence of HighT2 has also 
been related to a history of non-sustained ventricular tachycardia. This raised 
the question whether HighT2 might be a valuable predictor of adverse events, 
SCD in particular. To assess its potential clinical impact we therefore investi-
gated in Chapter 6 whether patients with HighT2 were more often at inter-
mediate to high risk according to the European and Northern American risk 
models. In addition, we explored the association of HighT2 with the projected 
SCD rates using the HCM Risk-SCD model. 
STUDY PROCEDURES OF THE BE STRONG HCM STUDY
In short, although echocardiography remains the cornerstone for imaging for 
HCM patients, CMR imaging provides unique opportunities for investigation 
of the HCM phenotype. The combination with promising biomarkers, such as 
troponin, provides further potential to increase insight in myocyte injury in 
HCM and how markers of myocyte injury may impact clinical management. In 
that regard, we  designed the BE STRONG HCM study, of which the results will 
be discussed in this thesis. 
In summary, for the BE STRONG HCM study we prospectively enrolled a 
cohort of two types of individuals: 1) clinical HCM patients, 2) subclinical HCM 
mutation carriers. The study examinations are graphically displayed in Figure 3. 
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All participants were asked to undergo a bicycle exercise test at baseline. 
Before the exercise test and 6 hours afterwards a blood sample was drawn for 
later biomarker assessment. Hs-cTnT was the biomarker of primary concern. In 
addition, all participants were planned to undergo CMR imaging prior the exer-
cise test. CMR imaging included three types of sequences: 1) cine imaging; 2) 
LGE imaging and 3) T2-weighted imaging. Follow-up is currently ongoing to 
assess the occurrence of adverse events such as the onset of arrhythmias or 
heart failure and will not be discussed in this thesis.
FIGURE 3. Study procedures of the BE STRONG HCM study
Baseline 
blood 
sample
CMR
imaging 
Bicycle 
exercise 
testing
Blood sample
@ T +6 hrs
Follow-up
@ T +2 & +5 yrs
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OUTLINE OF THIS THESIS
Although CMR imaging is the current gold standard for assessment of myocar-
dial geometry and function, differences in image analysis may have important 
clinical implications for risk stratification and clinical follow-up in HCM. In 
Chapter 2 we assess the impact of the papillary muscles on the quantification 
of LV EF and mass.
In the general population, troponin concentrations are related to LV mass 
and the risk of future cardiovascular events. However, little is known about 
these associations in HCM, characterised by LVH. In Chapter 3 we report on 
the association of LV mass, as assessed with CMR imaging, and the Fram-
ingham 10-year risk score with troponin T concentration.
Tissue characterisation with T2-weighted and LGE CMR imaging is increas-
ingly important in HCM. Although HighT2 is suggested to represent oedema 
after ischemic myocardial injury, little data exist to support this hypothesis in 
HCM. In Chapter 4 we report on the association between HighT2 and elevated 
cardiac troponin T concentration.
In Chapter 5 we investigate the impact of exercise on the concentration of 
troponin T in clinical HCM patients and subclinical HCM mutation carriers. In 
addition, we assess the association of clinical variables with exercise-induced 
troponin release in clinical HCM patients.
With regard to risk stratification, it has been suggested that HighT2 might be a 
predictor of SCD in HCM, based on previously reported associations with LGE 
and non-sustained ventricular tachycardia. To further explore the potential 
clinical value of HighT2, we report in Chapter 6 on the association of HighT2 
with SCD risk categorisation according to the European and Northern Amer-
ican guidelines.
With increasing interest in CMR imaging for SCD risk stratification, experts in 
the field suggested to use extensive LGE as a risk factor for SCD in low-inter-
mediate risk HCM patients. In Chapter 7 we report on prediction and exclu-
sion of extensive LGE in HCM using routinely assessed clinical variables and a 
comprehensive panel of biomarkers, including troponin.
Chapter 8 summarizes the main findings and conclusions of the previous 
chapters. Moreover, in an epilogue we address the mechanisms for HighT2 
and troponin release in HCM and future perspectives regarding the use of 
CMR imaging and biomarkers in HCM. In Chapter 9 a Dutch translation of the 
summary is provided
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CHAPTER 2
IMPACT OF THE PAPILLARY MUSCLES 
ON CARDIAC MAGNETIC RESONANCE 
IMAGE ANALYSIS OF IMPORTANT LEFT 
VENTRICULAR PARAMETERS
IN HYPERTROPHIC CARDIOMYOPATHY
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ABSTRACT
BACKGROUND
The use of cardiac magnetic resonance (CMR) analysis has increased in patients 
with hypertrophic cardiomyopathy (HCM). Quantification of left ventricular 
(LV) measures will be affected by the inclusion or exclusion of the papillary 
muscles as part of the LV mass, but the magnitude of effect and potential 
consequences are unknown.
METHODS
We performed Cine-CMR in 1) clinical HCM patients (n=55) and 2) subclin-
ical HCM mutation carriers without hypertrophy (n=14). Absolute and relative 
differences in LV ejection fraction (EF) and mass were assessed between algo-
rithms with and without inclusion of the papillary muscles. 
RESULTS
Papillary muscle mass in group 1 was 6.6±2.5 g/m2 and inclusion of the papil-
lary muscles resulted in significant relative increases in LVEF of 4.5±1.8% and 
in LV mass of 8.7±2.6%. For group 2 these figures were 4.0±0.9 g/m2, 3.8±1.0% 
and 9.5±1.8%, respectively. With a coefficient of variation of 4%, this 9% differ-
ence in LV mass during CMR follow-up will be considered a change, while in 
fact the exact same mass may have been assessed according to two different 
algorithms. 
CONCLUSIONS
In clinical HCM patients, CMR quantification of important LV measures is signifi-
cantly affected by inclusion or exclusion of the papillary muscles. In relative 
terms, the difference was similar in subjects without hypertrophy. This under-
scores a general need for a uniform approach in CMR image analysis.
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INTRODUCTION
Over the past few years, the use of cardiac magnetic resonance (CMR) 
imaging has steadily increased in patients with hypertrophic cardiomyopathy 
(HCM). Although CMR is not yet part of the current risk stratification,1 several 
studies have been undertaken to address the impact of CMR for future patient 
management.2,3 In recent publications it was demonstrated that left ventricular 
(LV) ejection fraction (EF) and LV mass can be used to identify HCM patients 
at high risk of adverse cardiac events.2,4-6 CMR is the current gold standard 
for quantification of these parameters, because of its superior accuracy and 
reproducibility.7 
In daily practice, uniformity in CMR image analysis is lacking on how to deal 
with measurements of the papillary muscles, despite recommendations in the 
current CMR guidelines. The guidelines state that LV volumes and LV mass 
should be quantified according to the same protocol as used for the reference 
ranges.8,9 In general, studies on normal values of LV parameters used to include 
the papillary muscles in the LV mass.10-12 Surprisingly, in most general hospitals 
exclusion of the papillary muscles has become the standard.13 In HCM patients 
the papillary muscle mass is higher than in normal healthy volunteers.14 There-
fore, especially in the HCM population, the impact of the papillary muscles on 
quantification of LV parameters might be substantial. We studied the impact of 
inclusion and exclusion of the papillary muscles on the quantification of LVEF and 
LV mass in clinical HCM patients with overt hypertrophy. In addition, we studied 
the impact in a group of subclinical HCM mutation carriers without hypertrophy. 
MATERIALS AND METHODS
STUDY POPULATION
Study participants were recruited from a population that visited a specialised 
HCM outpatient clinic, which routinely performs repeated echocardiographic 
imaging, clinical follow-up and genetic testing according to a cascade strategy. 
Between April 2008 and May 2011 we systematically asked them to participate 
in a study program, which also included CMR analysis.15 Patients with a history 
of septal reduction therapy, with LV hypertrophy due to other disorders that 
explain the myocardial hypertrophy (amyloidosis, MELAS, Anderson-Fabry 
etc.) or any contraindication to CMR imaging were not eligible.
Participants in the present study were either patients with an echocardio-
graphically proven HCM according to the ACC/ESC guidelines or subjects with 
an HCM-related pathogenic mutation without hypertrophy on echocardiog-
36
raphy.16 The former will be referred to as clinical HCM patients (group 1, with 
overt hypertrophy), the latter will be referred to as subclinical HCM mutation 
carriers (group 2, without hypertrophy). 
FIGURE 1. Different methods of assessment of LV parameters regarding 
 papillary muscles and trabecularisations
Legend: Various image analysis protocols regarding the papillary muscles and trabecularisations exist. In 
this study method A and B were compared. A. LV mass and volume assessed with inclusion of the papil-
lary muscles in the LV blood pool. B. LV mass and volume assessed with inclusion of the papillary muscles 
in the LV mass. At the base of the papillary muscles the circular shape of the endocardial contour was 
maintained to avoid inclusion of papillary muscle mass in the endocardial contour. C. LV mass and 
volume assessed with inclusion of the papillary muscles and the trabecularisations in the LV mass. Only 
those slices comprising papillary muscle are displayed. 
A
B
C
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CMR IMAGE ANALYSIS: HANDLING OF PAPILLARY MUSCLES
The endo- and epicardial contours were manually drawn by one observer in the 
short-axis images in the LV end-diastolic and end-systolic phase using QMass® 
version 7.0 (Medis, Leiden, The Netherlands) (Fig. 1A). The end-diastolic phase 
corresponded to the first image in the cine sequence after ECG triggering. The 
end-systolic phase was chosen based on the smallest LV cavity at the mid-ven-
tricular level. At the base of the heart, slices were included if more than 180° of 
the LV cavity was surrounded by LV myocardium.17
Secondly, the papillary muscles were defined on the short- and long-axis 
images as structures attached to the LV free wall and contiguous with the mitral 
valve via the chordae tendinae.14 The contours of the papillary muscles were 
manually drawn on the short-axis cine images for each slice that contained 
papillary muscle. A separate contour was used for the anterolateral and postero-
medial papillary muscle. In case of accessory papillary muscles, a continuous 
contour was used with two lines across the blood overlapping each other to 
avoid inclusion of LV blood pool as papillary muscle mass (Fig. 1B).
CMR imaging was performed using a 1.5T MR scanner (Achieva, Philips 
Healthcare, Eindhoven, The Netherlands) with a cardiac coil. Cine images were 
acquired using a breath-hold ECG-triggered segmented SSFP sequence in 3 
long-axis views (2-, 3-, and 4-chamber view) and in multiple short-axis views 
with a slice thickness of 10 mm (no gap), covering the LV from base to apex.
LEFT VENTRICULAR PARAMETERS
The LVEF and LV mass were calculated as previously described.13,18,19 These 
calculations were performed with results assessed according to two different 
protocols: 1) with inclusion of the papillary muscles in the LV mass and 2) with 
exclusion of the papillary muscles from the LV mass (Fig. 1A and B).
Absolute differences between results according to both protocols were calcu-
lated by subtraction. The absolute differences were transformed to relative 
differences for each LV parameter according to the following formula: 
PM mass was obtained according to the following formula: 
RELATIVE DIFFERENCE IN LV PARAMETER =
(result with inclusion of PMs in LV mass - result with exclusion of PMs from LV mass)
Result with exclusion of PMs from LV mass
 x 100%
PM MASS=
(LV mass with inclusion of PMs in LV mass) - (LV mass with exclusion of PMs from LV mass
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STATISTICAL ANALYSIS
LVEF, mass and papillary muscle mass were indexed to body surface area 
and expressed as mean±SD. Within-group differences were compared using 
a paired samples t-test. Between group differences were compared using an 
independent samples t-test. A p-value of <0.05 was considered significant. 
Statistical analysis was performed with IBM SPSS Statistics 20.0 (IBM Corp, 
Armonk, NY, USA).
RESULTS
STUDY POPULATION
Of the 125 attendees of the outpatient clinic, 71 underwent CMR and in 2 data 
were inadequate for further analysis (Fig. 2). Finally, we analysed 69 subjects: 
55 clinical HCM patients (with overt hypertrophy) and 14 subclinical HCM muta-
tion carriers (without hypertrophy). Baseline characteristics are displayed in 
Table 1. Fifty-three clinical HCM patients (96%) were asymptomatic to mildly 
symptomatic (NYHA 1-2) and most pathogenic mutations were located in the 
MYBPC3 gene (70%).
IMPACT OF THE PAPILLARY MUSCLES ON LV PARAMETERS
The results for LVEF and LV mass are displayed per group in Table 2. For clin-
ical HCM patients papillary muscle mass was 6.6±2.5 g/m2. Inclusion or exclu-
sion of the papillary muscles resulted in relative differences of 4.5±1.8% for 
LVEF and 8.7±2.6% for LV mass (p<0.01). 
For subclinical HCM mutation carriers the papillary muscle mass was 4.0±0.9 
g/m2. The relative differences in LVEF and LV mass were 3.8±1.0% and 9.5±1.8% 
(p<0.001) respectively, and not different from the relative figures observed in 
clinical HCM patients.
The observed absolute differences in LV mass differed significantly between 
groups 1 and 2 (p<0.01), while the absolute differences in LVEF were not signif-
icant (p=0.13).
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FIGURE 2. Flowchart of study population
TABLE 1. Baseline characteristics
TOTAL
(N=69)
CLINICAL HCM
(N=55)
SUBCLINICAL HCM
MUTATION  CARRIERS
(N=14)
Age (years) 51 ± 16 54 ± 16 40 ± 10
Male 38 (55) 34 (62) 4 (29)
Pathogenic mutation present 37 (54) 23 (42) 14 (100)
NYHA class I / II 67 (97) 53 (96) 14 (100)
NYHA class III 2 (3) 2 (4) -
Data are presented as mean ± standard deviation or numbers (percentages). NYHA New York Heart 
Association.
 HCM OUTPATIENT CLINIC ATTENDANTS SCREENED
N = 125
Eligible for study participation
N = 71
Participants included for analysis
N = 69
 No study participation 1
N = 54
 Participants with inadequate MR data 2 
N = 2
Legend: 1. Reasons for non-participation: 15 not willing to participate; 10 Morrow myectomy/percuta-
neous transluminal septal myocardial ablation; 7 implantable cardioverter-defibrillator or pacemaker; 
5 could not be contacted; 5 claustrophobia; 12 other. 2. Reasons for inadequate MR imaging data: 1 
claustrophobia; 1 inadequate MR image quality. MR Magnetic resonance.
40
TABLE 2.  Impact of in- or exclusion of the papillary muscles in LV mass on 
 LV EF and LV mass
CLINICAL HCM (N = 55)
EXCLUSION OF PMS 
FROM LV MASS 
INCLUSION OF PMS
 IN LV MASS
ABSOLUTE  
DIFFERENCE
RELATIVE
DIFFERENCE*
LV EF (%) 58.2 ± 7.2 60.8 ± 7.6 2.6 ± 1.1 4.5 ± 1.8
LV MASS (G/M2) 78.5 ± 28.4 85.2 ± 30.3 6.6 ± 2.5 8.7 ± 2.6
SUBCLINICAL HCM MUTATION CARRIERS (N = 14)
EXCLUSION OF PMS 
FROM LV MASS 
INCLUSION OF PMS
 IN LV MASS
ABSOLUTE  
DIFFERENCE
RELATIVE
DIFFERENCE*
LV EF (%) 57.8 ± 6.1 60.0 ± 6.5 2.2 ± 0.7 3.8 ± 1.0
LV MASS (G/M2) 42.7 ± 9.9 46.7 ± 10.5 4.0 ± 0.9 9.5 ± 1.8
Data are presented as mean ± standard deviation. Within group differences: p<0.01. * Relative differ-
ences in LV EF and mass are both indicated in percentages. EF Ejection fraction.
DISCUSSION
To our knowledge this is the first study that addresses the basic question of 
how much inclusion or exclusion of the papillary muscles affects everyday 
CMR image analysis in patients with HCM in particular, but also in relation to a 
group of controls without hypertrophy. In HCM patients, inclusion of the papil-
lary muscles resulted in significant relative increases of 9% in LV mass and 
4% in LVEF. Despite the involvement of the papillary muscles in the disease 
process of HCM, the relative differences were in the same order of magnitude 
in the control subjects without hypertrophic myocardium. This underscores 
the general need for uniform protocols, given the potential impact for clinical 
decision-making based upon values of LV mass, volume and function.
In recent studies on different CMR image analysis protocols, the papillary 
muscle mass was combined with that of the trabecularisations (Fig. 1C). Inclu-
sion or exclusion of both the papillary muscles and the trabecularisations as 
part of the LV mass led to significant differences in LVEF and LV mass.20-22 
This was confirmed in HCM patients.13,23 Reports on normal values with CMR 
imaging are limited and refer to studies that considered the papillary muscles 
and trabecularisations to be part of the LV mass.10-12 In daily practice, however, 
these structures are often not included, resulting in underestimation of LVEF 
and LV mass. Normal values for this more practical approach of CMR image 
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analysis are scarce. Our study points out the need for either uniform CMR 
image analysis including these structures, or the need for studies on normal 
values of the more practical approach.
This is illustrated when our results are put in the context of the excellent repro-
ducibility of CMR image analysis, with a coefficient of variation of 4%.13,17,20,24 
Based on the coefficient of variation we can make statistical inferences about 
the expected results when a particular LV mass is measured repeatedly, 
provided the same methodology of CMR image analysis is followed. Appre-
ciating the 4% coefficient of variation, the relative differences of the repeated 
measurements of that particular LV mass will lie between -8% and +8% in 95% 
of cases. In a setting of uniform CMR analysis, this means that a true change 
in LV mass will be present if the results differ by more than a relative 8%. Our 
finding that the two different approaches of CMR analysis result in a 9% rela-
tive difference in LV mass should be interpreted in this context. Given the mean 
relative difference of 9%, the exact same LV mass will seem to have changed 
in at least half of the cases. This indicates that non-standardised assessment 
of LV mass may have important implications for both research and daily clin-
ical practice. As for LVEF, the relative difference of 4% seems less important. 
In the setting of clinical trials, for example, there is a growing interest in 
studies reporting LV mass and the extent of fibrosis relative to LV mass.25,26 In 
case of CMR follow-up studies on this subject, CMR image analysis should be 
performed according to the same protocol at baseline and follow-up. Other-
wise, differences in LV mass can be interpreted as a true change, while in fact it 
could be the result of two CMRs analysed according to two different protocols.
As for daily clinical practice, the use of CMR in HCM patients has increased 
over the years, even though it is not yet part of the routine clinical work-up for 
risk stratification.1 This development is partly related to its excellent reproduc-
ibility, but may also be influenced by the growing body of evidence reported by 
CMR studies in the field of HCM. For example, increased LV mass assessed by 
CMR (i.e. >91 or > 69 g/m2 for men and women respectively) has been suggested 
as a more sensitive marker of adverse outcome than LV maximal wall thick-
ness6. A cut-off value (<50%) has been reported to predict an adverse prog-
nosis in HCM, not only for LV mass but also for LVEF.4,5 In the latter case, the 4% 
difference we observed could have implications for patients with values near 
the cut-off. In that regard, it has previously been demonstrated that depending 
on the imaging technique, differences in LVEF assessment may have important 
clinical consequences in ICD candidates.27 In addition, the amount of fibrosis 
relative to LV mass has the potential to become an additional risk factor in the 
selection of candidates for primary prevention with an ICD.2,3 Again, this under-
scores the importance of uniform assessment of LV mass.
42
In order to achieve uniformity, a guideline statement with regard to the 
preferred method of analysis should be a first initiative. In the above-men-
tioned context of increasing use of CMR data, the recent initiative to validate 
the accuracy of SSFP CMR imaging should be appreciated.28 Importantly, 
these figures on accuracy were obtained with inclusion of both the papillary 
muscles and the trabecularisations. On the other hand, algorithms incorpo-
rating quantification of trabecularisations have been questioned with regard 
to reproducibility, given the possible overestimation of LV mass due to partial 
volume artefacts.17,29 If exclusion of the papillary muscles were to become the 
method of choice, normal values obtained with contemporary sequences in an 
adequately sized series of healthy controls would be required.30 In the present 
era of non-uniform CMR analysis, reliable comparison between previous and 
future studies is difficult. This underscores the need for investigators to report 
the CMR analysis algorithm, and clinicians should be aware of the protocol 
used at their centre when interpreting CMR parameters. 
In the present comparison of the two algorithms, the associated absolute 
differences in LV mass were higher in clinical HCM patients than in subjects 
who were HCM mutation carriers without hypertrophy. On the other hand, the 
relative changes in LVEF and LV mass were similar in both groups. This can 
be explained by the fact that in HCM patients the proportion of the papillary 
muscle mass in relation to the total LV mass was similar to that in subjects 
without hypertrophy. Subsequently, after transformation of the absolute differ-
ences to relative differences, the impact of inclusion or exclusion of the papil-
lary muscles was comparable in both groups. This suggests that our results 
apply not only to patients with overt hypertrophy, but may apply to the general 
population as well, although more study subjects are necessary to substantiate 
this. This is supported by a study in healthy controls, which reported a similar 
impact of the papillary muscles on LV mass.31 
It should be appreciated that this study did not address accuracy, due to 
lack of a comparative standard. We merely described the impact of a more 
practical MRI algorithm in terms of quantification of LV parameters, and with 
regard to potential consequences for research questions and daily clinical 
practice. In order to put our findings into context, we referred to the well-ac-
cepted 4% coefficient of variation, i.e. a relative difference of 8% or more indi-
cates a true change.13,17,20,24 In a random set of 20 of our participants, intra- and 
interobserver variability were 4.69 and 4.49% for LVEF and 4.76 and 4.86% for 
LV mass, respectively. 
In summary, our findings indicate that non-uniform CMR image analysis 
will render incorrect conclusions with regard to the presence or absence of 
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CHAPTER 3
RELATION OF HIGHLY SENSITIVE 
CARDIAC TROPONIN T IN 
HYPERTROPHIC CARDIOMYOPATHY 
TO LEFT VENTRICULAR MASS AND 
CARDIOVASCULAR RISK
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ABSTRACT
Elevated cardiac troponin can be seen in patients with left ventricular (LV) 
hypertrophy and in asymptomatic individuals with a high a priori risk of cardio-
vascular disease (CVD). In hypertrophic cardiomyopathy (HCM) troponin can 
be detected as well, but little is known about the contribution of LV mass on 
the one hand, and the long-term risk of CVD on the other. In an observational 
single centre study of 62 HCM patients, without a history of CVD, we assess 
the Framingham Heart 10-year risk scores (FH10yrs), LV mass index (LVMI) 
using MRI, and highly sensitive cardiac troponin T (hs-cTnT). Hs-cTnT (>3ng/L) 
is detectable in 74% of patients (46/62). Hs-cTnT is elevated in 26% (16/62) of 
patients (≥ the 99th percentile reference limit of 14 ng/L). Between 3 and 14ng/L, 
patients are older, more often have hypertension, and the FH10yrs is higher. 
Hs-cTnT correlates positively with LVMI (p<0.001), and maximal wall thickness 
(p<0.001). In addition, LVMI and hypertension are independently associated 
with increasing hs-cTnT concentrations in linear regression. Using multivariable 
binary logistic regression both LVMI and FH10yrs are independently associated 
with a detectable hs-cTnT. In contrast, only LVMI is associated with an elevated 
hs-cTnT. In conclusion, hs-cTnT is detectable in three quarters, and elevated in a 
quarter of our patients with HCM. Whereas a detectable hs-cTnT is associated 
with both LV mass and CVD risk, an elevated hs-cTnT relates to LV mass only. 
This indicates that hypertrophy more than the risk of CVD seems the most 
important drive for hs-cTnT to occur in these patients.
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INTRODUCTION
 
Elevated cardiac troponin has been associated with left ventricular (LV) mass 
and the a priori risk of cardiovascular disease (CVD) in asymptomatic indi-
viduals.1 In patients with hypertrophic cardiomyopathy (HCM) the few reports 
available demonstrate an association between cardiac troponin and increased 
LV wall thickness, LV dysfunction and late gadolinium enhancement (LGE) with 
magnetic resonance imaging (MRI).2-6 However, the contribution of mass and 
the a priori long-term risk of CVD have never been studied. Moreover, previous 
studies did not address the range of detectable troponin concentrations below 
the upper reference limit of normal. In the present report we describe the rate 
of a detectable and of an elevated troponin (≥99th percentile) in a well-defined 
population of patients with clinical HCM, using a highly sensitive assay. Subse-
quently, we study the associations between troponin and the aforementioned 
variables, i.e. LV cardiac mass measures - as determined with MRI - and the 
Framingham Heart 10-year risk score (FH
10yrs
) as a measure of the predicted 
CVD risk.7
METHODS
All participants were patients of a large outpatient clinic that is specialized in 
HCM and performs mutation screening, repeated echocardiographic imaging 
and clinical follow-up on a routine basis. Patients with 2-dimensional echo-
cardiographic evidence of LV hypertrophy (maximal wall thickness ≥15mm, 
or ≥13mm in case of an identifying gene mutation and/or compelling factors 
associated with HCM) without another cardiac or systemic cause at the time 
of HCM diagnosis were potential candidates to participate in the present 
study.8 For each subject the HCM diagnosis was carefully reviewed. In case 
of a discrepancy between the treating physician and the investigators a third 
opinion of an independent reviewer was decisive. Subjects with known coro-
nary artery disease (previous myocardial infarction, >50% stenosis on coro-
nary angiogram, previous percutaneous coronary intervention, previous coro-
nary artery bypass grafting), a previous stroke, peripheral arterial disease, 
significant valvular heart disease, previous septal myectomy or septal alcohol 
ablation were excluded (Figure 1).
Eligible patients without contraindications for MRI (renal impairment 
defined as MDRD <30mL/min, an implantable cardiac defibrillator, claustro-
phobia) were invited to the hospital to undergo MRI according to a standard 
protocol. Medical history, NYHA class, medication use and echocardiographic 
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data were recorded. Echocardiographical LV indices were derived from an 
echocardiogram performed within a year of the MRI study. At the day of MRI 
study, a blood sample was drawn for later assessment of biomarker status and 
for immediate determination of renal function. Whether other clinical investi-
gations had to be performed was left to the discretion of the treating physician, 
who was blinded for MRI and biomarker results. For each patient classical risk 
factors for CVD were collected from hospital records, to calculate the Fram-
ingham Heart 10-year risk score.7 The study protocol was approved by the 
local ethical committee. All participants provided written informed consent.
Cardiac MRI studies were performed on a 1.5T cardiac MRI system (Philips 
Achieva, Best, The Netherlands). All images were acquired with electrocardio-
gram gating and during repeated breath-holds of 10-15 seconds, depending on 
the heart rate to minimize the influence of cardiac and respiratory motion on data 
collection. Steady-state free precession cine imaging was used to quantify LV 
function (short axes stack with slice thickness of 10mm from base to apex) and 
to determine myocardial mass by means of standard criteria. Segmented inver-
sion-recovery fast gradient-echo imaging was used to assess LGE 10 minutes 
after the administration of 0.2 mmol/kg contrast medium (Dotarem; Guerbet). 
Images were analyzed offline with the use of Qmass software (Version 7.2; 
Medis, Leiden, The Netherlands) by two observers unaware of the subjects’ 
clinical and biomarker information. The endo- and epicardial borders of the 
myocardium were manually drawn in end-diastole and end-systole on the 
short-axis cine images. Volumes were derived by summation of discs, and ejec-
tion fraction was calculated accordingly. LV mass was calculated by subtracting 
endo- from epicardial volume at end-diastole and multiplied by 1.05 g/cm.3,9 All 
volumes and mass were normalized to body surface area. To evaluate maximal 
wall thickness, the short-axis LV stack was divided into 3 approximately equal 
levels (basal, mid and apical). These levels were divided automatically by the 
software into the standardized 16 segments model excluding the apex. LV wall 
thickness was then automatically measured per segment at end-diastole.10 The 
greatest thickness measured was recorded as the maximal wall thickness. LGE 
was visually assessed and determined per segment as either present or absent.
Blood samples were obtained in a standard fashion at the clinical laboratory 
by trained personnel and processed within 60 minutes after phlebotomy, and 
stored at –80°C until further analysis. For the determination of troponin T the 
highly sensitive cardiac troponin T (hs-cTnT) assay was used and performed on 
the Elecsys 2010 system (Roche Diagnostics). The lower measurement range 
of this test is 3ng/L, the 99th percentile reference limit 14ng/L, and the concen-
tration with a coefficient of variation of less than 10% is 13ng/L. All biochemical 
testing was performed by laboratory personnel who were unaware of clinical 
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information and MRI data.
Baseline characteristics are presented according to three groups (troponin 
≤3ng/L; between 3ng/L and 14ng/L; and ≥14ng/L). For each group means ± SD, 
medians ± interquartile ranges or percentages, whenever appropriate, are calcu-
lated. Differences between these 3 groups are analyzed using either Kruskall-
Wallis 1-way analysis of variance or chi-square testing. In case of comparisons 
between 2 groups, either Student’s t-test or the Mann-Whitney U test is used; 
proportions were compared using chi-square. P-values of 0.05 or less were 
considered to indicate statistical significance. Spearman’s correlation is used 
to test for associations between continuous variables, and linear regression to 
identify factors that are associated with hs-cTnT (transformed by natural loga-
rithm to approximate a normal distribution). To compare the proportions of 
patients with a detectable (>3ng/L) and elevated troponin (≥14ng/L) across 
tertiles of indexed LV mass (LVMI) and FH
10yrs
 chi-square testing is performed. 
A similar approach is followed to compare the proportions of patients with a 
troponin concentration between 3 and 14ng/L in the respective tertiles. Multi-
variable binary logistic regression analysis is performed to study the associa-
tion between LVMI and a detectable, and an elevated troponin independent of 
the FH
10yrs
. 
RESULTS
Of the cohort of 74 individuals that fulfilled the pre-specified in- and exclusion 
criteria 12 patients were excluded as either the troponin measurement or MRI 
failed (Figure 1). The hs-cTnT concentration is ≤3ng/L in 16 (26%), detectable 
but not elevated above the 99th percentile in 30 (48%), and elevated ≥14ng/L in 
16 (26%) patients. In total, a troponin level above the lower range of measure-
ment of 3ng/L is seen in 46 (74%) patients.
Baseline characteristics are presented in Table 1. Patients with a detectable 
but not elevated troponin concentration (>3ng/L and <14ng/L) and those with 
an elevated troponin concentration (≥14ng/L) are older (p=0.02), and more 
likely to have hypertension (p=0.007), and have a higher FH
10yrs
 (p=0.005). 
Patients with an elevated troponin have a higher heart rate (p=0.05), a higher 
maximal wall thickness (p=0.007), and a higher LVMI (p<0.001) than patients 
with an undetectable troponin, and detectable but not elevated troponin 
concentrations. In the 24 patients with a history of hypertension hs-cTnT is 
undetectable in only one, without a history of hypertension 40% (15/38) of 
patients has undetectable levels.
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Legend: PTSMA percutaneous transluminal septal myocardial ablation, MRI magnetic resonance imaging.
PATIENTS WITH EITHER HCM PHENOTYPE 
AND/OR GENOTYPE 
ACCORDING TO TREATING PHYSICIAN 
N = 148
Exclusion:
• 17 HCM mutation carriers
• 5 no HCM phenotype according 
to 3rd observer
Exclusion:
• 18 not willing to participate
• 10 history of Morrow 
myectomy / PTSMA
• 7 could not be reached
• 3 history of cardiovascular disease
• 14 other exclusion criteria
Eligible HCM patients
N = 74  
Exclusion:
• 6 troponin unavailable
• 6 MRI unavailable
Eligible HCM patients with 
available troponin and MRI
N = 62
Patients with HCM phenotype
N = 126
FIGURE 1.  Flow diagram of study population
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TABLE 1.  Baseline characteristics according to three highly sensitive cardiac 
 troponin T groups of HCM patients
VARIABLE TOTAL
(N=62)
UNDE-
TECTABLE
(≤3NG/L)
(N=16)
DETECTABLE 
NOT ELEVATED
(>3<14NG/L)
(N=30)
ELEVATED
(≥14 NG/L)
(N=16)
P-VALUE*
Age (years) 54 ± 16 46 ± 13 59 ± 15 51 ± 19 0.02
Men 36 (58) 8 (50) 18 (60) 10 (63) 0.74
CARDIOVASCULAR RISK
Hypertension 24 (39) 1 (6) 16 (53)  7 (44) 0.007
Systolic blood pressure 
(mmHg)
133 ± 24 129 ± 21 138 ± 26 128 ± 23 0.27
Body mass index (kg/m2) 26 ± 3 26 ± 3 26 ± 3 27 ± 4 0.39
Current smoker 14 (23)  4 (25) 7 (23) 3 (19) 1.0
Creatinin (µmol/L) 88 ± 16 83 ± 9 88 ± 14 91 ± 22 0.49
Framingham Heart 
10-year risk score (%)
14 (4-29) 5 (3-11) 21 (9-30) 16 (1-30) 0.005
SYMPTOMS
Chest pain 13 (21) 4 (25) 5 (17)  4 (25) 0.78
Dyspnoea 31 (50) 6 (38) 13 (43) 12 (75) 0.06
THERAPY
Beta-blocker 29 (47) 5 (31)  17 (57) 7 (44) 0.25
Calciumantagonist 13 (21) 3 (19) 8 (27) 2 (13) 0.61
ECHOCARDIOGRAPHY
Interventricular septal
 thickness (mm)
16 (14-20) 16 (14-19) 15 (13-18)  19 (15-24) 0.07
LV posterior wall thickness (mm) 11 (10-12) 10 (8-11) 11 (10-12)  14 (10-16) 0.002
LV outflow tract gradient 
≥30 mmHg
15 (24) 2 (13) 9 (30) 4 (25) 0.54
Systolic anterior motion 27 (44) 6 (38) 13 (45) 8 (50) 0.77
Mitral valve regurgitation 
(mild or more)
40 (65) 11(69) 19 (63) 10 (63) 0.92
MAGNETIC RESONANCE IMAGING
Maximal LV wall thickness (mm) 18 (13-21) 15 (13-19) 17 (13-20) 21 (18-24) 0.007
LV mass indexed to BSA (g/m2) 65 (52-91) 52 (43-70) 64 (54-89) 101 (67-130) <0.001
LV ejection fraction (%) 58 (54-65) 61 (55-66)  58 (55-63)  56 (50-65) 0.46
LGE present 31 (50) 7 (44) 13 (43) 11 (69) 0.22
Data are presented as mean ± SD or number (percentage) or median (interquartile range); *P-value for 
differences across the groups. LGE Late gadolinium enhancement
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Legend P-values for differences across tertiles. BSA Body surface area; IQR Interquartile range.
Hs-cTnT as a continuous variable correlates positively with maximal wall 
thickness, and LVMI (Table 2). With linear regression analysis hs-cTnT, trans-
formed by natural logarithm, is univariably associated with heart rate (p=0.01), 
LV maximal wall thickness (p=0.003), and LVMI (p=0.001). There is a nearly 
significant association with hypertension (0.057). In multivariable analysis only 
hypertension (p=0.048) and LVMI (p=<0.001) are independently associated 
with increasing levels of hs-TnT. The median troponin level significantly differs 
across tertiles of LVMI, but not across tertiles of FH
10yrs
 (Figure 2).
FIGURE 2.  Concentrations (medians and interquartile range) of highly 
 sensitive cardiac troponin T across tertiles of indexed left 
 ventricular mass and Framingham Heart 10-year risk score
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The percentages of patients with a troponin level above 3ng/L increase from 
50%, to 76%, and 95% across tertiles of LVMI (p=0.004), and from 55%, to 71%, 
and 95% with respect to FH
10yrs
 (p=0.01) (Figure 3). Across tertiles of LVMI this 
increase is explained by the number of patients with elevated hs-cTnT levels 
(≥14ng/L) reaching a total of 48% (10/21) in the highest tertile. For the FH
10yrs
 
a nearly significant increase in the percentage of patients with a troponin 
level between 3ng/L and 14ng/L from 30% in the lowest to 67% in the highest 
tertile (p=0.063) is observed, whereas for an elevated hs-cTnT proportions 
are similar. In the absence of hypertension, patients with a low LVMI (lowest 
tertile) only 8% (1/13) has an elevated hs-cTnT, in contrast to 55% (6/11) of 
patients within the highest tertile of LVMI. In univariable logistic regression 
analysis LVMI and FH
10yrs
 are significantly associated with a hs-cTnT >3ng/L. 
Using a stepwise forward method, both FH
10yrs 
and LVMI have an independent 
association with a detectable troponin. With respect to hs-cTnT levels ≥14ng/L 
there is a univariable association between troponin and LVMI, maximal wall 
thickness and dyspnoea (NYHA class ≥ II) complaints. In multivariable anal-
ysis, LVMI was the single variable that was independently associated with an 
elevated troponin (Table 3). 
TABLE 2.  Spearman’s correlation coefficients of continuous variables with 
 levels of highly sensitive cardiac troponin T
VARIABLE ALL PARTICIPANTS
(N=62)
SPEARMAN’S RHO P-VALUE
Age (years) 0.156 0.23
Systolic blood pressure (mmHg) 0.022 0.86
Framingham Heart 10-year risk score (%) 0.198 0.12
Creatinin (µmol/L) 0.148 0.28
Interventricular septal thickness (mm)* 0.143 0.27
Posterior wall thickness (mm)* 0.493 <0.001
Maximal wall thickness (mm)† 0.348 <0.001
LV mass indexed to BSA (g/m)† 0.513 <0.001
LV ejection fraction (%)† -0.194 0.13
* assessed with echocardiography; † assessed with MRI. BSA Body surface area.
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Legend: Margins of LVMI tertiles: 0-54.9 g/m2; 55.0-80.5 g/m2; 80.6 or more g/m2. Margins of FH10yrs tertiles: 
0-7.4%; 7.5-25.2%; 25.3% or more. # a significant difference across tertiles in the proportion of patients with 
a troponin >3ng/L (p≤0.01). * a significant difference across tertiles in the proportion of patients with a 
troponin ≥14ng/L (p=0.02). BSA Body surface area.
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FIGURE 3.  Percentages of detectable and elevated highly sensitive cardiac 
 troponin T across tertiles of indexed left ventricular mass (LVMI) 
 and Framingham Heart 10-year risk score (FH
10yrs
)
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TABLE 3.  Multivariable logistic regression analysis for the association of 
 indexed left ventricular mass and Framingham Heart 10-year risk 
 score with a detectable (>3ng/L) and elevated (≥14ng/L) hs-cTnT 
 in clinical HCM patients
DETECTABLE HS-cTNT (>3NG/L) ELEVATED HS-cTNT (≥14NG/L)
OR 95% CI P-VALUE OR 95% CI P-VALUE
UNADJUSTED
LVMI* 1.69 1.15-2.48 0.007 1.54 1.20-1.96 0.001
FH10yrs† 1.70 1.19-2.43 0.007 ns ns ns
ADJUSTED
LVMI*‡ 2.00 1.25-3.20 0.004 1.62 1.24-2.11 <0.001
FH10yrs†§ 2.12 1.33-3.38 0.002 ns ns ns
*Odds ratios are per 10 grams indexed left ventricular mass increase; † Odds ratios are per 5% Fram-
ingham Heart 10-year risk score increase; ‡ adjusted for variables univariably associated with detectable 
(FH10yrs, age, hypertension, and posterior wall thickness), or elevated hs-cTnT (posterior wall thickness, 
interventricular wall thickness, maximal wall thickness, and dyspnoea complaints); § adjusted for variables 
univariably associated with detectable hs-cTnT (LVMI, age, hypertension, and posterior wall thickness). 
Hs-cTnT highly sensitive cardiac troponin T; OR odds ratio; CI confidence interval; LVMI indexed left ventric-
ular mass; FH10yrs Framingham Heart 10-year risk score; ns not significant.
DISCUSSION
The present study in patients with HCM demonstrates that troponin release 
seems to be related to both cardiac mass and the risk of CVD, with the inter-
esting finding that the contribution of both factors seems to differ in relation 
to the serum troponin concentration. Both hypertension and LVMI are related 
to increasing troponin concentrations independent of other variables. Notably, 
the fact that the FH
10yrs
 is independently associated with a detectable troponin 
(i.e. >3ng/L), but not with an elevated troponin (≥99th percentile) suggests that 
LV mass rather than the predicted risk of CVD is the main drive for an elevated 
troponin in patients with HCM.
In our HCM population of 62 patients troponin is elevated above 14ng/L 
in 1 out of every 4 patients. Previous studies reported an elevated troponin in 
40-55% of patients,2,11 and studied associations with concentrations exceeding 
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the 99th percentile. In the present analysis, we also address the more subtle 
troponin concentrations between 3 and 14 ng/L. In addition, we not only 
explored the association with cardiac mass, but also with the predicted cardio-
vascular risk, a factor that has consistently been related to measurable troponin 
concentrations in different study populations of apparently healthy individuals 
without known structural heart disease.1,12-16
Although previous studies in patients with HCM have demonstrated that LV 
indices correlated with troponin,2-4 this is the first report in which the impact of 
cardiac mass is described, independent of the predicted CVD risk, making use 
of MRI. LVMI together with maximal LV wall thickness has the strongest posi-
tive correlation with troponin, and a strong association remains after adjust-
ment for all the variables significantly associated with troponin in linear regres-
sion analysis, i.e. hypertension, heart rate and maximal wall thickness. Overall, 
it seems that concentrations of troponin in serum of patients with HCM steadily 
increase with increasing mass and that the same goes for the proportion of 
patients with a detectable and elevated level, which increases across tertiles of 
LVMI. The relation between cardiac mass and troponin has only been described 
once before in patients with HCM. In this particular report it is shown that 
echocardiographically determined LV mass is higher in the group with elevated 
troponin T,16 while others reported on associations with maximal wall thickness, 
myocardial dysfunction, and LGE.2,4-6 
In populations quite different than patients with HCM, ranging from healthy 
individuals to patients with aortic valve stenosis a similar relation between 
increasing LV mass and troponin was observed.1,12,17,18 These observations 
suggest that mass is an important factor in an as of yet unknown mechanism 
of troponin release, independent of the underlying aetiology, and with, as a 
general rule, an increase in serum troponin when LV mass increases. Although it 
is reasonable to assume that LV mass is the most important factor for troponin 
release, there are no studies available that have adjusted for CVD risk factors 
when interpreting troponin results in patients with HCM. 
Interestingly, it has been demonstrated that troponin is associated with indi-
vidual risk factors for CVD, and the a priori long-term risk of CVD, as expressed 
by the FH
10yrs
.1,12,19 In our population, hypertension proves to be associated 
with increasing troponin levels, even after correction for LV mass measures. 
In addition, the FH
10yrs
 is independently associated with a detectable troponin, 
suggesting that the predicted cardiovascular risk might also be a factor in 
patients with HCM to consider. This is underscored by the observation that 
patients with hypertension have a detectable troponin in almost all patients, 
whereas in patients without hypertension troponin is undetectable in more 
than a third of patients. Interestingly, among patients with essential hyper-
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tension troponin is associated with signs of end organ damage, such as renal 
dysfunction and electrocardiographic signs of hypertrophy.20 With regard to 
cardiovascular risk factors, patients with hs-cTnT levels >3ng/L and <14ng/L 
were older, more likely to have hypertension and had a higher FH
10yrs 
than 
patients with an undetectable troponin. Therefore, besides cardiac mass, the a 
priori long-term risk of CVD contributes to the number of HCM patients with a 
detectable troponin in the low range below the 99th percentile reference limit.
The phenomenon of cardiac troponin in the circulation of patients with 
HCM may have several underlying mechanisms. Importantly, hypertension and 
atherosclerotic heart disease share elements of the same pathological path-
ways that also occur in patients with HCM. Microvascular dysfunction, next to 
increased pressure load and decreased capillary density, has been reported 
to cause ischemia in both secondary hypertrophy and HCM.21,22 Hypertrophy 
plays an important role in this, whereas other mechanisms, less dependent 
on hypertrophy, may also contribute to the release of troponin. In this respect 
myocyte disarray has been mentioned to be the result of myocyte growth due 
to alterations in myocardial energetics and calcium handling leading to ineffi-
cient energy usage.23,24 Reduced sarcomere responsiveness to stretch has been 
proposed as a general mechanism of disease causing myocardial dysfunction 
with reduced maximal force generation.25,26 It is quite imaginable that dysfunc-
tional sarcomeres will not be able to adapt sufficiently to the changing circum-
stances and demands under stressful conditions such as exercise, ultimately 
leading to cellular injury with release of troponin into the circulation. The latter 
mechanisms of disease seem less dependent on phenotype and may already 
be activated before development of hypertrophy. Likewise, it has been shown 
that biomarkers of fibrosis can be demonstrated in mutation carriers without 
the hypertrophic phenotype, and without visual evidence of fibrosis on MRI.27 
In these patients, cardiac troponin may also prove to be an interesting early 
marker of disease for future research, as it may precede the development 
of cardiac fibrosis. In this respect, exercise-induced troponin release could 
prove an indicator of disease progression which might be prevented by beta-
blockade.28
There are some limitations to this study that should be recognized. First, we 
did not study a control group of patients without HCM. Especially with controls 
matched on mass measures and risk factors for CVD, it would be possible 
to better elucidate to what extent mass by itself is the important factor, or if 
the more HCM specific characteristics (i.e. sarcomere dysfunction, myocyte 
disarray, and/or microvascular disease) are also of importance in the process 
of troponin release. Second, excluding patients with an implantable cardiac 
defibrillator, and with a population of primarily NYHA class II dyspnoea, this 
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study population is not representative of the entire HCM population. However, 
even in the absence of higher risk patients the association between mass and 
troponin is quite evident. Therefore, we expect the relation to be even stronger 
in a higher risk population. In addition, it should be appreciated that ideally 
all patients should have undergone coronary angiography to exclude impor-
tant coronary artery disease. Patients included have no clinical and/or imaging 
evidence of CVD. The FH
10yrs
 that we use is a well established indicator for the 
a priori long-term risk of CVD, and has been associated with baseline troponin 
concentrations in asymptomatic individuals.11,12 Although we use this score as 
an indicator for ‘atherosclerotic burden’, it should be noted that the prognostic 
impact for atherothrombotic events has not been studied in HCM patients. 
Finally, our relatively small sample size precludes adequately powered multi-
variable analyses. 
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CHAPTER 4
HIGH T2-WEIGHTED SIGNAL INTENSITY  
IS ASSOCIATED WITH ELEVATED 
TROPONIN T IN HYPERTROPHIC
CARDIOMYOPATHY 
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ABSTRACT
OBJECTIVE
Areas of high signal intensity (HighT2) on T2-weighted cardiovascular magnetic 
resonance (CMR) imaging have been demonstrated in hypertrophic cardiomy-
opathy (HCM). It has been hypothesized that HighT2 may indicate active tissue 
injury in HCM. In this context, we studied HighT2 in relation to cardiac troponin.
METHODS
Outpatient HCM patients without a history of coronary artery disease under-
went CMR imaging at 1.5 Tesla using T2-weighted, cine and late gadolinium 
enhancement (LGE) imaging to assess HighT2, left ventricular (LV) function, 
LV mass and presence and extent of LGE. Highly sensitive cardiac troponin 
T (hs-cTnT) was assessed as a marker of injury, with hs-cTnT ≥14 ng/L and >3 
ng/L defined as an elevated and detectable troponin.
RESULTS
HighT2 was present in 28% of patients (28/101). An elevated hs-cTnT was 
present in 54% of patients with HighT2 (15/28) compared to 14% of patients 
without HighT2 (10/73) (p<.001). Hs-cTnT was detectable in 96% of patients 
with HighT2 (27/28) compared to 66% of patients without HighT2 (48/73) 
(p=.002). In case of an undetectable hs-cTnT, HighT2 was only seen in 4% 
(1/26). In addition, the extent of HighT2 was related with increasing hs-cTnT 
concentrations (Spearman’s rho: 0.42, p<.001).
CONCLUSIONS
In this CMR study of HCM patients, we observed HighT2 in a quarter of patients, 
and demonstrated that HighT2 was associated with an elevated hs-cTnT. This 
observation, combined with the very high negative predictive value of an unde-
tectable hs-cTnT for HighT2, provides supportive evidence for the hypothesis 
that HighT2 is indicative of recently sustained myocyte injury.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most common inheritable cardio-
myopathy, characterized by unexplained left ventricular (LV) hypertrophy.1,2 
Myocardial ischemia is considered to play a pivotal role in the pathophysiology 
of this disease, based on previous observations of perfusion abnormalities and 
fibrosis using various imaging techniques.3,4
Several reports have described elevated concentrations of highly sensitive 
cardiac troponin T (hs-cTnT) in about 25-50% of HCM patients.5-7 In analogy to 
other conditions, the first study has been reported that suggests that hs-cTnT 
is associated with adverse long-term clinical outcome in HCM as well.6 With 
growing interest in cardiovascular magnetic resonance (CMR) imaging in HCM, 
hs-cTnT as a biomarker of myocardial injury has been associated with late 
gadolinium enhancement (LGE) as an imaging marker of fibrosis.7,8 Previously, 
a few small-sized studies of selected HCM patients have demonstrated areas 
of high signal intensity with the use of T2-weighted CMR imaging (HighT2).9-15 
Interestingly, these areas of HighT2 were almost exclusively present in patients 
with LGE, occurring within the boundaries of LGE. It has been postulated that 
areas with HighT2 might be indicative of myocardial oedema as a result of 
ischemic injury, representative of a more active disease state in patients with 
HCM.9,12 Although ischemic injury is considered the final common pathway, the 
pathophysiology of ischemia in HCM distinctly differs from, for example, acute 
myocardial infarction and myocarditis. This requires additional research on 
CMR imaging and the interpretation of HighT2 in HCM.  In the abovementioned 
context, we aimed to explore the association between HighT2 and hs-cTnT in a 
well-defined cohort of patients with a clinical HCM.
METHODS
STUDY POPULATION
Enrolment of our cohort of consecutive adult HCM patients took place between 
April 2008 and January 2014 at two outpatient clinics (Radboud University 
Medical Centre, Nijmegen and Albert Schweitzer Hospital, Dordrecht, The 
Netherlands) that perform mutation screening, repeated echocardiography, 
CMR imaging and clinical follow-up. Patients had an echocardiographically 
confirmed HCM,1,2 including a careful case-by-case chart review, especially in 
those with a history of hypertension. In case of a discrepancy between the 
treating physician and the investigators, a third opinion of an independent 
reviewer was decisive. Patients with known coronary disease, stroke, aortic 
68
stenosis, previous septal reduction therapy, contraindication for CMR imaging 
or renal impairment (defined as MDRD <30ml/min) were excluded.5 The study 
complies with the Declaration of Helsinki and the protocol was approved by the 
local ethical committees and conducted accordingly. All participants provided 
written informed consent.
STUDY PROTOCOL
Eligible patients were invited to the hospital to plan and undergo CMR imaging. 
At baseline, symptoms and medical therapy were recorded and risk factors for 
cardiovascular disease risk and sudden cardiac death were scored.1,16 A blood 
sample was drawn for determination of renal function and assessment of cTnT 
concentration.
CMR imaging protocol
Image acquisition - CMR imaging was performed on a 1.5T cardiac CMR system 
Philips Achieva (Philips Healthcare, Best, The Netherlands) or Siemens Avanto 
(Siemens Health Care, Erlangen, Germany) according to local protocol. All 
images were acquired with ECG-gating and during repeated breath-holds of 
10-15 seconds. Breath-hold triple inversion-recovery T2-weighted images with 
fat-saturation were acquired (short-axis stack covering the LV from base to 
apex) to assess the presence of HighT2 (typical imaging parameters: TR: 2RR; 
TE: 100 ms; slice thickness: 10mm; FOV: 320x320mm). A long-axis image was 
obtained to exclude artefacts.17 For the assessment of LV function, cine imaging 
was performed using a steady-state free precession sequence (short-axis stack 
covering the LV from base to apex, typical imaging parameters: TR: 3.4ms; TE: 
1.7ms; slice thickness: 10mm; phases per cardiac cycle: 35; FOV: 320x320mm). 
T1-weighted inversion-recovery imaging was performed to assess LGE 10 
minutes after the administration of 0.2 mmol/kg contrast medium (Dotarem; 
Guerbet, Gorinchem, The Netherlands) (typical imaging parameters: TR: 4.0ms; 
TE: 1.3ms; slice thickness: 5mm; FOV: 330x330mm; TI was based on TI scout).
Assessment of LV function and mass - Images were analyzed with commer-
cially available software (QMass 7.5, Medis, Leiden, The Netherlands) by two 
observers (FG and JB) unaware of the subjects’ clinical and biomarker infor-
mation. The endo- and epicardial borders of the LV myocardium were manually 
drawn in end-diastole and end-systole on the short-axis cine images. Volumes 
were derived by summation of discs, and ejection fraction was calculated 
accordingly. LV mass was calculated by subtraction of the endo- from epicar-
dial volume at end-diastole and multiplication by 1.05 g/cm3 and indexed to 
body surface area. LV maximal wall thickness at end-diastole was automatically 
69
CHAPTER 4  HIGH T2-WEIGHTED SIGNAL INTENSITY IN ASSOCIATION WITH ELEVATED TROPONIN T
measured per segment of the AHA-17-segment-model, except for the apex. 
Assessment of HighT2 and LGE - The presence of HighT2 and LGE was 
assessed after equally dividing the LV in basal, mid and apical slices. Then, all 17 
segments of the AHA-model were analyzed separately. HighT2 and LGE were 
scored visually per segment as either present or absent. In case of discrepancy 
between both observers on the presence of LGE or HighT2, a third observer 
(HD) reviewed the images for final adjudication. The extent of LGE was scored 
according to a semi-quantitative score and expressed as a percentage of LV 
mass filled with LGE.18 Areas visually identified as HighT2 were manually delin-
eated for determination of the extent of HighT2 as a percentage of the LV 
volume filled with HighT2. To be incorporated in the extent of HighT2, the signal 
intensity (SI) of visually identified areas of HighT2 had to be above the mean SI 
plus 2 standard deviations of remote non-thickened myocardium, as described 
previously.10
Assessment of troponin T
For the determination of cTnT the highly sensitive cTnT assay was used and 
performed on the Elecsys 2010 system (Roche Diagnostics, Almere, The Neth-
erlands).5 This test has a limit of blank of 3 ng/L, a 99th percentile cut-off point 
of 14 ng/L and a coefficient of variation of less than 10% at 13 ng/L. 
AIM OF THE STUDY
We sought to assess the association between HighT2 and an elevated hs-cTnT 
(>14 ng/L). In addition, we studied the association with a detectable hs-cTnT 
(>3 ng/L) and we explored the association between the extent of HighT2 and 
hs-cTnT as a continuous variable.
STATISTICAL ANALYSIS
Continuous variables are presented as means ± standard deviations or medians 
(interquartile ranges (IQR)). Comparisons between groups were made with 
use of the Student’s t or Mann-Whitney U tests, in case of two groups, or 
one-way ANOVA or Kruskal-Wallis, in case of three. Dichotomous variables 
were compared using a Chi-square or Fisher’s exact test, whichever appro-
priate. In case of missing values we did not use data imputation (99% of base-
line data was complete). In our primary analysis, we compared the propor-
tions of patients with an elevated hs-cTnT between patients with and without 
HighT2. As a secondary analysis, we compared the proportions of patients with 
a detectable hs-cTnT. Finally, Spearman’s rho was calculated to study the rela-
tion between the extent of HighT2 and the hs-cTnT concentration. To study the 
association between HighT2 and hs-cTnT, we followed the general approach to 
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adjust for (confounding) variables by multivariate logistic regression. First, we 
identified variables that differed (p<0.10) between patients with and without 
HighT2. The second step was to check for relevant confounding of each of 
these variables by separately adding these to HighT2 as independent variable. 
We defined relevant confounding as a ≥10% change of the regression coef-
ficient of the association between HighT2 and elevated hs-cTnT. Based upon 
previous reports in HCM on the association between LV mass and hs-cTnT, we 
planned to study the association between HighT2 and an elevated hs-cTnT, with 
specific focus on the relation with LV mass, and also in relation to LGE status.5,7,8 
A p-value of <0.05 was considered significant (two-sided). Statistical analysis 
was performed with IBM SPSS Statistics 20.0 (IBM Corp, Armonk, NY, USA).
RESULTS
STUDY POPULATION
Baseline clinical and imaging characteristics of the 101 included HCM patients 
are displayed in Table 1, of whom 28 patients (28%) had HighT2. LGE was signifi-
cantly more often present, and its extent was higher in patients with HighT2. A 
characteristic example of a patient with HighT2 is displayed in Figure 1. 
Legend: A characteristic example of a patient with HighT2. HighT2 was focally present in the left ventricle, 
at the insertion point of the right ventricle, with increased wall thickness and a larger area of  LGE on  
A T2-weighted and B LGE imaging. HighT2 High signal intensity on T2-weighted CMR imaging; LGE Late 
gadolinium enhancement.
FIGURE 1.  Example of a patient with HighT2, increased wall thickness and LGE 
A B
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TABLE 1. Baseline characteristics of HCM patients with and without HighT2
TOTAL
(N=101)
HIGHT2+
(N=28)
HIGHT2-
(N=73)
P-VALUE
Age (years) 54 ± 15 52 ± 15 55 ± 15 0.38
Men 54 (54) 19 (68) 35 (48) 0.07
Men Age at diagnosis (years) 47 ± 16 44 ± 15 49 ± 16 0.23
Pathogenic mutation present 55 (58) 14 (56) 41 (59) 0.82
Atrial fibrillation 16 (16) 5 (18) 11 (15) 0.77
CARDIOVASCULAR RISK
Hypertension 36 (36) 9 (32) 27 (37) 0.65
Current smoker 17 (17) 7 (25) 10 (14) 0.23
Dyslipidaemia 25 (25) 6 (21) 19 (26) 0.63
Diabetes 5 (5) 1 (4) 4 (6) 1.0
Recent creatinin (μmol/l) 84 ± 16 87 ± 17 82 ± 15 0.21
Systolic blood pressure (mmHg) 131 ± 22 131 ± 19 132 ± 23 0.86
Heart rate (beats/minute) 74 ± 13 79 ± 15 72 ± 12 0.01
Framingham 10-year heart risk (%) 12 (5-25) 15 (8-28) 12 (5-25) 0.68
RISK FACTORS FOR SCD
Aborted cardiac arrest / sustained VT - - - -
Family history of SCD 11 (11) 3 (11) 8 (11) 1.0
Syncope 5 (5) 2 (7) 3 (4) 0.62
Non-sustained VT (holter) 17 (18) 6 (24) 11 (16) 0.38
Abnormal BP response 12 (12) 7 (25) 5 (7) 0.04
Maximal wall thickness ≥30mm 3 (3) 1 (4) 2 (3) 1.0
SYMPTOMS
Chest pain 21 (21) 3 (11) 18 (25) 0.12
Dyspnoea (NYHA class ≥ II) 47 (47) 17 (61) 30 (41) 0.08
THERAPY
Beta-blocker 45 (45) 13 (46) 32 (44) 0.81
Calciumantagonist 16 (16) 3 (11) 13 (18) 0.55
ECHOCARDIOGRAPHY
LV outflow tract gradient at rest ≥30 mmHg 19 (19) 5 (18) 14 (19) 0.88
Systolic anterior motion mitral valve 36 (36) 11 (39) 25 (35) 0.67
Left atrial diameter (mm) 43 (39-49) 43 (40-54) 43 (39-48) 0.33
CMR IMAGING
Maximal LV wall thickness (mm) 18 (14-21) 21 (19-24) 16 (13-19) <0.001
LVMI (g/m2) 61 (52-83) 85 (63-116) 57 (50-73) <0.001
LVMI ≥ median 50 (50) 22 (79) 28 (39) <0.001
LV ejection fraction (%) 59 ± 7 55 ± 7 61 ± 6 <0.001
LGE present (n) 66 (65) 26 (93) 40 (55) <0.001
LGE extent (% of LV mass) 3 (0-10) 10 (4-19) 1 (0-7) <0.001
Data are presented as means ± standard deviations, medians (interquartile ranges) or numbers 
(percentages). BP Blood pressure; CMR Cardiovascular magnetic resonance; HighT2 High signal inten-
sity on T2-weighted CMR imaging; LGE Late gadolinium enhancement; LVMI LV mass indexed to body 
surface area; NYHA New York Heart Association; SCD Sudden cardiac death; VT Ventricular tachycardia.
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In 26 patients HighT2 was observed midwall within an area of LGE, in the other 
2 patients with HighT2 there were no segments with LGE. In 4 of these 26 
patients with co-localised HighT2 and LGE, HighT2 was also observed in a 
segment without LGE. Of all the 96 segments with HighT2 87 (91%) also demon-
strated LGE. Furthermore, segments with HighT2 had a higher wall thickness 
than segments without HighT2 (17 vs. 12mm, p<0.001). 
HIGHT2 AND HS-CTNT
Hs-cTnT was elevated in 54% (15/28) of patients with HighT2 and in 14% (10/73) 
of patients without HighT2 (p<0.001). Also, a detectable hs-cTnT was more 
often present in patients with HighT2 compared to those without (96% (27/28) 
vs. 66% (48/73), p=0.002). In the 26 patients without a detectable hs-cTnT, 
HighT2 was present in only one (4%) (Table 2). The median extent of HighT2 
comprised 1.2% (0.6%-2.9%) of the LV myocardial volume. The median hs-cTnT 
concentration increased according to the extent of HighT2; from 7 ng/L (3-12) 
in patients with no HighT2 to 23 ng/L (9-33) in patients with a HighT2 extent 
above the median (p<.001) (Figure 2). Lastly, the extent of HighT2 significantly 
correlated with the concentration of hs-cTnT (Spearman’s rho: 0.42, p<0.001).
Legend: The median hs-cTnT concentrations increased according to the extent of HighT2 (Spearman’s 
rho .42, p<0.001). Box and whiskers display median, IQR 10 and 90 th percentile. IQR interquartile range. 
HighT2 High signal intensity on T2-weighted cardiovascular MRI.
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FIGURE 2.  Troponin T concentrations according to extent of HighT2 
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TABLE 2.  Troponin T in HCM patients with and without HighT2
TOTAL
(N=101)
HIGHT2+ 
(N=28)
HIGHT2-
(N=73)
P-VALUE
PRIMARY OUTCOME
Hs-cTnT ≥14 ng/L 25 (25) 15 (54) 10 (14) <0.001
SECONDARY OUTCOMES
Hs-cTnT >3 ng/L 75 (74) 27 (96) 48 (66) 0.002
Hs-cTnT (ng/L) 8 (3-14) 15 (8-26) 7 (3-12) <0.001
Data are presented as medians (interquartile ranges) or numbers (percentages). HCM Hypertrophic 
cardiomyopathy; HighT2 High signal intensity on T2-weighted cardiovascular MRI; Hs-cTnT Highly sensitive 
cardiac troponin T.
HIGHT2 AND HS-CTNT: RELATION TO LV MASS AND THE PRESENCE 
OF LGE
HighT2 was univariately associated with an elevated hs-cTnT (odds ratio (OR): 
7.3; 95% CI: 2.7-19.7) (Table 3). Also LVMI, the presence and the extent of LGE 
were associated with an elevated hs-cTnT. 
LVMI - Of the 28 patients with HighT2 there were 22 (79%) with an LVMI ≥ 
the median. In patients with an LVMI ≥ the median (n=50), an elevated hs-cTnT 
was seen in 64% of patients with HighT2 (14/22) and 21% in patients without 
HighT2 (6/28) (p=.002). In patients with an LVMI < the median (n=50), an 
elevated hs-cTnT was seen in 1 out of 6 patients with HighT2 (17%) and in 4 out 
of 44 patients (9%) without HighT2 (p=.49). After correction for LVMI, HighT2 
remained associated with an elevated hs-cTnT (adjusted OR: 3.6; 95% CI: 1.2-11.1).
 
LGE - Of the 28 patients with HighT2, only 2 did not have LGE (7%) (hs-cTnT 
was 7 ng/L in both). Therefore, further analysis of the association between 
HighT2 and hs-cTnT among patients without LGE was not performed. Although 
in the total cohort (n=101) the extent of LGE was associated with an elevated 
hs-cTnT, this association was no longer observed in case only patients with LGE 
(n=66) were considered. Among the 66 patients with LGE, those with HighT2 
had an elevated hs-cTnT in 58% (15/26) compared to 18% of those without 
HighT2 (7/40) (p=0.001). In addition, the patients with both LGE and HighT2 
(n=26) also had the highest median hs-cTnT concentration (Table 4). 
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TABLE 3.  Logistic regression analysis for the association of HighT2 with an 
 elevated hs-cTnT
OR (95%CI) P-VALUE
UNIVARIATE
HighT2 7.3 (2.7-19.7) <0.001
aOR (95%CI) P-VALUE
ADJUSTED FOR LVMI
HighT2 3.6 (1.2-11.1) 0.025
Multivariable analyses revealed that other variables (sex, heart rate, dyspnoea, LV ejection fraction) had 
no relevant impact on the association between HighT2 and an elevated hs-cTnT. OR odds ratio; 95%CI 
95 percent confidence interval; aOR adjusted odds ratio; LVMI Left ventricular mass indexed to body 
surface area. 
TABLE 4.  Characteristics of HCM patients with and without LGE and/or 
 HighT2
LGE- 
& HIGHT2-
(N=33)
LGE+ 
& HIGHT2-
(N=40)
LGE+ 
& HIGHT2+
(N=26)
P-VALUE
Age (years) 56 ± 16 54 ± 15 51 ± 15 0.54
Men 12 (36) 23 (58) 18 (69) 0.03
CMR IMAGING
Maximal LV wall thickness (mm) 14 (13-16) 18 (15-21) 21 (19-24) <0.001
LVMI(g/m2) 52 (46-61) 62 (51-75) 85 (62-115) <0.001
LV ejection fraction (%) 62 ± 6 60 ± 7 55 ± 7 <0.001
LGE extent (% of LV mass) - 7 (3-10) 10 (6-21) <0.001
HIGHLY SENSITIVE CARDIAC TROPONIN T
Cardiac troponin T (ng/L) 6 (3-11) 8 (3-12) 15 (9-28) <0.001
Cardiac troponin T >3 ng/L 20 (61) 28 (70) 25 (96) 0.007
Cardiac troponin T ≥14 ng/L 3 (9) 7 (18) 15 (58) <0.001
Data are presented as means ± standard deviations, medians with interquartile ranges or numbers and 
percentages. BSA Body surface area; CMR Cardiovascular magnetic resonance; HCM Hypertrophic 
cardiomyopathy; HighT2 High signal intensity on T2-weighted cardiovascular MRI; LGE Late gadolinium 
enhancement; LV Left ventricle. 
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DISCUSSION
To our knowledge, this manuscript reports on the largest cohort of HCM 
patients, in which the association between HighT2 and an elevated hs-cTnT 
has been addressed so far. In this outpatient cohort of HCM patients, we have 
demonstrated that HighT2 was present in about one quarter of patients. In the 
presence of HighT2 the chances of an elevated hs-cTnT were threefold higher, 
and the concentration of hs-cTnT was significantly related with a higher extent 
of HighT2. Notably, in case of an undetectable hs-cTnT we observed a very high 
negative predictive value for HighT2 (>95%). These observations corroborate 
with the hypothesis that HighT2 in HCM may be indicative of recently sustained 
myocardial injury.
  Based upon the concept that myocardial injury is associated with adverse 
prognosis, the impact of troponin as well as of HighT2 have been addressed in 
clinical studies. Elevated hs-cTnT has been demonstrated in up to 50% of HCM 
patients, and has been related to adverse remodelling and prognosis in HCM.6,7 
HighT2 has been shown to be associated with malignant ventricular arrhyth-
mias.10,11,14 The present report is the first to demonstrate an association between 
HighT2 and hs-cTnT, independent of LVMI. Moreover, in patients with an unde-
tectable troponin concentration, chance of HighT2 is extremely low (<5%). As 
previously suggested by others,12,19,20 our results support that HighT2 is indeed 
indicative of recently sustained myocardial tissue injury in HCM. For the inter-
pretation of HighT2 contrasting theories have been postulated varying from 
myocardial injury due to ischemia,9,10,12 to regional myocardial differences in 
water content, and the suggestion that HighT2 merely reflects specific charac-
teristics of various collagen species.12,21,22 
Currently, the possible mechanisms involved in the appearance of HighT2 
at CMR imaging in HCM patients have not been thoroughly studied. Given the 
distinct differences in pathophysiology between myocarditis, myocardial infarc-
tion and HCM, the interpretation of HighT2 in areas of LGE may not be inter-
changeable, as it may not reflect the similar histological process.23,24 Whereas 
in myocardial infarction information on the evolution of the extent and co-exis-
tence of HighT2 and LGE is available, follow-up information on HighT2 in HCM 
is lacking. Importantly, patterns in myocardial infarction can be explained by 
a front of (transmural) ischemia that extends from areas near the endocar-
dium with HighT2 coinciding with LGE (i.e. necrotic tissue) to more epicardi-
ally located HighT2, outside the area of LGE as indicator of salvaged myocar-
dium. In HCM, however, the areas of ischemia are not defined by the territory 
of the supplying infarct related artery, and thus do not result in circumscript 
segments of jeopardized myocardium. In fact, the observed pattern of injury 
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in HCM is not endo- to epicardial, but is characterised by focal midwall areas 
of LGE containing HighT2. This may be related to the distinct difference in 
the aetiology of ischemia, with diffuse microvascular disease, myocyte disarray 
and sarcomere dysfunction. Interestingly, in areas of fibrosis there is histolog-
ical proof of viable cardiomyocytes.25 Although the interpretation of HighT2 in 
areas of LGE remains speculative, these cells could form the substrate respon-
sible for HighT2 in areas of LGE. Our finding that an elevated troponin is three 
times more likely in patients with than in patients without HighT2 could be 
the first clue to support this hypothesis, but requires confirmative studies and 
CMR-follow up.
In HCM, HighT2 and hs-cTnT may be indicative of the same, i.e. recently 
sustained myocardial injury, but it needs to be elucidated which mechanisms 
contribute to injury in HCM. One of the proposed causes of injury might be 
an increase in oxygen demand due to LV hypertrophy. This is supported by 
the fact that in both HCM patients and the general population, LV mass has 
been associated with hs-cTnT.5,26 Moreover, in previous studies on HighT2 in 
HCM it has consistently been reported that HighT2 was almost exclusively 
present in hypertrophic myocardium.9,14 Other causes of injury include small 
vessel disease, myocardial disarray and sarcomere dysfunction,27,28 which 
may account for insufficient myocardial perfusion, which has been related to 
areas of HighT2.10,13 Notably, in patients with an LVMI below the median, we 
still observed an elevated hs-cTnT in about 10% and HighT2 in 20% percent. 
In short, various mechanisms may contribute to active tissue injury in HCM, 
evident at some point in time as HighT2. This may finally result in evidence of a 
more chronic form of injury, visualized by LGE, which is present in the majority 
of HCM patients.9,12 Due to the crosssectional design of our study, this scenario 
remains hypothetical, and requires confirmation  in larger studies with sequen-
tial CMR imaging.
In analogy to previous reports, we observed that the presence of LGE was 
associated with hs-cTnT.7,8 This corroborates with the general concept that LGE 
is considered to represent fibrosis, i.e. advanced stage injury. Though not the 
primary aim of our study, our finding that patients with both LGE and HighT2 
had the highest hs-cTnT concentrations is interesting, and requires further 
study. Hypothetically, in HCM LGE with HighT2 might indicate active, ongoing 
tissue injury, as compared to a more burnt-out phase in which active injury is 
no longer present and LGE occurs without HighT2. This would imply a potential 
clinical use of HighT2 in HCM for assessment of the stage of LGE resembling the 
current use of HighT2 in patients with ischemic heart disease, in which HighT2 is 
able to discriminate acute from chronic myocardial infarction.23 Currently, LGE 
has been demonstrated to be associated with a detrimental disease course in 
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HCM, but does not effectively discriminate low and high risk patients, due to its 
high prevalence in HCM.29 Hypothetically, HighT2 may allow for better differen-
tiation of patients with LGE into higher and lower risk patients.
Finally, it should be appreciated that in the absence of HighT2, hs-cTnT 
was still detectable in two thirds and even elevated in about one eighth of the 
patients. One might speculate that hs-cTnT is more sensitive to injury and may 
serve as an early marker of active disease. 
In this study, we have provided supportive evidence for the assumption that 
HighT2 is representative of recently sustained myocyte injury in HCM patients. 
Additional insights may be provided by studies on the impact of exercise and by 
(CMR) follow-up studies. It has been suggested that exercise in HCM patients 
may result in (additional) ischemia with a troponin rise afterwards, which can 
be blunted or prevented with the use of beta-blockers.30 With CMR follow-up 
we would be able to study whether areas of HighT2 - as a marker of active 
tissue injury - may evolve into (larger) areas of ‘chronic injury’, as represented 
by (the extent of) LGE. A first indication of this concept has been described in 
8 HCM patients, which suggested that hs-cTnT is associated with an increase of 
LGE at CMR follow-up8. Given the association of LGE with adverse prognosis,29 
the next step would be to assess and compare the predictive value of HighT2 
to other (much easier) promising markers, such as hs-cTnT for adverse clinical 
events, in a study adequately powered for clinical outcome. 
LIMITATIONS
Although this is, as of yet, the largest HCM cohort with systematic T2-weighted 
CMR imaging, our results should be considered as pilot data. Both the assess-
ment of HighT2 and LGE are subject to interpretation. First, T2-weighted image 
interpretation is often quite challenging due to a limited signal-to-noise ratio 
and artefacts such as the slow flow phenomenon. Unfortunately at the start 
of our study T2- and T1-mapping sequences were not widely available, but 
these techniques seem very promising and may lead to more objective data. 
In analogy to previous studies in HCM, the presence of HighT2 was visually 
assessed by two independent observers (FG and JB).9,13 In 14 out of 101 patients 
(14%) a third observer was necessary (Cohen’s kappa: 0.61). Although ancillary 
SI analysis demonstrated that there was marked contrast in SI between areas, 
visually identified as HighT2, and normal non-thickened myocardium (data not 
shown), the interpretation of an area of high SI remains subjective with moderate 
inter-individual agreement. HighT2 was associated with an elevated hs-cTnT 
regardless of whether we used data on the presence of HighT2 of observer 1 or 
2. Lastly, LGE extent was assessed according to a validated semi-quantitative 
score, but quantitative analysis could have provided more detailed insights.18
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CONCLUSIONS
In this CMR study on an outpatient cohort of HCM patients, we observed 
HighT2 in a quarter of patients, and demonstrated that HighT2 was associated 
with a markedly higher risk of an elevated hs-cTnT. This observation, combined 
with the very high negative predictive value of an undetectable troponin for 
HighT2, provides supportive evidence for the hypothesis that HighT2 is indica-
tive of recently sustained myocyte injury. Confirmative studies are warranted, 
as well as additional research with regard to the potential future role of HighT2 
in HCM risk stratification and/or treatment.
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CHAPTER 5
EXERCISE-INDUCED RELEASE OF HIGHLY 
SENSITIVE CARDIAC TROPONIN T IN 
HYPERTROPHIC CARDIOMYOPATHY
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ABSTRACT
BACKGROUND
Highly sensitive cardiac troponin T (hs-cTnT) is elevated in 25-50% of hyper-
trophic cardiomyopathy (HCM) patients. High signal intensity on T2-weighted 
cardiovascular magnetic resonance (CMR) imaging (HighT2) is seen in about 
a third, and reflects an active state of disease with recently sustained myocar-
dial injury. In a controlled study, we assessed the incidence of post-exercise 
troponin rises in HCM, and evaluated its relation with clinical and imaging char-
acteristics.
METHODS
Subjects participated in a Dutch multicenter project on HCM. HCM patients 
(n=127) and mutation carriers without hypertrophy (n=53) performed a 
symptom limited bicycle test with hs-cTnT assessment pre- and 6-hours 
post-exercise. Baseline CMR imaging was performed in HCM patients (n=109) 
to assess: maximal wall thickness (MWT), LV mass, late gadolinium enhance-
ment (LGE) and HighT2. 
RESULTS
A troponin rise was detected in 18% (23/127) of HCM patients, and in 4% (2/53) 
of mutation carriers (p=0.011). HCM patients with a troponin rise had higher 
maximum heart rates (157±19 vs 143±23, p=0.004) and MWT (20 mm (IQR: 
15-23) vs 17 mm (IQR: 14-20), p=0.023). Median LV mass was 72 g/m2 (IQR: 
53-112) versus 61 g/m2 (IQR: 52-75) (p=0.112). HighT2 was seen in 65% (13/20) 
and 19% (15/79), respectively (p<0.001). HighT2 was the only independent 
predictor of a troponin rise. The latter was seen in 46% of patients with and 
10% of patients without HighT2 (OR 7.9; 95% CI 2.7-23.3; p<0.001).
CONCLUSIONS
A post-exercise troponin rise was seen in about 20% of HCM patients, almost 5 
times more frequent than in mutation carriers. Patients with HighT2 are partic-
ularly at risk, which suggests that episodes of high oxygen demand may induce 
additional injury especially in case of an active state of disease. 
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INTRODUCTION
From recent studies it has become evident that highly sensitive cardiac troponin 
(hs-cTn) is elevated in about 25-50% of patients with hypertrophic cardio-
myopathy (HCM).1-3 In analogy to other cardiac disorders, the first long-term 
follow-up data suggest that troponin is associated with adverse outcome in 
HCM.1 Little is known about the factors that contribute to troponin release in this 
particular group of patients. Troponin concentrations have been related to left 
ventricular (LV) mass and the presence of imaging signs of myocardial injury.2-5 
Importantly, it is widely appreciated that the hypertrophic phenotype in HCM is 
related to pathophysiological abnormalities in vasculature, myocardial structure 
and function,6-8 which may contribute to the occurrence of myocardial isch-
emia.9-11 Cardiac magnetic resonance (CMR) imaging studies have correlated 
areas of ischemia with segmental late gadolinium enhancement (LGE) and high 
signal intensity on T2-weighted imaging (HighT2).12-14 HighT2 has been demon-
strated to correlate strongly with troponin in HCM, and is considered to repre-
sent an active state of disease.4, 15 In the abovementioned context, episodes 
of high oxygen demand may pose a challenge and could result in additional 
myocardial injury. However, whereas studies in ischemic heart disease and even 
in healthy individuals have already studied post-exercise troponin release and 
contributing variables,16-19 data in HCM is limited.20, 21 With mutation carriers 
without hypertrophy as a control group, we aimed to assess and compare the 
proportion of HCM patients with a troponin rise after a symptom limited bicycle 
stress test. In follow-up on studies that addressed baseline troponin concentra-
tions and associated variables, we focused on clinical and CMR imaging vari-
ables that were associated with a post-exercise troponin rise.
MATERIALS AND METHODS
STUDY POPULATION
Subjects participated in a Dutch multicenter study on CMR imaging and 
biomarkers in HCM patients and mutation carriers without hypertrophy. 
Three specialized HCM outpatient clinics, i.e. the Albert Schweitzer Hospital, 
Dordrecht, the Erasmus Medical Centre, Rotterdam, and the Radboud Univer-
sity Medical Centre, Nijmegen, The Netherlands, collaborated in this project.4 
Two groups were identified: 1) clinical HCM patients, defined echocardiograph-
ically with a maximal wall thickness of ≥15 mm, or ≥13 mm in case of a proven 
sarcomeric gene mutation; and 2) carriers of a proven sarcomeric gene muta-
tion, without echocardiographic evidence of hypertrophy. Exclusion criteria 
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were cardiac hypertrophy with a known cause other than a sarcomeric gene 
mutation, a history of coronary artery disease (>50% stenosis), myocardial 
infarction, or stroke; a history of septal reduction therapy; a contraindication to 
perform exercise testing. The study complies with the Declaration of Helsinki, 
the protocol was approved by the local ethics committee, and all participants 
gave written informed consent.
STUDY PROTOCOL
At the day of the exercise test, New York Heart Association class, medication 
use, vital parameters, and a resting ECG were recorded and renal function was 
assessed prior to CMR imaging. Participants performed a bicycle exercise test, 
with blood samples drawn at baseline and 6-hours after stress testing. 
Bicycle exercise test - The exercise protocol prescribed an increase of exercise 
load every minute by 10 Watts. During exercise blood pressure, heart rate and 
electrocardiogram were recorded every 2 minutes. Participants were asked to 
continue intake of heart rate reducing medication until the day before the test. 
The test was symptom limited, or terminated in case the participant was no 
longer able to maintain a cycling frequency above 40rpm. In all other cases the 
test was continued until a workload of 30 Watts above the expected maximum. 
A symptom limited test was defined as the occurrence of any of the following 
during exercise: severe angina, abnormal blood pressure response, blood pres-
sure exceeding 250/130mmHg, onset of arrhythmias, ST-segment depression 
of more than 3mm in any lead, syncope during exertion.
Measurement of serum cardiac troponin T - After processing, serum samples 
were stored at –80°C until further analysis. For determination of cardiac 
troponin T the hs-cTnT assay was used (Roche Diagnostics). This test has a 
limit of blank of 3ng/L, a limit of detection of 5ng/L, and a 99th percentile 
upper reference limit of 14ng/L. The coefficient of variation is reported to be 
less than 10% at 13ng/L. A troponin rise was defined according to the level of 
imprecision. In case of a baseline troponin concentration <13ng/L an increase 
of at least 50% was required to qualify for a rise in troponin; for baseline values 
≥13ng/L a >20% increase was defined as a rise in troponin.
CMR imaging - CMR imaging studies were performed on a 1.5T MR imaging 
system (Philips Achieva, Philips Healthcare, Best, The Netherlands; or Siemens 
Avanto, Siemens Health Care, Erlangen, Germany) and analyzed according 
to a previously described protocol.4 In short, breath-hold triple inversion-re-
covery T2-weighted images with fat suppression were obtained to assess the 
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presence of oedema. Secondly, steady-state free precession cine imaging 
was used to quantify LV geometry. Finally, ten minutes after administration 
of 0.2 mmol/kg contrast medium (Dotarem; Guerbet, Gorinchem, The Neth-
erlands) the presence of LGE was assessed with T1-weighted inversion-re-
covery imaging. Images were analyzed offline with the use of Qmass software 
(Version 7.5; Medis, Leiden, The Netherlands) by two observers unaware of 
patient characteristics. LV mass was calculated by subtraction of endocardial 
from epicardial volume and multiplication by 1.05 g/cm3. LV mass was normal-
ized to body surface area; an increased LV mass was defined as >91 g/m2 for 
men, and >69 g/m2 for women.22 A per segment analysis was performed auto-
matically to assess LV maximal wall thickness at end diastole. According to 
the AHA-model, all 17 LV segments were visually analyzed by two observers 
(JB, FG) who assessed both the presence of HighT2 and LGE, independent of 
each other, and unaware of troponin results. In case of a discrepancy between 
observers a third reader independently re-evaluated all images for final adju-
dication (HD).
STATISTICAL ANALYSIS
Continuous variables were described as means ± standard deviations, or 
medians with interquartile ranges, whenever appropriate. Categorical vari-
ables were expressed as frequencies and percentages. To compare two inde-
pendent groups the Student’s t or the Mann Whitney U test for continuous 
variables, and Chi-square or Fisher exact test for dichotomous variables were 
used, respectively. The median difference between troponin concentrations 
pre- and post-exercise was tested with the Wilcoxon signed rank test. 
Clinical HCM patients with and without an exercise-induced troponin rise 
were compared. Variables associated with a troponin rise in univariable anal-
ysis (p-value <0.10) were subsequently tested in multivariable analyses to 
investigate their independent association with a troponin rise using logistic 
regression. P-values <0.05 indicated statistical significance. All analyses were 
performed using IBM SPSS22.
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RESULTS
PRE-EXERCISE CHARACTERISTICS
The final study population consisted of 180 of a total of 194 participants: in 
10 troponin test results were unavailable, 3 were unable to perform the exer-
cise test, and in 1 data of the exercise test was incomplete. In total, we studied 
127 clinical HCM patients, and 53 mutation carriers without hypertrophy. 
A mutation was identified in 66% of patients with a clinical HCM. In 81% of 
cases the mutation was located in the MYBPC3 gene; for mutation carriers 
without hypertrophy in 74%. Baseline characteristics are displayed in Table 1. 
HCM patients were older and more often male than mutation carriers, they 
more often reported symptoms (NYHA 1-2: 93%) and medication use. In HCM 
patients the interventricular septum (p<0.001) and posterior wall (p<0.001) 
were thicker, and the median left atrial diameter was larger compared to muta-
tion carriers (p<0.001).
BICYCLE EXERCISE TEST
Exercise parameters for the participants are depicted in Table 1. Clinical HCM 
patients were prescribed heart rate reducing medication in 53% of cases; in 
those with, mean resting heart rate was 72±11 beats/min versus 75±14 beats/
min in patients without (p=0.175). With respect to heart rates at maximum 
exercise the mean rate was 137±21 beats/min in patients with, and 155±21 beats/
min in those without these prescriptions (p<0.001). The absolute and relative 
loads achieved were lower in HCM patients as compared to mutation carriers 
(p<0.05). Accordingly, the duration of exercise was shorter, and more often 
HCM patients did not reach 80% of the expected load (p<0.01). Heart rates 
at maximum exercise were lower in HCM patients than in mutation carriers 
(p<0.001). They also had lower heart rate pressure products as compared to 
mutation carriers (p=0.04).
POST-EXERCISE TROPONIN RISE
The proportion of patients with a significant troponin rise after exercise was 
18% (23/127) in patients with HCM, compared to 4% (2/53) in mutation carriers 
without hypertrophy (p=0.011). The pre-exercise median troponin concentra-
tion was 8.3ng/L versus 9.9ng/L post-exercise (p<0.001). In HCM patients 
pre-exercise levels ≥14ng/L occurred in 24%, whereas post-exercise it was 32% 
(Table 2). Among mutation carriers without hypertrophy there were no individ-
uals with a hs-cTnT ≥14ng/L, neither before nor after exercise. 
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TABLE 1. Baseline characteristics of clinical HCM patients and mutation 
 carriers without left ventricular hypertrophy
CLINICAL 
HCM
(N=127)
MUTATION 
CARRIERS
(N=53)
P-VALUE
Age (years) 53±14 41±11 <0.001
Men 76 (60) 20 (38) 0.007
Hypertension 44 (35) 4 (8) <0.001
Implantable cardiac defibrillator 10 (8) 0 (0) 0.04
History of atrial fibrillation 20 (16) 0 (0) 0.002
NYHA functional class ≥ 2, n (%) 56 (44) 1 (2) <0.001
Body mass index (kg/m2) 26±3 25±4 0.05
MEDICATION
Beta-blocker 59 (47) 2 (4) <0.001
Calcium channel blocker 17 (13) 0 (0) 0.005
EXERCISE STRESS TEST
Resting heart rate (beats/min) 74±13 75±11 0.553
Resting systolic blood pressure (mmHg) 129±21 118±16 0.001
Heart rate at maximum exercise (beats/min) 145±23 164±17 <0.001
Maximum systolic blood pressure (mmHg) 180±32 172±29 0.14
Achieved exercise load (Watts) 140 (120-180) 160 (130-190) 0.02
Relative achieved exercise load (%) 89 (74-107) 100 (89-112) 0.005
Achieved load <80% of expected 45 (35) 8 (15) 0.006
HRPP (mmHg*beats per minute) 26178±6099 28214±5578 0.04
ECHOCARDIOGRAPHY
Interventricular septum thickness (mm) 16 (13-20) 10 (8-11) <0.001
Posterior wall thickness (mm) 10 (10-12) 9 (7-9) <0.001
Left atrial diameter (mm) 43 (39-49) 38 (32-40) <0.001
LVOT gradient ≥30mmHg 18 (14) 0 (0) 0.01
Continuous variables are described as means ± standard deviations or medians with interquartile 
ranges. HCM hypertrophic cardiomyopathy; NYHA New York Heart Association; HRPP Heart Rate Pressure 
Product; LVOT Left ventricular outflow tract.
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TABLE 2. Highly sensitive cardiac troponin T results in clinical HCM patients 
 and mutation carriers without left ventricular hypertrophy
CLINICAL 
HCM
(N=127)
MUTATION CARRIERS
(N=53)
P-VALUE
HIGHLY SENSITIVE CARDIAC TROPONIN T (NG/L)
Before exercise 8.3 (3.4-13.9) 3.0 (3.0-3.0) <0.001
6-hours after exercise 9.9 (4.3-16.7) 3.0 (3.0-3.0) <0.001
ELEVATED TROPONIN (≥14 NG/L)
Before exercise 31 (24) 0 (0) <0.001
6-hours after exercise 40 (32) 0 (0) <0.001
Exercise-induced cardiac troponin rise 23 (18) 2 (4) 0.01
Continuous variables are described as medians with interquartile ranges. HCM hypertrophic cardiomy-
opathy.
CONTRIBUTORS TO POST-EXERCISE TROPONIN RISE IN HCM 
Clinical and imaging characteristics associated with a troponin rise are depicted 
in Table 3. HCM patients with a post-exercise troponin rise had higher pre-ex-
ercise heart rates (p=0.031), higher maximum heart rates (p=0.004), and the 
percentage of patients with a pre-exercise troponin level ≥14ng/L tended to 
be higher than observed in patients without a rise (p=0.069). In 109 of the 127 
HCM patients CMR imaging was performed (Table 3). Median MWT was 20 mm 
(15-23 mm) in patients with a rise, and 17mm (14-20 mm) without (p=0.023). 
The difference in LV mass was not significant (72 g/m2 (53-112 g/m2) versus 61 
g/m2 (52-75 g/m2); p=0.112). Troponin rises are depicted according to tertiles 
of MWT and LV mass in Figure 1. The presence of LGE was confirmed in 85% 
(17/20) of patients with a rise and in 57% (51/89) without (p=0.021). HighT2 was 
seen in 65% (13/20) and 19% (15/79) (p<0.001), respectively. Of the 28 patients 
with evidence of HighT2, a post-exercise troponin rise was seen in 46% (13/28), 
which was more than 4 times more often than in patients without these signals 
(7/71). In multivariable logistic regression analysis only the presence of HighT2 
was independently associated with a post-exercise troponin rise (OR 7.9; 95% 
CI 2.7-23.3; p<0.001). 
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TABLE 3.  Baseline characteristics according to presence or absence of 
 post-exercise troponin rise
CLINICAL HCM WITH
TROPONIN RISE
(N=23)
CLINICAL HCM WITH- 
OUT TROPONIN RISE
(N=104)
P-VALUE
Age (years) 51±15 54±14 0.405
Male 14 (61) 62 (60) 0.912
Hypertension 7 (30) 37 (36) 0.639
NYHA functional class ≥ II2 12 (52) 44 (42) 0.388
Body mass index (kg/m2) 26±4 26±3 0.728
MEDICATION
Beta-blocker 8 (35) 51 (49) 0.215
Calcium channel blocker 2 (9) 15 (14) 0.736
EXERCISE STRESS TEST
Resting heart rate (beats/min) 79±15 73±12 0.031
Heart rate at maximum exercise (beats/min) 157±19 143±23 0.004
Resting systolic blood pressure (mmHg) 128±18 129±22 0.86
Maximum systolic blood pressure (mmHg) 179±30 180±32 0.959
Achieved exercise load (Watts) 170 (120-200) 140 (113-178) 0.125
Relative achieved exercise load (%) 93±20 90±21 0.579
Achieved load <80% of expected 7 (30) 38 (37) 0.580
Duration of exercise (minutes) 15 (10-18) 13 (8-17) 0.223
HRPP (mmHg*beats per minute) 28119±4889 25740±6278 0.091
CMR IMAGING (N= 109)
LV mass indexed by BSA (g/m2) 72 (53-112) 61 (52-75) 0.112
Increased LV mass 7 (35) 16 (18) 0.127
Maximal wall thickness (mm) 20 (15-23) 17 (14-20) 0.023
Presence of LGE 17 (85) 51 (57) 0.021
Presence of HighT2 13 (65) 15 (19) <0.001
HIGHLY SENSITIVE CARDIAC TROPONIN T CONCENTRATION
Before exercise (ng/l) 8.8 (4.8-19.9) 8.2 (3.3-13.1) 0.195
6-hours after exercise (ng/l) 17.1 (8.6-24.9) 9.2 (3.2-14.2) <0.001
ELEVATED TROPONIN (≥14 NG/L)
Before exercise 9 (39) 22 (21) 0.069
6-hours after exercise 14 (61) 26 (25) 0.001
Continuous variables are described as means ± standard deviations or medians with interquartile 
ranges. HCM hypertrophic cardiomyopathy; NYHA New York Heart Association; HRPP heart rate pressure 
product; CMR Cardiac magnetic resonance; LV Left ventricular; BSA Body surface area; LGE Late gado-
linium enhancement; HighT2 High signal intensity on T2-weighted imaging.
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Legend: Top panel: Percentages of clinical HCM patients with a pre-exercise elevated and a post-exer-
cise rise in cardiac troponin T according to tertiles of maximal wall thickness; *p-value across tertiles 0.007, 
**p-value across tertiles 0.018.
Bottom panel: Percentages of clinical HCM patients with a pre-exercise elevated and a post-exercise 
rise in cardiac troponin T according to tertiles of left ventricular mass; *p-value across tertiles <0.001, 
**p-value across tertiles 0.165. BSA Body surface area.
FIGURE 1.  Percentages of clinical HCM patients with a pre-exercise elevated 
 hs-cTnT concentration and a post-exercise troponin rise according 
 to tertiles of maximal wall thickness or left ventricular mass
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DISCUSSION
To our knowledge we are the first to report on a prospective, controlled study 
that describes the frequent occurrence of exercise related troponin release 
in HCM, and to provide more detailed insight into potential mechanisms of 
myocardial injury in this setting, supported by CMR imaging. We demon-
strated a post-exercise troponin rise in about 20% of patients, almost five-
fold more frequent than in mutation carriers. Notably, this difference was 
observed despite the relatively lower exercise intensities achieved by clinical 
HCM patients. 
The observed univariable associations with maximal wall thickness and 
heart rate are in line with the concept that a mismatch in oxygen demand and 
supply contributes to new injury. Intriguingly, the only independent association 
with a post-exercise troponin rise was observed for HighT2 at CMR imaging. 
This suggests that a pre-existing active state of disease, with imaging signs of 
oedema, reflects a condition prone for additional myocardial injury in situa-
tions of high oxygen demand. In summary, our findings give rise to the hypoth-
esis that repetitive episodes of high oxygen demand may result in ‘bouts’ of 
troponin release, and that CMR imaging may identify the particularly vulner-
able patients. 
TROPONIN RELEASE IN HCM
With regard to troponin status under resting conditions, various mechanisms 
have been implicated to explain detectable concentrations in different sets 
of populations. Whereas in HCM some of these mechanisms may be disease 
specific, there will also be overlap with other patient populations, and even 
with healthy individuals.23-25 In the community dwelling population, there was a 
clear association between LV mass and the observed baseline hs-cTnT concen-
tration.23 Also in HCM there is an association between measures of LV hyper-
trophy and baseline cTnT.4 In HCM, however, cardiac hypertrophy is character-
ized by impaired myocardial structure and function, with myocyte disarray and 
inefficient energy utilization. In addition, perfusion abnormalities and impaired 
microvascular function are also part of the clinical picture. These characteris-
tics are additional conditions that may contribute to troponin release, which 
may become especially apparent in situations of high oxygen demand, such 
as exercise. Appreciating that post-exercise troponin rises are also observed in 
healthy individuals,19 a group of mutation carriers without hypertrophy served 
as a reference. Exercise intensity was markedly higher in the group of mutation 
carriers, and is a well-known determinant of post-exercise troponin in healthy 
individuals.19 Despite this difference, we observed a fivefold higher rate of post 
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exercise troponin rises in the patients with HCM, which suggests that HCM 
specific pathophysiology largely contributes to the observed difference.21
IMAGING STUDIES IN HCM
The key mechanism that has been studied in HCM is ischemia. Both at resting 
conditions and during stress, hypoperfusion has been demonstrated.12-14 This 
was especially observed in areas of hypertrophy. However, mismatch between 
supply and demand may also occur in other myocardial areas. Interestingly, 
a previous study addressed the issue of inefficient energy utilization in HCM 
and demonstrated that exercise worsened the energy deficit in these patients, 
independent of hypertrophy and fibrosis.26 This aspect may have contributed 
to the troponin rises in patients with only moderate hypertrophy, and may 
explain why release after exercise is not confined to patients with the highest 
LV mass and/or wall thickness.
Our current findings that in the HCM patients heart rate and maximal wall 
thickness were clearly associated with a troponin rise fit in the abovementioned 
context. Under resting conditions, we have demonstrated a strong associa-
tion between HighT2 and baseline hs-cTnT.4 In fact, the absence of a detect-
able baseline hs-cTnT had a very high (>95%) negative predictive value for 
HighT2.4 As for a post-exercise troponin rise, the only independent association 
was observed for the presence of HighT2 at CMR imaging. Appreciating that 
the CMR was performed prior to the bicycle test, supports the concept that 
patients with signs of oedema respresent a group with active disease, vulner-
able to new injury. In fact, it has been suggested that based on CMR findings 
different disease stages might be differentiated. On the one hand, patients with 
signs of oedema have been reported to express more ischemic symptoms, and 
have a more patchy fibrosis pattern at CMR. On the other hand, in patients 
without oedema, and more expanded fibrosis more often had reduced LV func-
tion and a more chronic stage of disease.13 Our findings provide additional infor-
mation into the potential role of CMR to differentiate different disease states. As 
of yet, more follow-up data is needed to assess whether patients with HighT2 
and signs of new exercise related injury might be prone to progression of 
disease, in terms of extension of LGE or deterioration of LV function.
IMPLICATIONS
As of yet, little information is available on the impact of exercise in HCM 
patients,27-31 and our report describes important first-time findings. Whereas 
the majority of HCM patients did not show a troponin rise after exercise, the 
presence of HighT2 seems to indicate a subgroup with an active disease state 
prone to additional myocardial injury after exercise. Given the various reports 
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on the adverse impact of troponin in other types of cardiac disease, and the 
first follow-up data in HCM on this subject, it may be possible that this specific 
group is at risk for disease progression.1 Additional follow-up studies on this 
subject are warranted. 
As far as potential interventions are concerned, we previously reported in a 
pilot study on patients with HCM that post-exercise release of troponin could 
be blunted with the use of a beta-blocker.20 In analogy, a large study in patients 
with atrial fibrillation showed that reducing heart rate (at rest) significantly 
lowered hs-cTnT concentrations.32 Finally, measurement of exercise-induced 
release of troponin is tangible and reproducible. Therefore, if troponin (rise) 
is indeed associated with adverse outcome, bicycle tests may become part of 
risk stratification, and individualized treatment aiming at reducing heart rate. 
LIMITATIONS
Although this is the largest prospective, controlled study addressing the impact 
of exercise on troponin release in HCM, our cohort is not sufficiently sized to 
allow for adequately powered subgroup comparisons, and we may have missed 
other variables associated with a post exercise troponin rise. Secondly, as HCM 
patients were selected from an outpatient clinic excluding those with a device, 
a history of cardiovascular disease and/or septal reduction therapy, findings 
cannot be generalized to the entire HCM population. 
In retrospect, a CMR imaging protocol including adenosine testing might 
have provided additional insights. With regard to the timing of blood samples 
6 hours post-exercise may be rather late. This was based on release patterns 
known at the time of study design from the conventional troponin assay in 
patients with coronary artery disease.
CONCLUSION
In patients with HCM, a post-exercise troponin rise is observed in about 20%, 
almost five times more frequent than in mutation carriers without hypertrophy. 
Maximal wall thickness and heart rate were associated with the occurrence 
of a rise, but the only independent association was found for the presence of 
HighT2 prior to exercise. These findings give rise to the hypothesis that, espe-
cially in case of an active disease state, episodes of high oxygen demand may 
elicit additional myocardial injury.
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CHAPTER 6
HIGH T2-WEIGHTED SIGNAL 
INTENSITY FOR RISK PREDICTION OF 
SUDDEN CARDIAC DEATH IN 
HYPERTROPHIC CARDIOMYOPATHY 
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ABSTRACT
In search of improved risk stratification in hypertrophic cardiomyopathy (HCM), 
CMR imaging has been implicated as a potential tool for prediction of sudden 
cardiac death (SCD). In follow-up of the promising results with extensive late 
gadolinium enhancement (LGE), high signal-intensity on T2-weighted imaging 
(HighT2) has become subject of interest given its association with markers 
of adverse disease progression, such as LGE, elevated troponin and non-sus-
tained ventricular tachycardia. In lack of follow-up cohorts, we initiated an 
exploratory study on the association between HighT2 and the internationally 
defined risk categories of SCD. 
In a cohort of 109 HCM patients from a multicenter study on CMR imaging 
and biomarkers, we estimated the 5-year SCD risk (HCM Risk-SCD model). 
Patients were categorized as low (<4%), intermediate (≥4-<6%) or high (≥6%) 
risk. In addition, risk categorization according to the ACC/AHA guidelines was 
performed. 
HighT2 was present in 27% (29/109). Patients with HighT2 were more often 
at an intermediate-high risk of SCD according to the European (28% vs. 10%, 
p=0.032) and American guidelines (41% vs. 18%, p=0.010) compared to those 
without HighT2. The estimated 5-year SCD risk of our cohort was 1.9% (IQR: 
1.3-2.9%), and projected SCD rates were higher in patients with than without 
HighT2 (2.8% vs. 1.8%, p=0.002).
In conclusion, HCM patients with HighT2 were more likely to be intermedi-
ate-high risk, with projected SCD rates that were 1.5 fold higher than in patients 
without HighT2. These pilot findings call for corroborative studies with more 
intermediate-high risk HCM patients and clinical follow-up to assess whether 
HighT2 may have additional value to current risk stratification. 
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most common inheritable cardio-
myopathy and the most frequent cause of sudden cardiac death (SCD) among 
young athletes.1-3 Unfortunately, identification of patients at risk of SCD remains 
challenging and new risk stratifiers such as biomarkers and imaging parame-
ters are under investigation.4-8 In this context, cardiovascular magnetic reso-
nance (CMR) imaging is increasingly used for assessment of the extent of late 
gadolinium enhancement (LGE), as an indicator of fibrotic burden.6,9,10 Another 
imaging feature with potential impact could be high signal intensity using 
T2-weighted CMR imaging (HighT2). This is based on the reported associations 
with markers of adverse disease progression, such as LGE, elevated troponin, 
and non-sustained ventricular tachycardia.5,6,11-13 Whereas LGE is observed 
in about 60-70% of patients, HighT2 is observed in about one-third of HCM 
patients. Notably, areas of HighT2 are almost exclusively present in patients 
with LGE, occurring within the boundaries of LGE.13-20 Appreciating that the 
prevalence of intermediate-high risk HCM patients is rather low, these specific 
characteristics of HighT2 may allow for refined stratification. In addition, we 
have recently reported an independent association with an elevated level of 
cardiac troponin T, which supports that HighT2 is likely indicative of recently 
sustained myocyte injury.20 In view of this, HighT2 may identify patients with 
a more active disease state, who might be vulnerable to adverse disease 
progression. The additional observations that HighT2 was associated with 
non-sustained ventricular tachycardia (NSVT) raised the question whether 
HighT2 might be a valuable predictor of adverse events, SCD in particular.14,16,18 
Importantly, studies with clinical follow-up on HighT2 are lacking. Therefore, 
we sought to provide the first pilot data on the association of HighT2 with the 
current SCD risk categorizations according to the ESC and ACC/AHA guide-
lines. We assessed the proportion of intermediate to high risk patients in rela-
tion to the presence or absence of HighT2. In addition, we performed an explor-
atory analysis on HighT2 and the associated projected SCD rates determined 
with use of the HCM Risk-SCD model, to provide insight into potential clinical 
implications.21
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METHODS
STUDY POPULATION
For the present analysis, we studied a series of HCM patients who under-
went T2-weighted CMR imaging, as participants of a Dutch multicentre HCM 
study project.20 In short, enrolment took place between 2008 and 2014 at 
different outpatient clinics that perform mutation screening, repeated echo-
cardiography, CMR imaging and clinical follow-up on a routine basis. Patients 
had to fulfil the diagnostic criteria for HCM according to the prevailing guide-
lines, which were assessed by a careful case-by-case chart review, especially in 
those with a history of hypertension.1,2,22 Patients with known coronary disease 
or stroke, a history of out-of-hospital cardiac arrest, aortic stenosis, previous 
septal reduction therapy, renal impairment (MDRD <30ml/min) or a contraindi-
cation for CMR imaging were excluded. The study complies with the Declara-
tion of Helsinki and the protocol was approved by the local ethical committees 
and conducted accordingly. All participants provided written informed consent.
CARDIOVASCULAR MAGNETIC RESONANCE IMAGE ACQUISITION 
AND ANALYSIS
CMR imaging was performed on a 1.5T CMR system (Philips Achieva - Philips 
HealthCare, Best, The Netherlands or Siemens Avanto - Siemens Health 
Care, Erlangen, Germany) according to local imaging protocols, as previously 
described in more detail.20 All images were acquired with ECG-gating and 
during repeated breath-holds of 10-15 seconds. To assess the presence 
of HighT2, breath-hold triple inversion-recovery T2-weighted images with 
fat-saturation were acquired (short-axis stack covering the left ventricle (LV) 
from base to apex). A long-axis image was obtained to exclude artefacts. For 
the assessment of LV function and mass, cine imaging was performed using a 
steady-state free precession sequence (short-axis stack covering the LV from 
base to apex). Segmented inversion-recovery imaging was performed to assess 
late gadolinium enhancement (LGE) 10 minutes after the administration of 0.2 
mmol/kg contrast medium (Dotarem; Guerbet, Gorinchem, The Netherlands). 
Images were analysed with commercially available software (QMass 7.5, 
Medis, Leiden, The Netherlands) by two observers (FG and JB) unaware of the 
subjects’ clinical information. All 17 segments of the AHA-model were analysed 
for the presence of HighT2 and LGE. HighT2 and LGE were scored visually per 
segment as either present or absent.15,17 In case of discrepancy between both 
observers on the presence of LGE or HighT2, a third observer (HD) reviewed the 
images for final adjudication. The observers were blinded for LGE data when 
analysing T2-weighted images. The extent of LGE was determined according 
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to a semi-quantitative score.23 LV volumes, mass and ejection fraction were 
assessed using a standard protocol, as previously described.24,25 
ASSESSMENT OF SUDDEN CARDIAC DEATH RISK
For all participants, the following risk factors were recorded at the day of 
CMR imaging: age at evaluation; family history of SCD; history of unexplained 
syncope; NSVT on 24-hour Holter monitoring; maximal LV wall thickness, LV 
outflow tract obstruction gradient (either resting or provocable gradient) and 
left atrial diameter measured using echocardiography; abnormal blood pres-
sure response during exercise. Missing data was ˞1%. For a detailed description 
and analysis of the risk factors, we refer to the appendix. 
Our primary objective was to study the association between HighT2 and 
the categorisation into low, intermediate or high risk of SCD according to the 
ESC and ACC/AHA guidelines.1,2 For the former, the HCM Risk-SCD calculator 
was used for estimation of the 5-year SCD risk, available at http://doc2do.
com/hcm/webHCM.html. An intermediate risk was defined as an estimated 
5-year SCD risk of ≥4-<6% and a high risk as ≥6%.1,26 According to the ACC/
AHA guidelines, patients were considered high risk in case of a family history 
of SCD, a history of unexplained syncope or extreme LV hypertrophy. In case 
of an abnormal blood pressure during exercise or NSVT on 24-hour Holter 
monitoring, patients were recorded as intermediate or low risk depending on 
whether a risk modifier was present or not. Risk modifiers were a LV outflow 
tract gradient ≥30mmHg or extensive LGE (≥15% of LV mass). Our secondary 
outcome measure was the estimated 5-year SCD risk as a continuous variable. 
STATISTICAL ANALYSIS
Continuous variables are presented as means ± standard deviations or medians 
(interquartile ranges (IQR)), and were compared between patients with and 
without HighT2 using a Student’s t or Mann-Whitney U test, whichever appro-
priate. Dichotomous variables were compared using a Chi-square or Fisher exact 
test, whichever appropriate. Given the previously reported co-localisation of 
HighT2 with LGE,20 we also compared SCD risk in relation to LGE status, using 
a Kruskall-Wallis and Chi-square test. A p-value of <.05 was considered statis-
tically significant. Statistical analysis was performed with IBM SPSS Statistics 
20.0 (IBM Corp, Armonk, NY, USA).
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RESULTS 
STUDY POPULATION
The present study population comprised of 109 HCM patients (56% male, age 
54±15 years), of whom the majority has previously been described.20 Fifty-
nine (58%) carried a pathogenic sarcomere mutation and atrial fibrillation was 
present in 18 (17%) patients (Table 1). Most patients were a- or mildly symptom-
atic with 105 (96%) patients in NYHA class I-II.
TABLE 1.  Baseline characteristics of HCM patients with and without HighT2
TOTAL
(N=109)
HIGHT2 
PRESENT
(N=29)
HIGHT2 
ABSENT
(N=80)
P-VALUE
Age (years) 54 ± 15 52 ± 14 55 ± 15 0.29
Men 61 (56) 20 (69) 41 (51) 0.10
Age at diagnosis (years) 47 ± 16 44 ± 15 49 ± 16 0.20
Pathogenic mutation present 59 (58) 15 (58) 44 (58) 0.99
Atrial fibrillation 18 (17) 5 (17) 13 (16) 1.0
Hypertension 40 (37) 9 (31) 31 (39) 0.46
SYMPTOMS
Chest pain 21 (19) 3 (10) 18 (23) 0.16
Dyspnoea (NYHA class ≥ II) 49 (45) 17 (59) 32 (40) 0.08
THERAPY
Beta-blocker 51 (47) 13 (45) 38 (48) 0.81
Calciumantagonist 16 (15) 3 (10) 13 (16) 0.55
Troponin T concentration (ng/L) 8 (3-14) 15 (8-25) 7 (3-12) <0.001
CMR IMAGING
LVMI (g/m2) 62 (52-87) 85 (63-116) 59 (51-74) <0.001
LV ejection fraction (%) 59 ± 7 55 ± 7 61 ± 6 <0.001
LGE present (n) 68 (65) 26 (93) 42 (55) <0.001
LGE extent (% of LV mass) 3 (0-10) 10 (4-19) 1 (0-7) <0.001
Data are presented as means ± standard deviations, medians (interquartile ranges) or numbers 
(percentages). HighT2 High signal intensity on T2-weighted imaging; NYHA New York Heart association; 
CMR Cardiovascular magnetic resonance; LVMI LV mass indexed to body surface area; LGE Late gado-
linium enhancement.
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Twenty-nine out of 109 (27%) were positive for HighT2. HighT2 was mostly 
observed midwall and co-localized within an area of LGE in hypertrophic 
segments, as previously described in more detail (Figure 1).20 In patients with 
HighT2, the median number of segments with HighT2 was 3 (IQR: 2-4).
Patients with HighT2 tended to be more dyspnoeic and had a higher LV mass 
indexed to body surface area and a lower LV ejection fraction. Furthermore, 
cardiac troponin T concentrations were higher in patients with than without 
HighT2. The proportion of patients with LGE and the extent of LGE were also 
higher in the former group (Table 1).
HIGHT2 AND RISK OF SUDDEN CARDIAC DEATH
Patients with HighT2 were more often at an intermediate-high SCD risk 
according to the ESC guidelines (28% vs. 10%, p=0.032) and ACC/AHA guide-
lines (41% vs. 18%, p=0.010) (Table 2 and Figure 2). Projected mortality rates 
were higher in patients with HighT2, with a median estimated 5-year SCD risk 
of 2.8% vs. 1.8% for patients without HighT2 (p=0.002). The analysis on HighT2 
combined with LGE status, demonstrated the lowest SCD risk in HCM patients 
without LGE and without HighT2. Moreover, in patients with LGE those with 
HighT2 had the highest SCD risk (Table 3). 
Legend: HighT2 was mostly demonstrated as a focal area in the hypertrophic anteroseptal wall at the inser-
tion point of the right ventricle, as displayed here.
FIGURE 1.  An imaging example of a HCM patient with HighT2
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TABLE 2.  SCD risk profile in HCM patients with or without HighT2
TOTAL
(N=109)
HIGHT2
PRESENT 
(N=29)
HIGHT2 
ABSENT
(N=80)
P-VALUE
RISK CATEGORY
ESC: Intermediate-high SCD risk 16 (15) 8 (28) 8 (10) 0.032
ACC/AHA: Intermediate-high SCD risk 26 (24) 12 (41) 14 (18) 0.010
QUANTITATIVE SCD RISK
Estimated 5-year risk (%) 1.9 (1.3-2.9) 2.8 (1.6-4.3) 1.8 (1.2-2.6) 0.002
Data are presented as numbers (percentages) or medians (interquartile ranges). HighT2 High signal 
intensity on T2-weighted imaging; SCD sudden cardiac death.
HighT2+ HighT2-
0
20
40
60
80
100
P
e
rc
e
n
ta
g
e
 o
f 
H
C
M
 p
a
ti
e
n
ts
ESC  Guidelines
HighT2+ HighT2-
0
20
40
60
80
100
ACC/AHA  Guidelines
Low SCD RiskIntermediate SCD RiskHigh SCD Risk
Legend: Left. According to the ESC guidelines, patients with HighT2 were more often at intermediate to 
high risk: 28% (8/29) vs. 10% (8/80), p=0.032. Of the 29 patients with HighT2, there were 21 at low risk of SCD; 
6 and 2 were at intermediate and high risk, respectively. Of the 80 patients without HighT2, there were 72 
at low risk of SCD; 5 and 3 were at intermediate and high risk, respectively. 
Right. According to the ACC/AHA guidelines, patients with HighT2 were more often at intermediate to high 
risk: 41% (12/29) vs. 18% (14/80), p=0.010. Of the 29 patients with HighT2, there were 17 at low risk of SCD; 6 and 
6 were at intermediate and high risk, respectively. Of the 80 patients without HighT2, there were 66 at low risk 
of SCD; 2 and 12 were at intermediate and high risk, respectively. SCD Sudden cardiac death.
FIGURE 2.  Risk categorization according to the ESC and ACC/AHA 
 guidelines, stratified by the presence of HighT2 
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TABLE 3.  SCD risk profile in HCM patients with or without HighT2/LGE
LGE- 
& HIGHT2-
(N=35)
LGE+ 
& HIGHT2-
(N=42)
LGE+ 
& HIGHT2+
(N=26)
P-VALUE
RISK CATEGORY
ESC: Intermediate-high SCD risk 1 (3) 7 (17) 8 (31) 0.012
ACC/AHA: Intermediate-high SCD risk 5 (17) 9 (21) 22 (42) 0.035
QUANTITATIVE SCD RISK
Estimated 5-year risk (%) 1.5 (1.1-1.9) 2.3 (1.4-3.0) 2.9 91.6-4.3) <0.001
Data are presented as numbers (percentages) or medians (interquartile ranges). LGE Late gadolinium 
enhancement; HighT2 High signal intensity on T2-weighted imaging; SCD sudden cardiac death.
 TABLE 4.  Individual risk factors and risk modifiers in HCM patients with or 
 without HighT2
TOTAL
(N=109)
HIGHT2
PRESENT 
(N=29)
HIGHT2 
ABSENT
(N=80)
P-VALUE
BINARY RISK FACTORS
Family history of SCD 12 (11) 4 (14) 8 (10) 0.73
Syncope 5 (5) 2 (7) 3 (4) 0.61
Non-sustained VT 17 (16) 6 (21) 11 (14) 0.38
Abnormal BP response 13 (12) 7 (24) 6 (8) 0.04
Extreme LV hypertrophy 3 (3) 1 (3) 2 (3) 1.0
CONTINUOUS RISK FACTORS
Age (years) 54 ± 15 52 ± 14 55 ± 15 0.29
Maximal wall thickness (mm) 17 (14-20) 19 (17-23) 16 (13-20) <0.001
Left atrial diameter (mm) 43 (39-50) 43 (40-54) 43 (39-48) 0.26
LV outflow tract gradient (mmHg) 8 (6-23) 8 (5-21) 8 (6-25) 0.74
RISK MODIFIERS
LV outflow tract gradient ≥30mmHg 21 (19) 5 (17) 16 (20) 0.75
Extensive LGE (≥15% of LV mass) 10 (9) 8 (28) 2 (3) <0.001
Data are presented as means ± standard deviations, medians (interquartile ranges) or numbers 
(percentages). HighT2 High signal intensity on T2-weighted imaging; SCD Sudden cardiac death; VT 
Ventricular tachycardia; BP Blood pressure; LGE Late gadolinium enhancement.
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Table 4 displays the prevalence of each of the respective risk factors and risk 
modifiers stratified for the presence of HighT2. In addition to the significantly 
higher maximal wall thickness in patients with HighT2, the numerically higher 
proportion of NSVT and younger age contributed to the higher estimated 
5-year SCD risk in these patients. With regard to the ACC/AHA risk model, 
extensive LGE was significantly more often present in patients with HighT2. 
Among HCM patients with an estimated low risk of SCD according to the ESC 
guidelines (n=93), those without HighT2 had a significantly lower SCD risk 
score than those with HighT2 (1.7% vs. 2.0%, p=0.021). Among those with an 
estimated high risk of SCD (n=5), those without HighT2 (n=3) had an estimated 
risk of SCD of 6.1%, 6.2% and 6.9% vs. 7.4% and 9.6% in those with HighT2 (n=2) 
(Supplementary Figure 1). 
DISCUSSION 
This report represents a first exploratory analysis in the largest HCM cohort 
so far on the association between HighT2 and the risk categories for sudden 
cardiac death, as defined by the European and AHA/ACC guidelines. Our pilot 
data demonstrate that HCM patients with HighT2 are more likely to be at inter-
mediate to high risk of SCD, with projected SCD rates that are 1.5 fold higher 
than in patients without HighT2. Importantly, apart from associations with some 
of the variables integrated in the HCM Risk-SCD model, HighT2 was also found 
to be related to markers of adverse disease progression not incorporated in the 
model (extensive LGE, LV mass and LV ejection fraction). When these findings 
are confirmed in larger cohorts with a higher proportion of intermediate-high 
risk patients, HighT2 may prove to be a valuable additive risk modifier or risk 
factor for future risk stratification schemes.
With the increasing use of CMR imaging in HCM, tissue characterization has 
become a topic of interest to further unravel pathophysiological aspects of the 
disease, and to determine the additional contribution of these imaging features 
in risk prediction of sudden death. From these studies we have learned that in 
almost all patients with HighT2 a substrate for arrhythmias was present in the 
form of fibrosis.13-20 In addition, it has been demonstrated that the sympathetic 
tone is higher in patients with HighT2 [18]. These observations may explain 
why HighT2 has previously been associated with the occurrence of NSVT.14,16,20 
In addition, association with other markers of advanced disease have been 
reported.18,20 In this context, it has been hypothesised that HighT2 might be a 
predictor of adverse events, SCD in particular.
In our HCM population, patients with HighT2 were more often at an interme-
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diate-high SCD risk, regardless of whether the European or Northern American 
guidelines were used. It is evident that in the large subset of our low risk HCM 
patients, projected SCD rates were significantly higher in patients with HighT2. 
Whether this can be extrapolated to intermediate-high risk patients remains to 
be determined. On the one hand, it should be noted that this observed asso-
ciation may be confounded due to the association between HighT2 and some 
of the conventional risk factors (LV wall thickness in particular (Table 4)). In 
addition, the predictive value of HighT2 does not seem to be high. However, it 
has repeatedly been demonstrated that the discriminative ability of the indi-
vidual risk factors of the models is rather poor, and that it is the combination of 
factors that improves the predictive ability. On the other hand, HighT2 was also 
associated with the risk modifier extensive LGE (ACC/AHA) and other indica-
tors of disease severity such as higher LV mass, lower LV ejection fraction and 
higher troponin T concentration.5,6,9,11,27,28 These results suggest that HighT2 is 
not a mere surrogate marker of risk factors already included in the prevailing 
risk models, but might be a valuable composite marker of arrhythmic risk, that 
would otherwise remain concealed with the current risk stratification schemes. 
Notably, fibrosis may be a confounder for HighT2 in the prediction of SCD. 
However, among those with fibrosis, we have demonstrated that the patients 
with HighT2 were more often at an intermediate-high risk of SCD. These find-
ings are supportive evidence to conduct larger studies on the potential impact 
of HighT2 in relation to LGE and the conventional risk factors. 
POTENTIAL IMPACT OF HIGHT2 ON CLINICAL PRACTICE
The observed 1.5 fold risk increase for SCD associated with HighT2 is in the 
same order of magnitude as observed for an extent of LGE of ≥15%, which is 
associated with an almost twofold increased risk6,9.  
Based on our findings, several hypotheses for both low risk and intermedi-
ate-high risk patients could be addressed in future studies as potential implica-
tions. Our findings in the large group of low risk patients imply that T2-weighted 
CMR imaging might be able to increase the negative predictive value of current 
risk stratification schemes. At present, sudden cardiac death still occurs among 
low risk patients, and because of the high proportion of low risk patients in the 
general HCM population absolute numbers of cases with SCD are still consid-
erable.29 In the absence of HighT2, we may identify a subgroup of low risk 
patients, who are really at very low SCD risk. This could implicate that they 
could reliably be assured that SCD is highly unlikely to occur.30 
As for the impact of HighT2 in intermediate-high risk patients, the small 
sample size does not allow firm conclusions. Possibly, the presence or absence 
of HighT2 could help to differentiate between higher and lower risk patients, 
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respectively. As for the former, we demonstrated associations with indicators 
of advanced disease, such as low ejection fraction and troponin. Moreover, our 
data suggest that HighT2 seems to differentiate among patients with LGE. 
It should be acknowledged that approximately half of the patients at inter-
mediate-high risk did not have HighT2. This may be interpreted as an undesir-
able “missing” of patients at a considerable estimated risk of SCD. However, it 
has been demonstrated in an independent validation cohort for the HCM-SCD 
risk model that with a SCD rate of around 5%, about 17 patients need an ICD 
implantation to prevent one SCD in 5 years.31 In addition, it was demonstrated 
that, especially in high risk patients, the predicted SCD risk was higher than the 
observed SCD risk.31 Consequently, in the majority of HCM patients at an esti-
mated intermediate-high risk no SCD occurs and ICD implantation may prefer-
entially have been avoided. It requires further study to investigate whether the 
absence of HighT2 in intermediate-high risk HCM patients may lower the odds 
of future SCD, and improve the number needed to treat to prevent one SCD. 
FUTURE DEVELOPMENTS: AN INTEGRATIVE CMR APPROACH
In search of refinement of the current risk stratification models that are based 
on echocardiographic and clinical variables, we agree with European and 
Northern American experts that incorporating myocardial tissue characteriza-
tion (LGE and HighT2) may be of additional value.32-35 
The positive predictive value of the mere presence of LGE proved to be 
limited by its prevalence of about 60-70% and the annual risk of SCD of 
only about 1% in a general HCM population. In response, the extent of LGE 
has become the topic of interest, with promising results in risk prediction.6,9,36 
Of interest, extensive LGE was more often present in patients with HighT2. 
However, more than half of the cases with HighT2 were observed in patients 
without extensive LGE. Inherently, there may be additional value for HighT2, 
which is also confirmed by our finding that among LGE positive patients those 
with HighT2 had the highest estimated SCD risk. Previously, we have demon-
strated that among HCM patients with LGE, those without HighT2 had the 
lowest troponin concentration, resembling that of patients without any LGE. 
Moreover, patients without HighT2 had a 9-fold lower chance of extensive LGE. 
Whereas the number of intermediate-high risk patients is limited, our findings 
in the large cohort of low risk patients are more robust and imply that it is 
likely that the absence of HighT2 could improve the negative predictive value 
in these patients. 
In summary, given the currently suboptimal risk stratification, the addition 
of HighT2 may be valuable to improve both negative and positive predictive 
values of the risk models. Incorporation of the abovementioned CMR variables 
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in (currently running) HCM follow-up studies may provide valuable information 
with regard to their independent association and additive predictive values.7,8
LIMITATIONS
Although this is the largest cohort of HCM patients with T2-weighted imaging 
information, the main limitation of this study is the low risk profile of the study 
population. At the time of this study 5-year follow-up was available for 70% 
of our cohort. With projected 5-year follow-up rates of about 2%, we decided 
that clinical endpoints rather than estimated sudden death rates would not 
provide much additional value for the current study question. 
In this context, we performed exploratory analyses on projected rates of 
SCD and our findings should therefore be considered as hypothesis generating, 
and do not validate HighT2 as a risk factor for SCD. Confirmative studies with 
clinical follow-up in a more intermediate-high risk population are warranted. 
Furthermore, the technique under investigation is limited by a high signal-to-
noise ratio and frequent artefacts. Unfortunately, T2-mapping sequences were 
not available at the start of our study, but these seem very promising and may 
lead to more objective data. In analogy to previous studies in HCM, the pres-
ence of HighT2 was visually assessed by two independent observers (FG and 
JB).15,17 A third observer was required for final adjudication in 14 of 109 patients 
(Cohen’s kappa: 0.631, p<.001). Regardless of whether results of observer 1 or 
2 were used, the differences in SCD risk between patients with and without 
HighT2 were consistent. Lastly, we are well aware of the fact that the validity of 
the HCM Risk-SCD model has recently been challenged for Northern American 
patients.37 Nonetheless, for the current analysis, the HCM Risk-SCD model has 
the advantage of quantification of projected risk of SCD. 
CONCLUSION
In an era where tissue characterization with CMR imaging has become topic 
of interest for SCD risk stratification, we are the first to demonstrate that 
HCM patients with HighT2 are more likely to be at intermediate to high risk 
of SCD, with projected SCD rates that are 1.5 fold higher than in patients 
without HighT2. Notably, HighT2 was not only associated with established risk 
factors, but also with several markers of a detrimental disease course, that are 
currently not incorporated in the HCM Risk-SCD model. The present findings 
should be considered as “pilot data”, but do put forward the hypothesis that 
HighT2 might be valuable for future SCD risk stratification models in HCM.
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SUPPLEMENTARY FIGURES
S. FIGURE 1. Estimated 5-year SCD risk, stratified by risk category and
  presence of HighT2 
Low risk*
HighT2+
(N=21)
Risk:
2.03 
(1.51-2.96) 
Intermediate risk
HighT2+
(N=6)
Risk:
4.58 
(4.28-4.69)
HighT2-
(N=5)
Risk:
4.43 
(4.38-5.46)
High risk
HighT2+
(N=2)
Risk:
7.39 & 9.58
HighT2-
(N=72)
Risk:
1.66 
(1.09-2.22) 
HighT2-
(N=3)
Risk:
6.14, 6.21, 
6.91
TOTAL POPULATION
(N = 109)
(N = 93) (N = 11) (N = 5)
Legend: Among patients with a low or high risk of SCD, those with HighT2 were at a higher risk of SCD 
according to the HCM Risk-SCD model. * The difference in risk was statistically significant (p=0.021).
118
119
Authors:
D.H.F. Gommans, G.E. Cramer, M.A. Fouraux, J. Bakker, M. Michels, H-J. Dieker, 
J. Timmermans, C.L.M. Marcelis, F.W.A. Verheugt, M-J. de Boer, M.J.M. Kofflard, 
R.A. de Boer, M.A. Brouwer 
Department of Cardiology, Radboud University Medical Centre, Nijmegen 
Department of Radiology, Albert Schweitzer Hospital, Dordrecht
Department of Cardiology, Erasmus Medical Centre, Rotterdam 
Department of Clinical Chemistry, Albert Schweitzer Hospital, Dordrecht 
Department of Clinical Genetics, Radboud University Medical Centre, Nijmegen
Department of Cardiology, Albert Schweitzer Hospital, Dordrecht
Department of Cardiology, University Medical Centre Groningen,  Groningen
American Journal of Cardiology. 2018;122:483-489. 
CHAPTER 7
PREDICTION OF EXTENSIVE 
MYOCARDIAL FIBROSIS IN NON-HIGH 
RISK PATIENTS WITH HYPERTROPHIC 
CARDIOMYOPATHY
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ABSTRACT
In non-high risk patients with hypertrophic cardiomyopathy (HCM) the pres-
ence of extensive late gadolinium enhancement (LGEext) at CMR imaging 
has been proposed as risk modifier in the decision process for ICD implanta-
tion. With a pre-test risk of about 10%, a strategy that alters the likelihood of 
LGEext could markedly affect efficacious CMR imaging. Our aim was to study 
the potential of clinical variables and biomarkers to predict LGEext. In 98 HCM 
patients without a clear indication for ICD implantation, we determined the 
discriminative values of a set of clinical variables and a panel of biomarkers 
(hs-cTnT, NTproBNP, GDF-15, Gal-3, CICP) for LGEext, i.e. LGE ≥15% of the left 
ventricular mass. LGEext was present in 10% (10/98) of patients. The clinical 
prediction model contained a history of non-sustained ventricular tachycardia, 
maximal wall thickness and reduced systolic function (c-statistic: 0.868, p < 
0.001). Of all biomarkers, only hs-cTnT was associated with LGEext, and addi-
tion to the clinical model improved diagnostic accuracy (p=0.04). A biomarker 
only strategy allowed for exclusion of LGEext in half of the cohort, in case of a 
hs-cTnT concentration < the optimal cut-off (Youden index; 8 ng/L - sensitivity 
100%, specificity 54%). In conclusion, in this non-high risk HCM cohort, the 
pre-test likelihood of LGEext can be altered with use of clinical variables and 
the addition of hs-cTnT. The promising findings with the use of hs-cTnT only call 
for new initiatives to study its impact on efficacious CMR imaging in a larger 
HCM population, either with or without additional use of clinical variables.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a major cause of sudden cardiac death 
(SCD) with an incidence of <1% per year, which poses a major clinical chal-
lenge for its prediction.1, 2 Importantly, the highest absolute number of SCD 
still occurs in the large group of non-high risk HCM patients without a clear 
indication for an implantable cardioverter-defibrillator (ICD).1-4 Recently, clin-
ical experts have suggested to incorporate extensive late gadolinium enhance-
ment (LGE) in clinical decision making for this category of HCM patients.5 As 
extensive LGE (≥15% of left ventricular (LV) mass) is only seen in about 10%,6 a 
strategy based on easily obtainable characteristics that would alter the pre-test 
likelihood, would be a more cost-effective approach than routine LGE CMR 
imaging.7, 8 In addition to various clinical variables, (e.g. LV mass, wall thickness 
and non-sustained ventricular tachycardia (NSVT)9-11) biomarkers like cardiac 
troponin, natriuretic peptides and markers of collagen turnover have repeat-
edly been associated with LGE in HCM.12-19 In the above clinical context, we 
aimed to identify predictors of extensive LGE among routinely assessed clin-
ical variables and a broad panel of biomarkers in non-high risk HCM patients. 
In addition, we demonstrate the predictive value of the addition of biomarkers 
in comparison to a prediction model with clinical variables only.
METHODS
For this analysis, we selected non-high risk patients from a large cohort of HCM 
patients who participated in a Dutch multicenter study on CMR imaging and 
biomarkers.20 In short, adult HCM patients from different hospitals were enrolled 
at 2 outpatient clinics (Radboud University Medical Centre, Nijmegen and Albert 
Schweitzer Hospital, Dordrecht, The Netherlands) between 2008 and 2014. 
Patients had to fulfil the diagnostic criteria for HCM according to the prevailing 
guidelines at the time of inclusion and did not have a history of coronary artery 
disease or septal reduction therapy. For this analysis, data on the extent of LGE 
had to be available. Furthermore, we selected HCM patients who are consid-
ered not to be at high SCD risk based on the AHA/ACC guidelines (i.e. low to 
intermediate risk HCM patients). Accordingly, we excluded patients with a family 
history of SCD, extreme hypertrophy (≥30mm) or a recent unexplained syncope 
(i.e. patients in whom ICD implantation is considered reasonable according to 
the latest AHA/ACC guidelines).2 The study complies with the Declaration of 
Helsinki and the protocol was approved by the local ethical committees and 
conducted accordingly. All participants provided written informed consent.
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CMR imaging was performed on 1.5T CMR systems (Philips Achieva (Philips 
Healthcare, Best, The Netherlands) or (Siemens Avanto (Siemens Health 
Care, Erlangen, Germany)) according to local imaging protocols, as previ-
ously described in more detail.20 T1-weighted inversion-recovery imaging was 
performed to assess LGE 10 minutes after the administration of 0.2 mmol/kg 
contrast medium (Dotarem; Guerbet, Gorinchem, The Netherlands).
Images were analyzed with commercially available software (QMass 7.5, 
Medis, Leiden, The Netherlands) by three observers (FG, JB and HD) unaware 
of the subjects’ clinical information. The extent of LGE was scored visually 
according to a semi-quantitative score, previously validated in HCM.21 The 
definition of extensive LGE was met in case the LGE extent comprised ≥15% of 
the LV mass. 
Blood samples were obtained by trained personnel and processed within 
60 minutes after phlebotomy, and stored at –80°C until further analysis. 
Serum samples were used for the determination of the following biomarkers: 
cardiac troponin T using the highly sensitive assay (hs-cTnT), N-termi-
nal-pro-B-type-Natriuretic Peptide (NTproBNP), Galectin-3 (Gal-3), soluble 
Tumorigenicity Suppressor2 (sST2), Growth Differentiation Factor-15 (GDF-15) 
and C-terminal Propeptide of Type I Collagen (CICP). Variability and perfor-
mance in healthy controls and patients with heart failure have been published.22 
We refer to Appendix A for detailed description of the assays. 
Continuous variables are presented as means (± standard deviations) or 
medians (interquartile ranges (IQR)) and were compared between patients 
with and without extensive LGE using a Student’s t or Mann-Whitney U 
test, whichever appropriate. Dichotomous variables were compared using a 
Chi-square or Fisher exact test, whichever appropriate. A p-value of <0.05 
was considered significant (two-sided). Then, multivariable regression analysis 
was performed. A stepwise forward approach was adopted to predict exten-
sive LGE based on the likelihood-ratio-test (P-in, 0.05; P-out, 0.10). Firstly, 
we constructed a model for prediction of extensive LGE with the clinical vari-
ables that differed between patients with and without extensive LGE (p<0.10) 
(model 1). Secondly, we constructed model 2 for prediction of extensive LGE 
with the addition of the biomarkers that differed between patients with and 
without extensive LGE (p<0.10). To assess the calibration of the models we 
used the Hosmer-Lemeshow goodness-of-fit statistical method. ROC anal-
ysis using c-statistics was performed to determine the area under the curve 
of both models, and of each biomarker variable included in model 2 sepa-
rately. The cut-off value for the continuous variables was determined using 
the Youden index. Statistical analysis was performed with IBM SPSS Statistics 
22 (IBM Corp, Armonk, NY, USA). 
123
CHAPTER 7  PREDICTION OF EXTENSIVE MYOCARDIAL FIBROSIS IN NON-HIGH RISK PATIENTS
RESULTS 
For the present analysis, 98 non-high HCM patients selected from our total 
HCM cohort of 141 HCM patients were studied (61% male, age 55 ± 14 years) 
(Figure 1 and Table 1).20 Most patients were a- or mildly symptomatic with 96 
(98%) in NYHA Class I-II. The presence of LGE was demonstrated in 56 (57%) 
patients. In these 56 patients, the extent of LGE comprised 8% (IQR: 3-13%) of 
the LV mass. In 10 (10%) patients the extent of LGE was ≥15%. 
Legend: Our total HCM population comprised 141 HCM patients. Twenty-six HCM patients were excluded 
because there was no data available on LGE extent. Seventeen HCM patients were excluded because 
they were considered to be at high SCD risk according to the ACC/AHA guidelines, in whom an ICD 
implantation is considered reasonable. LGE Late gadolinium enhancement; SCD Sudden cardiac 
death; ICD Implantable cardioverter defibrillator; MRI Magnetic resonance imaging; FH-SCD Family 
history of sudden cardiac death.
FIGURE 1.  Flow chart of our HCM study population
N=141
HCM pts with LGE extent available
HCM pts with LGE extent available 
& not at high 
SCD risk
N=115
N=98
No MRI due to:
• ICD/pacemaker: 12
• Claustrophobia: 2
• Other: 5
Inadequate MRI quality: 7
High SCD risk due to:
• Extreme hypertrophy: 2
• Syncope:  3
• FH-SCD: 12
TOTAL HCM POPULATION
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TABLE 1.  Baseline characteristics stratified according to extensive late 
 gadolinium enhancement
VARIABLE TOTAL LGE EXTENT P-VALUE
(N=98)
<15%
(N=88)
≥15%
(N=10)
Age at participation (years) 55 ± 14 55 ± 15 57 ± 12 0.74
Men 60 (61) 53 (60) 7 (70) 0.74
Age at diagnosis (years)* 49 ± 16 50 ± 16 40 ± 16 0.09
Pathogenic mutation present 46 (53) 39 (50) 7 (78) 0.16
Atrial fibrillation* 18 (18) 14 (16) 4 (40) 0.08
Hypertension 40 (41) 35 (40) 5 (50) 0.74
Current smoker 15 (15) 14 (16) 1 (10) 1.0
Dyslipidemia§ 29 (30) 24 (27) 5 (50) 0.16
Diabetes mellitus 5 (5) 4 (5) 1 (10) 0.42
Creatinine (μmol/l) 84 ± 16 84 ± 16 89 ± 20 0.37
Systolic blood pressure (mmHg) 131 ± 22 131 ± 22 133 ± 20 0.76
Heart rate (beats/minute) 73 ± 12 73 ± 12 76 ± 15 0.36
Framingham 10-year heart risk (%) 15 (5-26) 15 (5-25) 23 (7-31) 0.37
RISK FACTORS FOR SCD
History of non-sustained VT* 14 (15) 10 (12) 4 (40) 0.04
Abnormal BP response* 11 (12) 8 (9) 3 (30) 0.09
SYMPTOMS
Chest pain 18 (18) 18 (21) - 0.20
Dyspnea (NYHA class ≥ II) 43 (44) 40 (46) 3 (30) 0.51
ECHOCARDIOGRAPHY
Maximal LV wall thickness (mm)* 16 (13-19) 16 (13-19) 18 (16-21) 0.08
LVMI (g/m2)* 125 (103-162) 124 (102-155) 160 (127-179) 0.05
Reduced LV systolic function* 8 (8) 5 (6) 3 (30) 0.03
LV outflow tract gradient at rest 
≥30mmHg
18 (19) 18 (21) - 0.20
Left atrial diameter (mm) 44 (39-50) 44 (39-48) 45 (42-58) 0.26
THERAPY
Beta-blocker 50 (51) 43 (49) 7 (70) 0.32
Calciumantagonist 12 (12) 10 (11) 2 (20) 0.35
Data are presented as means ± standard deviations, medians (interquartile ranges) or numbers 
(percentages). * These variables were used for multivariate logistic regression analysis. § Dyslipidemia was 
defined as a total cholesterol > 6.5mmol/l. BP Blood pressure; LGE Late gadolinium enhancement; LVMI 
LV mass indexed to body surface area; NYHA New York Heart Association; SCD Sudden cardiac death; VT 
Ventricular tachycardia.
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TABLE 2.  Biomarkers stratified according to extensive late gadolinium 
 enhancement
BIOMARKERS TOTAL LGE EXTENT P-VALUE
(N=98)
<15%
(N=88)
≥15%
(N=10)
Hs-cTnT (ng/L)* 8 (4-14) 8 (3-13) 16 (11-27) 0.001
NTproBNP (ng/L) 120 (76-351) 120 (69-323) 238 (106-360) 0.30
sST2 (ng/mL) 25 (19-34) 25 (19-35) 22 (18-31) 0.71
GDF-15 (ng/L) 837 (515-1212) 837 (510-1181) 1007 (717-1352) 0.24
Gal-3 (ng/mL) 18 (14-20) 17 (14-20) 18 (13-20) 0.79
CICP (ng/mL) 126 (106-160) 126 (106-159) 126 (104-184) 0.69
Data are presented as means ± standard deviations or medians (interquartile ranges). * This variable 
was used for multivariable logistic regression analysis. LGE Late gadolinium enhancement.
Patients with extensive LGE tended to be younger at the time of diagnosis 
compared to patients without extensive LGE (Table 1). Atrial fibrillation tended 
to be more often present in patients with extensive LGE. A history of NSVTs 
was more often present in these patients. With regard to echocardiographic 
parameters, patients with extensive LGE had a higher LV mass indexed to BSA 
and had a numerically higher maximal LV wall thickness. Lastly, 3 out of 10 
patients with extensive LGE had a reduced LV systolic function compared to 5 
out of 88 patients without extensive LGE.
The median hs-cTnT concentration was twice as high in patients with exten-
sive LGE (Table 2). No significant differences were observed for NTproBNP or 
any of the other biomarkers.
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After multivariable regression analysis with the clinical variables, the clinical 
prediction model consisted of a history of NSVT, reduced LV systolic func-
tion and maximal echocardiographic LV wall thickness (model 1). As for model 
2, addition of hs-cTnT significantly improved the model (difference in -2 log 
likelihood: 4.206, p=0.04) (Table 3). The calibration of the two models was 
adequate (Hosmer-Lemeshow goodness-of-fit significance level, >0.05). For 
model 1, ROC analysis demonstrated a high discriminative ability (area under 
the curve, c-statistic: 0.868 [95% CI: 0.780-0.956, p<0.001]). For model 2, the 
discriminative ability was even slightly higher (area under the curve, c-statistic: 
0.900 [95% CI: 0.836-0.964], p<.001) (Figure 2). As a single variable, none 
of the clinical characteristics (history of NSVT, abnormal LV function and LV 
wall thickness) demonstrated valuable discriminative ability for prediction of 
extensive LGE (c-statistics, p=n.s.). In contrast, ROC analysis of hs-cTnT as a 
single variable demonstrated good discriminative value (area under the curve, 
c-statistic of 0.818 [95% CI: 0.716-0.920], p=0.001) (Figure 3). Based on the 
Youden index, the optimal cut-off value for hs-cTnT was 8ng/L. Of note, this 
was also the median concentration of our cohort. Using this cut-off, the sensi-
tivity and specificity of hs-cTnT for extensive LGE were 100% and 54%, respec-
tively. Consequently, the negative and positive predictive values for extensive 
LGE were 100% and 19% in our population
TABLE 3.  Models 1 and 2 for prediction for extensive late gadolinium 
 enhancement
MODEL 1: ROUTINE CLINICAL VARIABLES ADJUSTED OR 95% CI P-VALUE
History of non-sustained VT 6.80 1.32-35.20 0.022
Maximal LV wall thickness (mm) 1.23 1.03-1.48 0.023
Reduced LV systolic function 9.31 1.48-58.40 0.017
MODEL 2: ROUTINE CLINICAL VARIABLES + BIOMARKERS ADJUSTED OR 95% CI P-VALUE
History of non-sustained VT 10.00 1.54-64.78 0.016
Maximal LV wall thickness (mm) 1.23 1.012-1.497 0.037
Reduced LV systolic function 9.57 1.33-68.86 0.025
Hs-cTnT (ng/L) 1.07 1.001-1.132 0.046
CI Confidence interval; LGE Late gadolinium enhancement; OR Odds ratio; VT Ventricular tachycardia.
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Legend: Figure 2 demonstrates the discriminative ability for extensive LGE with clinical variables only (a 
history of NSVT, reduced LV systolic function and maximal LV wall thickness on echocardiography) (Model 1: 
c-statistic: 0.868). Model 2 represents the discriminative ability with the addition of hs-cTnT (c-statistic: 0.900). 
Hs-cTnT Cardiac troponin T assessed with a highly sensitive assay; LGE Late gadolinium enhancement.
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Legend: Figure 3 demonstrates the discriminative ability of hs-cTnT for extensive LGE in our cohort of 
low-intermediate risk HCM patients. Hs-cTnT Cardiac troponin T assessed with a highly sensitive assay; LGE 
Late gadolinium enhancement.
FIGURE 2. ROC curves for prediction of extensive LGE with clinical variables 
 only (model 1) and with addition of hs-cTnT (model 2)
FIGURE 3.  ROC curve of hs-cTnT for the prediction of extensive LGE 
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DISCUSSION
In an era of increasing interest in CMR imaging as part of the workup to assess 
whether non-high risk HCM patients qualify for ICD implantation, we herein 
describe predictors of extensive LGE. We found that a set of three clinical vari-
ables had a high discriminative value, with a significant improvement in diag-
nostic accuracy after addition of hs-cTnT. Even without accounting for the 
history of NSVT, reduced LV systolic function and maximal LV wall thickness 
on echocardiography, a strategy based on the use of hs-cTnT by itself showed 
remarkable results. Based on the optimal cut-off for hs-cTnT, extensive LGE 
could reliably be excluded in half of the cohort. 
Previous reports have associated various clinical variables with the presence 
of LGE, such as a history of NSVT and measures of LV hypertrophy.9-11 Moreover, 
maximal wall thickness on CMR imaging was reported to be independently 
predictive of the presence of LGE.13 As the clinical importance of the mere pres-
ence of LGE is limited, we focused on the prediction of extensive LGE and only 
with variables available prior to CMR imaging. Our finding that a history of NSVT 
and a reduced LV systolic function on echocardiography were associated with 
extensive LGE corroborates with previous findings. Clearly, myocardial scar, 
which is suggested by the presence of extensive LGE, is a substrate for ventric-
ular arrhythmias and leads to adverse remodeling.11 The association between 
maximal LV wall thickness and extensive LGE corresponds with previous obser-
vations that HCM patients with more hypertrophy more often have LGE.9, 10 This 
can most likely be explained by an increased myocardial oxygen demand and 
consequent ischemia with myocardial cell death. 
Cardiac troponin, natriuretic peptides and markers of collagen turnover 
have been associated with the presence of LGE in HCM.12-18 In addition, some 
studies addressed the predictive value of these biomarkers for the presence of 
LGE in HCM.12-14 Notably, a correlation was demonstrated between biomarker 
concentrations and the extent of LGE, though data are limited.13-17, 19
The other biomarkers in our panel (Gal-3, sST2 and GDF-15) have been impli-
cated in myocardial fibrosis, stress and inflammation in heart failure. Gal-3 has 
been associated with LGE in non-ischemic dilated cardiomyopathy patients, 
but in HCM this association could not be confirmed.23, 24 25Regarding sST2 in 
relation to LGE CMR imaging, only two reports in HCM are available, of which 
one suggested an association with LGE extent.25, 26 To our knowledge, we are 
the first to describe GDF-15 in relation to LGE CMR imaging in HCM.27-29
With regard to our results, the observed association between hs-cTnT 
and extensive LGE corroborates with previous studies and can be explained 
by the fact that both hs-cTnT and LGE are markers of myocyte injury.12, 13, 15, 18 
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Legend: Figure 4, upper panel, shows identification of low to intermediate risk HCM patients with use of the 
conventional risk factors. Among these patients, about 10% will have extensive LGE (red). The middle panel 
demonstrates the stratification based on hs-cTnT. A hs-cTnT concentration <8ng/L safely excludes extensive 
LGE. This represents half of our cohort. Moreover, in case of an hs-cTnT concentration ≥8ng/L the chance 
of extensive LGE increased from 1 in 10 to 1 in 5 patients. Hs-cTnT Cardiac troponin T assessed with a highly 
sensitive assay; LGE Late gadolinium enhancement; CMR Cardiovascular magnetic resonance.
FIGURE 4.  Potential management algorithm for low to intermediate risk HCM 
 patients
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Concerning NTproBNP, we did not observe a difference between HCM 
patients with or without extensive LGE, despite a difference in systolic func-
tion between groups. Possibly, the absence of a difference in NTproBNP may 
be related to the fact that we have included a non-high risk HCM population 
with, in general, low biomarker concentrations and a low incidence of extensive 
LGE limiting the statistical power. As for concentrations of CICP and the more 
novel markers (sST2, GDF-15 and Galectin-3), we did not observe differences in 
relation to extensive LGE. This observation may be explained by the hypothesis 
that the systemic concentrations of these markers are only partly or indirectly 
reflective of myocardial fibrosis present in the LV myocardium.12, 30 To further 
assess the potential for these markers, larger studies are warranted.24 Notwith-
standing our modest sample size, our current results put hs-cTnT forward as 
the most promising biomarker for prediction of extensive LGE in non-high risk 
HCM patients.
Based on a recent meta-analysis, clinical experts have suggested the use of 
extensive LGE as a SCD risk modifier for non-high risk HCM patients.19 The 
prevalence of extensive LGE can roughly be estimated at about 10% in these 
patients and implies an approximately two-fold higher risk of SCD and the 
consideration of ICD implantation.5, 6 Notably, the majority of HCM patients 
is at non-high SCD risk and only 1 out of 10 would demonstrate extensive 
LGE on CMR imaging. In this context, it has recently been hypothesized that 
biomarkers, and hs-cTnT in particular, may be used as a “gateway” to perform 
LGE CMR imaging.7, 8 A strategy based on easily obtainable characteristics 
that would alter the pre-test likelihood of extensive LGE prior to CMR imaging 
would increase efficacious use of LGE CMR imaging for SCD risk stratification 
in HCM.7, 8 This may especially be valuable for institutions with limited resources 
to perform CMR imaging.
In our cohort, we demonstrated that extensive LGE can be predicted with 
a high discriminatory ability with a set of clinical variables. Importantly, the 
addition of hs-cTnT not only improved prediction, but the use of hs-cTnT by 
itself yielded a high discriminatory ability that approximates that of the set 
of clinical variables. Obviously, prediction in daily clinical practice based on 
one biomarker result is more convenient than prediction based on the integra-
tion of three different variables. To appreciate the potential of a management 
strategy with hs-cTnT only, our data are put in clinical perspective in Figure 
4, demonstrating two important implications. First, with a 100% sensitivity at 
8ng/L we may be able to exclude extensive LGE in 50% of low to interme-
diate risk HCM patients. Accordingly, in half of the patients one might consider 
not to perform LGE CMR imaging for risk stratification as no extensive LGE is 
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expected to be found. Secondly, in the other half (hs-cTnT ≥8ng/L) the pre-test 
probability of finding extensive LGE has increased from 10% to 20%. As such, 
these data should be appreciated as the first evidence that corroborates with 
the previously suggested hypothesis that hs-cTnT may be used as a gateway to 
perform LGE CMR imaging.7, 8 
Importantly, this example is intended to demonstrate potential future impli-
cations and is not meant to be implemented in clinical practice. Many institu-
tions have adopted CMR imaging in their standard initial workup for patients 
with suspected HCM, as CMR imaging may aid in the identification of hyper-
trophy that goes unnoticed on echocardiography. Moreover, LGE CMR imaging 
provides important information that may help to differentiate between sarco-
meric and non-sarcomeric causes of LV hypertrophy. Given these unique 
strengths of CMR imaging, it would not be sensible to, in general, waive CMR 
imaging based on a low hs-cTnT concentration. On the other hand, in case 
there is little doubt concerning the diagnosis of HCM, or in case of (relative) 
contraindications for LGE CMR imaging, hs-cTnT may provide valuable infor-
mation on the (pre-test) likelihood of extensive LGE.
Given the limited number of cases with LGEext and the moderate size of our 
study population, our findings warrant confirmation. Secondly, the definition of 
non-high SCD risk is not uniform, due to discrepancies between the AHA/ACC 
and ESC guidelines.1,2 In this context, we performed an ancillary analysis based 
on the HCM SCD Risk-score1 and demonstrated that hs-cTnT was independently 
predictive of extensive LGE in low to intermediate risk patients according to 
the ESC guidelines as well. With regard to extensive LGE, we acknowledge 
that it is not (yet) included in the guidelines, and that there is no consensus 
on the preferred method of LGE quantification. Where some advocate visual 
assessment, others use a signal-intensity-based cut-off, and we chose to use 
a semi-quantitative score.19 In view of the above, caution is warranted with 
regard to the use of a rigid cut-off. Our ancillary analyses with various cut-offs 
for extensive LGE demonstrated that hs-cTnT remained strongly associated 
with extensive LGE (Appendix B). Consequently, these results did not materi-
ally change our conclusions on the potential that hs-cTnT may have for future 
clinical risk stratification schemes in HCM.
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APPENDIX A 
DESCRIPTION OF THE ASSAYS
C-terminal Propeptide of Type I Collagen (CICP) - An enzyme immuno-
assay for the quantitative determination of CICP (Quidel, San Diego, California, 
United States) was used. In a testing cohort of adults over 25 years of age 
values ranged from 69 to 163 ng/mL. The limit of detection is 0.2 ng/mL. At a 
mean concentration of 98.1 ng/mL the within- and between-run coefficients of 
variation were 5.5% and 7.2%, respectively.
Galectin-3 (Gal-3) - An enzyme-linked immunosorbent assay for the quanti-
tative determination of Gal-3 (BG Medicine, Waltham, Massachusetts, United 
States) was used. The limit of blank and limit of detection are 0.86 ng/mL and 
1.13 ng/mL, respectively. At a mean concentration of 17.6 ng/mL the coefficient 
of variation was 5.1%.
Growth differentiation factor 15 (GDF-15) - An enzyme-linked immunosorbent 
assay for the quantitative determination of GDF-15 (R&D Systems, Abingdon, 
United Kingdom) was used. Intra- and interassay coefficients of variation are  ̴ 
2-6%. Measurement range in serum of healthy controls was 337-1060 pg/mL.
Highly sensitive cardiac troponin T (hs-cTnT) - For the determination of 
troponin T concentrations, the highly sensitive cardiac troponin T (hs-cTnT) 
assay was used and performed on the Elecsys 2010 system (Roche Diagnos-
tics; Almere, The Netherlands). The limit of blank and detection for this test are, 
respectively, 3 and 5 ng/L, the 99th percentile reference limit 14 ng/L, and at 13 
ng/L the coefficient of variation is 10%.
N-terminal-pro-B-type-natriuretic peptide (NTproBNP) - An enzyme immu-
noassay for the quantitative determination of NT-proBNP (Biomedica, Vienna, 
Austria) was used. The limit of detection is 3pmol/l. Intra- and interassay coef-
ficients of variation were  ̴ 3-7%.
Soluble Tumorigenicity Suppressor2 (sST2) - An enzyme-linked immunosor-
bent assay (Presage®, Critical Diagnostics, San Diego, California, United States) 
was used for sST2. The limit of blank and detection are 0.5 and 1.8 ng/mL. 
A clinical prognostic cutpoint has been determined at 35 ng/mL. At a mean 
concentration of  ̴ 30 ng/mL the coefficient of variation was  ̴ 8%.
136
APPENDIX B
 
In our manuscript we have defined extensive LGE as an extent of  ≥15% of 
LV mass.
In appreciation of the fact that the definition of extensive LGE may differ in 
the future, and that information on the predictive value of hs-cTnT for different 
extents of LGE might be valuable, we performed additional analyses for the 
following alternative outcome measures:
• The presence of LGE
• An LGE extent of ≥5%
• An LGE extent of ≥10%
• An LGE extent of ≥12.5%
• An LGE extent of ≥20%
The following analyses were performed:
1. We determined whether hs-cTnT was predictive for each of these outcome 
measures using logistic regression analysis. 
2. For each of the outcome measures, we performed an ROC-analysis to 
determine the c-statistic of hs-cTnT, the cut-off for hs-cTnT with the highest 
discriminative ability based on the highest Youden index and for each 
cut-off, we determined sensitivity, specificity, negative and positive predic-
tive value.
3. Lastly, we assessed whether the addition of hs-cTnT to a prediction model 
with the clinical variables only improved prediction of each of the outcome 
measures.
With regard to the first, hs-cTnT was univariately associated with each of the 
outcome measures.
The results for analysis 2 are systematically displayed in Supplementary Table 1.
 With regard to the latter, addition of hs-cTnT to a set of clinical variables 
significantly improved prediction of the presence of LGE, an LGE extent of 
≥10% and an LGE extent ≥12.5% (p<0.05). For an LGE extent of ≥5% and ≥20%, 
hs-cTnT showed a trend towards significant improvement (p=0.19 and p=0.08), 
respectively.
Conclusion: Regardless of the definition of the outcome measure concerning 
LGE (presence or extent), our analyses demonstrated that hs-cTnT might be 
valuable for prediction of the outcome of LGE CMR imaging. As such, these 
analyses are in line with the main conclusions of our manuscript.
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SUPPLEMENTARY TABLE 1
DEFINITION C-STATISTIC FOR 
HS-CTNT
P OPTIMAL 
CUT-OFF
SENSITIVITY SPECIFICITY NPV PPV
Presence of 
LGE
0.657 
(0.548-0.766)
0.010 15ng/L 36% 97% 51% 95%
LGE extent 
≥5%
0.666 
(0.551-0.782)
0.006 12.5ng/L 50% 83% 69% 69%
LGE extent 
≥10%
0.756
(0.636-0.875)
0.001 15ng/L 60% 91% 86% 71%
LGE extent 
≥12.5%
0.774 
(0.636-0.912)
0.001 14.5ng/L 67% 84% 93% 43%
LGE extent 
≥20%
0.807 
(0.684-0.929)
0.004 8ng/L 100% 53% 100% 17%
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SUMMARY
Chapter 1 is the general introduction and provides the definition of hypertrophic 
cardiomyopathy (HCM), the mechanisms of disease, the clinical present ation; 
in addition, it outlines the use of troponin and cardiovascular magnetic reso-
nance (CMR) imaging in HCM. In that context, the design of the BE STRONG 
HCM study and the outline of this thesis are addressed.
Chapter 2 reports on the basic question of how much inclusion or exclusion 
of the papillary muscles affects everyday CMR image analysis of left ventric-
ular (LV) mass and ejection fraction (EF) in patients with HCM in particular, 
but also in relation to a group of controls without hypertrophy. CMR imaging 
is the current gold standard for quantification of LV mass and EF, which can 
be used to identify HCM patients at high risk of adverse cardiac events, such 
as sudden cardiac death (SCD) and heart failure. Notably, uniformity in CMR 
image analysis of these prognostic parameters is lacking on how to deal with 
measurements of the papillary muscles. The guidelines state that LV volumes 
and mass should be quantified according to the same protocol as used for the 
reference ranges. In general, studies on normal values of LV parameters used 
to include the papillary muscles in quantifying LV mass. Surprisingly, in most 
general hospitals exclusion of the papillary muscles has become the standard. 
In HCM patients the papillary muscle mass is higher than in normal healthy 
volunteers. Therefore, especially in the HCM population, we sought to investi-
gate the impact of the papillary muscles on quantification of LV parameters. We 
demonstrated that in HCM patients, inclusion of the papillary muscles resulted 
in significant relative increases of 9% in LV mass and 4% in LV EF. Despite the 
involvement of the papillary muscles in the disease process of HCM, the rela-
tive differences were in the same order of magnitude in the control subjects 
without hypertrophic myocardium. Given the potential impact for clinical deci-
sion-making based upon values of LV mass, volume and function, our results 
underscore the general need for uniform protocols on CMR image analysis.
In Chapter 3 we describe the rate of a detectable, and of an elevated 
troponin (≥99th percentile) in a well-defined population of patients with clin-
ical HCM, using a highly sensitive assay. In asymptomatic healthy individuals 
elevated cardiac troponin has been associated with LV mass, as assessed with 
CMR imaging, and the a priori risk of cardiovascular disease (CVD). In HCM 
patients the few reports available demonstrate an association between cardiac 
troponin and increased LV wall thickness, LV dysfunction, and late gadolinium 
enhancement (LGE). However, the contribution of mass and the a priori long-
term risk of CVD had never been studied in HCM. Moreover, previous studies 
did not address the range of detectable troponin concentrations below the 
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upper reference limit of normal. In the abovementioned context, we studied 
the association between troponin and the Framingham Heart 10-year risk score 
(FH10yrs) as a measure of the predicted CVD risk. In addition, we describe the 
association between troponin and LV mass. In a cohort of 62 HCM patients, 
troponin assessed with a highly sensitive assay (hs-cTnT) was detectable 
(>3ng/L) in 74% of patients (46/62). Hs-cTnT was elevated (≥99th percentile 
reference limit of 14 ng/L) in 26% (16/62) of patients. Using multivariable binary 
logistic regression both LV mass and FH10yrs were independently associated 
with a detectable hs-cTnT. In contrast, only LV mass was associated with an 
elevated hs-cTnT. This indicates that hypertrophy more than the risk of CVD 
seems the most important driver of elevated hs-cTnT concentrations in these 
patients.
In Chapter 4 we explored the association between areas of high signal inten-
sity on T2-weighted CMR imaging (HighT2) and hs-cTnT in patients with clinical 
HCM. As a biomarker of myocardial injury, hs-cTnT has previously been linked 
with the presence of LGE, which is considered the imaging marker of fibrosis. 
Only a few reports have so far addressed HighT2 in HCM, and only in selected 
small-sized populations. Interestingly, areas of HighT2 were almost exclusively 
present in patients with LGE, occurring within the boundaries of LGE. It has been 
postulated that areas with HighT2 might be indicative of myocardial oedema 
as a result of ischemic injury, representing a more active disease state in these 
patients with HCM. Although ischemic injury is considered the final common 
pathway, the pathophysiology of ischemia in HCM distinctly differs from, for 
example, acute myocardial infarction. This requires additional research on CMR 
imaging and the interpretation of HighT2 in HCM. In a relatively large cohort 
of 101 HCM patients, we investigated the association between HighT2 and an 
elevated hs-cTnT. In this outpatient cohort of HCM patients, we have demon-
strated that HighT2 was present in about one quarter of patients. In the pres-
ence of HighT2 the chances of an elevated hs-cTnT were threefold higher, and 
the concentration of hs-cTnT was significantly related with a higher extent of 
HighT2. Notably, in case of an undetectable hs-cTnT we observed a very high 
negative predictive value for HighT2 (>95%). These observations corroborate 
with the hypothesis that HighT2 in HCM may be indicative of recently sustained 
myocardial injury. 
In Chapter 5 we addressed the impact of exercise on hs-cTnT concentra-
tions in clinical HCM patients and subclinical HCM mutation carriers. It is widely 
appreciated that the hypertrophic phenotype in HCM is related to pathophysi-
ological abnormalities in vasculature, myocardial structure and function, which 
may contribute to the occurrence of myocardial ischemia. CMR imaging studies 
have correlated areas of ischemia with segmental LGE and HighT2. HighT2 has 
142
been demonstrated to correlate strongly with troponin in HCM, and is consid-
ered to represent an active state of disease. In the abovementioned context, 
episodes of high oxygen demand may pose a challenge and could result in 
additional myocardial injury. Whereas studies in ischemic heart disease and 
even in healthy individuals have already demonstrated post-exercise troponin 
release, data on this phenomenon in HCM is limited. We demonstrated that 
after a bicycle exercise test a rise in hs-cTnT concentration can be observed 
in almost 20% of our cohort of 127 HCM patients. This rate of post-exercise 
rises was markedly different from the rate observed in the control group of 
53 subclinical HCM mutation carriers without hypertrophy (4%). Importantly, 
troponin release occurred despite a relative intolerance to exercise of clin-
ical HCM patients as compared to mutation carriers (i.e. clinical HCM patients 
had a lower maximally achieved exercise performance compared to mutation 
carriers). With regard to the associations with a hs-cTnT rise, we observed that 
HCM patients with a rise had higher heart rates, and showed a trend towards 
higher heart rate pressure products, suggesting a role for exercise intensity. 
In addition, troponin rises were clearly linked to measures of LV hypertrophy 
(wall thickness) and myocardial injury (LGE and HighT2). Intriguingly, the only 
independent association with a post-exercise troponin rise was observed for 
HighT2. This suggests that a pre-existing active state of disease, with imaging 
signs of oedema, reflects a condition prone for additional myocardial injury 
in situations of high oxygen demand. In summary, our findings give rise to 
the hypothesis that repetitive episodes of high oxygen demand may result in 
‘bouts’ of troponin release, and that CMR imaging may identify the particularly 
vulnerable patients with on the long-term development of fibrosis. 
In Chapter 6 and 7 the focus is on the potential implications of, respec-
tively, HighT2 and hs-cTnT for daily clinical practice concerning risk stratifi-
cation for SCD. On the one hand, we describe in Chapter 6 the association 
between HighT2 and the estimated risk of SCD. On the other hand, in Chapter 
7 we study potential predictors of extensive LGE, which has been suggested 
as a risk factor for SCD, among both clinical variables and a set of biomarkers. 
In view of the association with troponin release, as previously described in 
this thesis, HighT2 may identify patients with a more active disease state, who 
might be vulnerable to adverse disease progression.  The additional obser-
vations by others that HighT2 was associated with non-sustained ventricular 
tachycardia raised the question whether HighT2 might be valuable predictor 
of adverse events, SCD in particular, which is addressed in Chapter 6. Studies 
with HighT2 and systematic prospective follow-up are lacking. Therefore, we 
sought to provide pilot data on HighT2 and SCD risk stratification. To assess its 
potential clinical impact, we investigated whether patients with HighT2 were 
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more often at intermediate to high risk according to the ESC and ACC/AHA 
risk stratification schemes. In addition, we explored the association of HighT2 
with the projected SCD rates using the HCM Risk-SCD model. We demon-
strated that HCM patients with HighT2 are more likely to be at intermediate 
to high risk of SCD, with projected SCD rates that are 1.5 fold higher than in 
patients without HighT2. Besides the associations with some of the variables 
integrated in the HCM Risk-SCD model, HighT2 was also found to be related to 
markers of adverse disease progression not incorporated in the model (exten-
sive LGE, LV mass and LV ejection fraction). These are additional arguments for 
the potential that HighT2 may have for refinement of risk stratification, which 
underscores the need for clinical follow-up studies in HCM on HighT2 and SCD.
In Chapter 7 we investigated potential predictors of extensive LGE to 
improve efficacious use of CMR imaging for SCD risk stratification. HCM is an 
important cause of sudden cardiac death (SCD) with an incidence of <1% per 
year, which poses a major clinical challenge for its prediction. Importantly, the 
highest absolute number of SCD still occurs in the large group of non-high risk 
HCM patients without a clear indication for an implantable cardioverter-de-
fibrillator. Recently, clinical experts have suggested to incorporate extensive 
LGE in clinical decision making for this category of HCM patients. As extensive 
LGE (≥15% of LV mass) is only seen in about 10%, a strategy based on easily 
obtainable characteristics that would alter the pre-test likelihood, would be 
a more cost-effective approach than routine LGE CMR imaging. In addition 
to various clinical variables, (e.g. LV mass, wall thickness and non-sustained 
ventricular tachycardia (NSVT)) biomarkers like cardiac troponin, natriuretic 
peptides and markers of collagen turnover have repeatedly been associated 
with LGE in HCM. In the above clinical context, we aimed to identify predic-
tors of extensive LGE among routinely assessed clinical variables and a broad 
panel of biomarkers in non-high risk HCM patients. In addition, we demon-
strate the predictive value of the addition of biomarkers in comparison to a 
prediction model with clinical variables only. We found that a set of three clin-
ical variables had a high discriminative value, with a significant improvement in 
diagnostic accuracy after addition of hs-cTnT. Even without accounting for the 
history of NSVT, reduced LV systolic function and maximal LV wall thickness 
on echocardiography, a strategy based upon hs-cTnT only showed remarkable 
results. With use of  the optimal cut-off for hs-cTnT (Youden-index), exten-
sive LGE could reliably be excluded in half of the cohort. These data should 
be appreciated as the first evidence that corroborates with the previously 
suggested hypothesis that hs-cTnT may be used as a gateway to perform LGE 
CMR imaging for SCD risk stratification.
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In short, we have demonstrated that elevated hs-cTnT concentrations can be 
observed in 1 out of 4 our HCM patients at rest.1 Secondly, our results suggest 
that LV mass is an important driver for elevated hs-cTnT concentrations in 
HCM.1 In addition to LV mass, HighT2 was strongly associated with an elevated 
hs-cTnT, indicative of recently sustained myocardial injury.2 Moreover, as a 
first time observation, patients with higher MWT and higher heart rates were 
more likely to demonstrate exercise-induced troponin release. This was espe-
cially the case for patients with HighT2.3 In addition, patients with HighT2 had 
a higher estimated risk of SCD.4 Lastly, hs-cTnT proved to be independently 
predictive of extensive LGE.5 In summary, these findings fuel the concept of 
disease progression in HCM as an active process of myocyte turnover in the 
presence of ischemia, which may eventually result in myocardial fibrosis and 
adverse clinical outcome. Next, the results of this manuscript will be discussed 
in more detail with regard to the proposed mechanisms underlying troponin 
release and HighT2 in HCM and how our results may affect future research and 
eventually clinical practice.
MECHANISMS OF TROPONIN RELEASE IN HCM
Currently, the mechanisms of troponin release in HCM are not completely 
understood. This can be explained by the fact that various mechanisms may 
contribute and while some of these mechanisms may be disease specific, 
others may overlap with mechanisms in other patient populations, or even 
healthy individuals.6-9 
It has been demonstrated in the general community that LV mass and base-
line hs-cTnT concentration are clearly associated.7 Normal myocyte turnover 
and leakage from intact but permeable membranes have been suggested as 
potential underlying mechanisms.10 In the context of the HCM phenotype, exag-
gerated myocyte turnover could be a contributing factor to troponin release 
in HCM.
In addition, troponin concentrations have consistently been associated 
with LGE in HCM, which suggests that troponin may be indicative of myocar-
dial injury.11-14 Our observation that hs-cTnT was strongly associated with LV 
mass, strongly support the concept of ischemic injury due to increased oxygen 
demand.1 Concurring phenomena such as microvascular dysfunction, increased 
pressure load and decreased capillary density may lead to insufficient myocar-
dial perfusion in HCM, which has also been demonstrated in patients with 
secondary hypertrophy due to hypertension and aortic valve stenosis.15-17 The 
combination of the abovementioned mechanisms may contribute to a situa-
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tion in which ischemia is likely to occur. This may especially be the case during 
exercise.18 In that regard, our observation that heart rate was associated with 
post-exercise troponin release corroborates with the concept of ischemia as 
a pivotal factor for myocardial injury in HCM.3 As an indicator of ischemic 
injury, hs-cTnT after exercise may be an interesting marker for prediction of 
an adverse clinical course in HCM. Secondly, heart rate may be an attractive 
target for medical intervention in HCM.
It remains, however, to be elucidated which disease-specific mechanisms 
contribute to injury in HCM. Notably, we still observed an elevated hs-cTnT in 
about 10% of our patients with an LV mass below the median.2 This suggests 
that other non-hypertrophy-related mechanisms may play a significant role 
in myocyte injury in HCM. Reduced sarcomere responsiveness to stretch has 
been proposed as a general mechanism of disease in HCM causing myocar-
dial dysfunction with reduced maximal force generation.19, 20 Exercise studies 
in HCM have addressed the issue of inefficient energy utilization and demon-
strated that exercise worsened the energy deficit in these patients, indepen-
dent of hypertrophy.21 One explanation may be that dysfunctional sarcomeres 
will not be able to adapt sufficiently to changing circumstances and demands 
under stressful conditions such as exercise, leading to cellular injury with ensuing 
release of troponin into the circulation. The latter mechanisms of disease seem 
less dependent on the hypertrophic phenotype and may already be activated 
before development of hypertrophy. Corroborating with the latter, biomarkers 
of fibrosis have been demonstrated in mutation carriers without the hyper-
trophic phenotype and without visual evidence of fibrosis on CMR imaging.22 
We hypothesized that preceding the development of hypertrophy and cardiac 
fibrosis troponin release may become evident in our cohort of subclinical HCM 
mutation carriers, especially with increased myocyte stress during exercise. 
Hs-cTnT concentrations, however, were generally very low and below the limit 
of blank, even after exercise.3 A similar observation has recently been described 
with hs-cTnI.23 Importantly, it should be noted that in the latter study and in the 
BE STRONG HCM study, troponin concentrations were reported 4 and 6 hours 
after exercise. Given the release kinetics of hs-cTnT after exercise observed in 
healthy athletes, blood sampling more directly after exercise might have been 
more timely and may allow to detect changes in hs-cTnT concentration more 
accurately, in clinical HCM patients but also even in subclinical HCM mutation 
carriers.24-26
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As we have demonstrated in this thesis, HighT2 and hs-cTnT are strongly asso-
ciated in HCM and some of the observations regarding HighT2 parallel that of 
hs-cTnT. Firstly, we demonstrated an association between HighT2 and LV mass 
and secondly, HighT2 was almost exclusively present in hypertrophic myocar-
dium, which suggest that HighT2 occurs in the setting of demand ischemia due 
to LV hypertrophy and concurring phenomena.2 In analogy to hs-cTnT, we also 
observed HighT2 in a proportion of our patients with an LV mass below the 
median (about 20%), suggesting that other non-hypertrophy related mecha-
nisms may play a role.
In addition to the above, the observation that HighT2 was almost exclu-
sively demonstrated in patients with LGE in our and in other HCM cohorts, is 
intriguing and deserves further attention.2, 27-33 In HCM, it is assumed that recur-
rent episodes of ischemic injury will lead to the formation of areas of patchy 
fibrosis. Probably, with the current limited CMR spatial resolution, each sepa-
rate bolt of injury in HCM will be of such limited size, that it will go undetected, 
for both LGE and T2-weighted imaging. However, in due course of time the 
accumulation of these small amounts of injury will become visible as larger 
areas of fibrosis, i.e. LGE. In contrast, the phenomenon of HighT2 is assumed 
to be transient. The injured areas will wax and wane, and therefore remain 
invisible. When the disease progresses, the volume within the areas of patchy 
fibrosis may get larger, and at some point may become detectable as HighT2 
as well. Interestingly, in areas of fibrosis in HCM there is histological proof of 
viable cardiomyocytes.34 Although the interpretation of HighT2 in areas of LGE 
remains speculative, these viable cells could form the substrate responsible 
for HighT2 in areas of LGE. The assumption that oedema is transient in HCM 
provides an explanation for the observation that HighT2 is less often demon-
strated than LGE. It may have subsided at the time of CMR, whereas fibrosis/
LGE, as a cumulative result of prior bolts of irreversible injury, remains present. 
In view of the above, areas of LGE in HCM probably reflect a composite of 
both chronic and acute tissue injury, wherein areas of acute tissue injury can 
be detected by HighT2, concurring with the release of troponin in the systemic 
circulation of HCM patients.
In view of the above, we demonstrated that HCM patients with HighT2 had 
the highest hs-cTnT concentrations (also among a selection of patients with 
LGE), indicative of recently sustained injury.2 In addition, the only independent 
association we observed for a post-exercise troponin rise was the presence 
of HighT2 at CMR imaging.3 Appreciating that CMR imaging was performed 
prior to the bicycle test, these findings support the concept that patients with 
signs of oedema (HighT2) represent a subgroup with active disease, vulner-
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able to new injury.31 This may ultimately lead to the formation of more myocar-
dial fibrosis and the occurrence of adverse events, as was also suggested by 
our observation that patients with HighT2 had a higher estimated risk of SCD.4 
In lack of CMR and clinical follow-up, these results should be considered as 
hypothesis-generating and require further study. 
IMPLICATIONS FOR FUTURE RESEARCH AND CLINICAL PRACTICE
In short, the results of this thesis suggest that both hs-cTnT and HighT2 may be 
indicative of a common pathway of myocardial injury in HCM patients, and that 
these markers may be associated with adverse clinical outcome. Consequently, 
these results provide impetus for the design of clinical follow-up studies to 
assess the predictive value of these markers for adverse events, also in rela-
tion to LGE. Secondly, the design of CMR follow-up studies would allow to 
confirm the hypothesis that hs-cTnT and HighT2 are indeed indicative of HCM 
patients with a more active disease state and these studies would allow to test 
whether these patients are more vulnerable to disease progression. Thirdly, 
studies using exercise-induced troponin release as an outcome measure may 
provide valuable insight in the mechanisms leading to injury in HCM and how 
injury may be averted. Next, each of these implications of this thesis will be 
concisely discussed.
Clinical follow-up studies - Previously, LGE has consistently been related to 
the risk of SCD and adverse prognosis.35, 36 However, the majority of HCM 
patients demonstrate LGE, thereby limiting the predictive ability of the mere 
presence of LGE. Therefore, there is an increasing interest in the potential risk 
factor of extensive LGE.37, 38 With additional markers of myocardial injury, such 
as hs-cTnT and HighT2, we may be able to further differentiate HCM patients 
into lower and higher risk patients. This may have important clinical implica-
tions with regard to decision making concerning ICD implantation.
With regard to hs-cTnT, there is limited data on event prediction, but an 
association between hs-cTnT and adverse outcome during long-term follow-up 
has been demonstrated in a Japanese HCM cohort (n=183).39 Currently, 5-year 
follow-up of the BE STRONG HCM study is ongoing, which may add additional 
information on event prediction with hs-cTnT and may provide the first clue on 
the predictive value of exercise-induced troponin release and HighT2, as well.
Concerning HighT2, we demonstrated that HCM patients with HighT2 had 
the highest projected rates of SCD; also among a selection of HCM patients 
with LGE.4 Consequently, the presence of HighT2 may identify HCM patients at 
the highest risk of SCD, which has also been suggested in a retrospective Japa-
nese HCM cohort.40 
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With regard to event prediction, the results of a large prospective cohort study 
(n=2,750) are eagerly awaited concerning the association of several markers 
of myocardial injury (i.e. hs-cTnI, LGE presence and extent, pre- and postcon-
trast T1 mapping times) with adverse clinical outcome.41 This study may finally 
establish the association between LGE (extent) and adverse clinical events 
in HCM. Moreover, it may elucidate whether cardiac troponin has additional 
predictive value. Unfortunately, T2-weighted CMR imaging sequences and/
or exercise-induced troponin release were not included in the study protocol. 
This may prohibit further differentiation among patients with LGE and further 
refinement of risk stratification models. 
Notably, due to the low event rate in HCM the primary endpoint of the afore-
mentioned study is a composite of both arrhythmic and heart failure events 
to achieve adequate power within a reasonable follow-up duration, with even 
a large group of >2,500 HCM patients.41 Appreciating our observation that 
patients with HighT2 had the highest projected SCD rates, markers of myocar-
dial injury (such as HighT2 and hs-cTnT) may be used to target a HCM popula-
tion which is at higher risk of adverse events. Inclusion of HCM patients with a 
higher a-priori risk may allow for smaller sample sizes, which would lower the 
costs and effort to perform a clinical follow-up study in HCM. In light of costs, 
with the development of newer methods to continuously assess a patients’ 
heart rhythm for longer period of time, the burden of non-sustained ventricular 
arrhythmias may be a valuable surrogate outcome measure.
Concerning clinical follow-up and event prediction, in Chapter 7 we 
provided the first clue that the use of hs-cTnT can alter the pre-test likelihood 
of extensive LGE on CMR imaging.5 The latter is a potential risk factor for SCD, 
but occurs in only a small minority of the HCM population.36, 37 A step-wise 
approach using a biomarker (i.e. hs-cTnT) as a gateway towards CMR imaging 
for SCD risk stratification of low-intermediate risk HCM patients may be attrac-
tive for daily clinical practice.42, 43 This approach warrants further investigation 
and the currently enrolling prospective cohort study of 2,750 HCM patients 
may provide important data.41
CMR follow-up studies - As previously stated, we hypothesized that Hs-cTnT 
and HighT2 may be used to identify a subgroup of HCM patients that is likely 
to have adverse disease progression in the form of the development of (more) 
fibrosis. To study this hypothesis a CMR follow-up study would be required 
with the development of (more) LGE as the most attractive outcome measure 
of adverse disease progression. A first clue that hs-cTnT is predictive of adverse 
disease progression was demonstrated in a small cohort of 8 Japanese HCM 
patients, in whom hs-cTnT at baseline was related to an increase in LGE.11 Our 
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observation that after exercise 1 in 3 clinical HCM patients had an elevated 
hs-cTnT concentration compared to 1 in 4 before exercise suggests that hs-cTnT 
after exercise might be a more sensitive marker for adverse disease progres-
sion than baseline hs-cTnT alone.3 Various other biomarkers that are currently 
under investigation or have demonstrated prognostic value in heart failure may 
also be tested in this setting.44 
With regard to HighT2, we have demonstrated a strong and independent 
association with elevated hs-cTnT concentrations at baseline and exercise-in-
duced troponin release, but currently there are no data on HighT2 with CMR 
follow-up.2, 3 Investigators may have been reluctant to use HighT2, because 
T2-weighted imaging sequences are notorious for poor signal/noise ratio 
and vulnerability to slow flow artefacts, leading to high variability between 
observers. Potentially, T2-mapping sequences might be interesting alternatives 
to identify HCM patients with recently sustained injury in a more objective and 
reproducible way. With regard to mapping sequences, T1-mapping sequences 
may provide an interesting alternative for LGE CMR imaging, because these 
sequences may be valuable for detection of diffuse myocardial changes.45, 46
Studies with exercise-induced troponin release - Lastly, the focus of this thesis 
is on the implications on potential strategies that may avert myocardial injury 
in HCM. Building on the hypothesis that exercise-induced troponin release is 
indeed an indicator of myocardial injury and adverse disease progression, this 
setting might be valuable to test the efficacy of medical interventions in a 
controlled and standardized matter. Given the association between heart rate 
and exercise-induced troponin release, heart rate seems an attractive target 
for medical intervention. We previously reported a pilot study on patients with 
HCM in which post-exercise release of troponin could be blunted with the use 
of a beta-blocker.47 This may be related to the lowering of heart rate, which 
reduces myocardial oxygen demand and thereby may prevent ischemic injury. 
This may be a beneficial effect in patients with hypertrophic phenotype, in 
whom beta-blockade is also the treatment of choice for symptom relief due 
to diastolic heart failure or LV outflow tract obstruction. On the other hand, 
basic studies with individual cardiomyocytes have suggested that pharmaco-
logic stimulation of the beta-adrenergic pathway may ameliorate sarcomeric 
dysfunction.20 Given the sympaticolytic effect of beta-blockers, it is currently 
unclear whether the effects of beta-blockade are purely beneficial or may also 
be detrimental in HCM patients or subclinical HCM mutation carriers. Espe-
cially for the latter group, without the hypertrophic phenotype, the potential 
detrimental effect on sarcomeric function may outweigh the potential benefits 
concerning ischemic injury. To further investigate the effects of beta-blockers 
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in HCM, a comparative study with ivabradine and a placebo might be valu-
able. Ivabradine lowers heart rate without interfering with the beta-adrenergic 
pathway. As such, the effects of purely lowering heart rate and the effects 
of blocking the beta-adrenergic pathway in comparison to a placebo may be 
unravelled in HCM patients. 
In addition to the above, our observation that heart rate and exercise-in-
duced troponin release were associated also gives rise to the suggestion that 
exercise may not be completely harmless in HCM. This is in line with concerns 
that exercise, and especially vigorous exercise, may provide the trigger for 
life-threatening arrhythmias in the HCM population.48 Data on vigorous exer-
cise are currently scarce and a potential positive effect on the hypertrophic 
phenotype has also been suggested.49 In addition, exercise has many beneficial 
effects on general and cardiovascular health. In light of these opposing argu-
ments for exercise in HCM and in light of the fact that clinicians are frequently 
confronted with HCM patients who request advice on exercise recommenda-
tions, a recent pilot study provided the first data that a moderate-intensity 
exercise program in a HCM population might be safe.50 Hypothetically, exer-
cise at moderate intensity and moderate maximum heart rate may not lead to 
myocyte injury in a significant proportion of HCM patients. The threshold to 
define moderate-intensity exercise is likely to be dependent on various factors 
that differ between HCM patients and subclinical HCM mutation carriers. Our 
observation that HighT2 was strongly associated with a post-exercise troponin 
rise suggests that a pre-existing active state of disease, with imaging signs of 
oedema, reflects a condition prone for additional myocardial injury in situa-
tions of high oxygen demand. This hypothesis warrants further study as this 
may have important implications for exercise recommendations in HCM. 
In this context, it is intriguing to hypothesize that we might be able to deter-
mine an exercise intensity threshold on an individual basis at which exercise-in-
duced troponin release does or does not occur. Although highly speculative at 
this point, a patient-tailored exercise recommendation based on CMR imaging 
and an exercise test with post-exercise troponin assessment might allow exer-
cise in HCM patients to that intensity at which a HCM patient can enjoy the 
positive effects on general health outcomes, and at which exercise-induced 
troponin release is unlikely to occur and as such, myocardial injury and adverse 
events can be avoided. 
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CONCLUSION
In conclusion, the results of this thesis put forward that with HighT2 and hs-cTnT 
we may be able to identify a group of HCM patients that has recently sustained 
myocardial injury and is vulnerable to adverse disease progression and adverse 
clinical outcome. As these results may be considered as hypothesis-generating, 
further study is required to substantiate this hypothesis with imaging and clin-
ical data. If hs-cTnT and HighT2 prove to be associated with adverse outcome, 
there may be a role for these markers in the development of future efficacious 
strategies to prevent disease progression in HCM.
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Hoofdstuk 1 is de algemene inleiding en bespreekt de definitie, de ziekteme-
chanismen en de klinische presentatie van hypertrofische cardiomyopathie 
(HCM). Daarnaast wordt het gebruik van troponine en cardiovasculaire MRI 
bij patiënten met HCM beschreven. Ook wordt de opzet van de BE-STRONG-
HCM-studie en deze thesis uiteengezet.
Hoofdstuk 2 richt zich op de basale vraag hoeveel de MRI-analyse van de 
linkerventrikel (LV) ejectiefractie (EF) en massa wordt beïnvloed door de in- 
of exclusie van de papillairspieren bij patiënten met een HCM; en vergeleken 
met een groep controleproefpersonen zonder hypertrofie. Cardiovasculaire 
MRI is de huidige goudstandaard voor de quantificatie van de LV EF en massa, 
die gebruikt kunnen worden om HCM patiënten te identificeren met een hoog 
risico op ongewenste medische gebeurtenissen, zoals plotse hartdood of hart-
falen. Het is opvallend dat er geen uniformiteit bestaat met betrekking tot hoe 
om te gaan met het meten van de papillairspieren. De richtlijnen stellen dat 
LV volumina en massa moeten worden gemeten volgens het protocol, zoals 
gebruikt bij het opstellen van de normaalwaarden. Bij de onderzoeken naar 
normaalwaarden was het in het algemeen gebruikelijk om de papillairspieren te 
includeren in de LV massa. In dat kader is het verrassend dat het in de meeste 
algemene ziekenhuizen de standaard is geworden om de papillairspieren te 
excluderen van de LV massa. Bij patiënten met HCM is aangetoond dat de 
massa van de papillairspieren groter is dan bij normale gezonde vrijwilligers. 
Daarom wilden wij, juist bij HCM patiënten, de impact van de papillairspieren 
op de bepaling van LV parameters onderzoeken. Wij lieten zien dat bij pati-
enten met HCM, de inclusie van de papillairspieren resulteerde in significante 
relatieve toenames van 9% in LV massa en 4% in LV EF. Ondanks de betrokken-
heid van de papillairspieren in het ziekteproces van HCM, waren de relatieve 
verschillen in dezelfde orde van grootte bij controleproefpersonen zonder 
hypertrofisch myocard. Gezien de potentiële impact op klinische besluitvor-
ming gedaan op basis van LV massa, volumina en functie, onderstrepen onze 
resultaten het algemene belang van uniforme protocollen voor MRI-analyse.
In Hoofdstuk 3 beschrijven wij het voorkomen van een detecteerbaar, en van 
een verhoogd troponine (≥99e percentiel) in een goed omschreven populatie 
van patiënten met HCM, gebruikmakende van een hoog sensitieve assay. In 
asymptomatische gezonde individuen is een verhoogd troponine geassocieerd 
met LV massa, gemeten met MRI, en het a priori risico op hart- en vaatziekten 
(HVZ). In de beperkt beschikbare publicaties bij patiënten met HCM wordt een 
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associatie gedemonstreerd tussen troponine en toegenomen LV wanddikte, 
LV disfunctie en late gadolinium aankleuring (LGA). Echter, de bijdrage van 
LV massa en het a priori risico op HVZ werd niet eerder beschreven bij HCM. 
Daarnaast werden detecteerbare troponine-concentraties onder de referen-
tiewaarde voor normaal in eerdere onderzoeken onbeschouwd gelaten. In 
bovenstaande context onderzochten wij de associaties tussen troponine en 
het Framingham Heart 10-jaarsrisico (FH10jr) als een maat voor het voorspelde 
risico op HVZ. Daarnaast beschrijven we de associatie tussen troponine en LV 
massa. In een cohort van 62 HCM patiënten was troponine, gemeten met een 
hoog sensitieve assay (hs-cTnT), in 74% (46/62) van de gevallen detecteer-
baar. Hs-cTnT was verhoogd in 26% (16/62) van de patiënten (≥99e percen-
tiel referentiewaarde van 14 ng/L). Uit de multivariabele binaire logistische 
regressieanalyse bleek dat zowel LV massa als FH10jr geassocieerd waren met 
een detecteerbare hs-cTnT concentratie. LV massa was echter als enige geas-
socieerd met een verhoogde hs-cTnT concentratie. Dit geeft aan dat hyper-
trofie meer dan het risico op HVZ een belangrijke factor is voor een verhoogde 
hs-cTnT concentratie bij deze patiënten.
In het licht van de toenemende interesse voor weefselkarakterisatie bij HCM, 
wilden wij in Hoofdstuk 4 de associatie onderzoeken tussen gebieden met 
verhoogde signaalintensiteit op T2-gewogen MRI beelden (HoogT2) en hs-cTnT 
bij patiënten met HCM. Als biomarker voor myocardiale schade is hs-cTnT gere-
lateerd aan de aanwezigheid van LGA. LGA wordt beschouwd als een indicator 
van fibrose op MRI. Er zijn slechts enkele publicaties over HoogT2 bij patiënten 
met HCM, en alleen in geselecteerde kleine populaties. Interessant was de 
bevinding dat HoogT2 zo goed als alleen voorkwam bij patiënten met LGA, en 
enkel binnen de gebieden met LGA. Er is eerder gesuggereerd dat gebieden 
met HoogT2 een indicatie kunnen zijn van myocardiaal oedeem als een resul-
taat van ischemische schade en derhalve representatief zouden kunnen zijn 
voor een actievere ziektestatus bij patiënten met HCM. Hoewel ischemische 
schade de “final common pathway” is bij zowel HCM als bij een acuut hart-
infarct, is het mechanisme van ischemie duidelijk anders. Daarom is er meer 
onderzoek nodig betreffende de interpretatie van HoogT2 bij patiënten met 
HCM. In een relatief groot cohort van 101 HCM patiënten, onderzochten wij 
de associatie tussen HoogT2 en een verhoogde hs-cTnT concentratie. In dit 
cohort van HCM patiënten, geïncludeerd op de polikliniek, laten we zien dat 
HoogT2 aanwezig was in één op de vier HCM patiënten. De aanwezigheid van 
HoogT2 verdrievoudigde de kans op een verhoogde hs-cTnT concentratie, 
en de concentratie van hs-cTnT was significant gerelateerd aan de mate van 
HoogT2. Opvallend, in geval van een ondetecteerbaar lage hs-cTnT concen-
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tratie, zagen we een zeer hoge negatieve voorspellende waarde voor HoogT2 
(>95%). Deze observaties sluiten aan bij de hypothese dat HoogT2 bij patiënten 
met HCM een indicatie kan zijn van recent doorgemaakte myocardiale schade.
In Hoofdstuk 5 onderzoeken we de impact van inspanning op hs-cTnT concen-
traties bij klinische HCM patiënten en bij subklinische HCM mutatiedragers. Het 
wordt algemeen aangenomen dat het hypertrofische fenotype bij HCM gere-
lateerd is aan pathofysiologische afwijkingen in de vasculatuur, myocardiale 
structuur en functie, die mogelijk bijdragen aan het ontstaan van ischemie. 
Eerdere MRI studies hebben gebieden van ischemie gecorreleerd aan LGA en 
HoogT2. Daarnaast is getoond dat HoogT2 sterk correleert met troponine in 
HCM. In dat kader wordt HoogT2 beschouwd als een indicator van een actieve 
staat van ziekte. In deze context kan worden veronderstelt dat episodes van 
hoge zuurstofbehoefte kunnen leiden tot nog meer myocardiale schade. Trop-
onine-vrijkomst na inspanning is, echter, alleen beschreven bij patiënten met 
ischemische hartziekten en gezonde vrijwilligers en niet bij patiënten met HCM. 
Wij laten zien dat na een fietsergometrie-onderzoek een stijging in hs-cTnT 
concentratie kan worden waargenomen in bijna 20% van ons cohort van 127 
HCM patiënten. Deze proportie was duidelijk anders dan de proportie van 
4% waargenomen in de controlegroep van 53 subklinische HCM mutatiedra-
gers. Belangrijk daarbij is dat deze observatie werd gedaan, ondanks dat de 
klinische HCM patiënten een significant lagere inspanning (uitgedrukt in het 
wattage dat maximaal werd gehaald) leverden dan de subklinische HCM 
mutatiedragers. Daarnaast zagen we dat HCM patiënten met een stijging van 
hs-cTnT een hogere pols hadden, en neigden naar een significant hoger hart-
slagbloeddrukproduct. Dit suggereert een rol voor inspanningsintensiteit. Een 
bijkomende bevinding was dat een stijging in hs-cTnT duidelijk gerelateerd was 
aan de mate van LV hypertrofie (wanddikte) en myocardiale schade (LGA en 
HoogT2). Het meest evident was de bevinding dat HoogT2 de enige onafhanke-
lijke voorspeller was van een hs-cTnT stijging na inspanning. Deze bevindingen 
suggereren dat een reeds bestaande actieve staat van ziekte, met tekenen 
van oedeem op MRI, indicatief kan zijn voor een situatie waarin meer myocar-
diale schade kan optreden in geval van hoge zuurstofbehoefte. Dit leidt tot de 
hypothese dat herhaaldelijke episodes van hoge zuurstofbehoefte resulteren 
in momenten van troponine-vrijkomst, en dat het met MRI mogelijk is patiënten 
te identificeren die hier meer gevoelig voor zijn en wellicht op de lange termijn 
fibrose ontwikkelen.
In Hoofdstuk 6 en 7 ligt de focus op de potentiële implicaties van HoogT2 en 
hs-cTnT voor de dagelijkse klinische praktijk met betrekking op risicostratifi-
161
CHAPTER 9  NEDERLANDSE SAMENVATTING
catie voor plotse hartdood (PHD). Enerzijds beschrijven we in Hoofdstuk 6 
de associatie tussen HoogT2 en het geschatte risico op PHD. Anderzijds, in 
Hoofdstuk 7, bestuderen we een set van klinische variabelen en een panel van 
biomarkers als voorspellers van uitgebreide LGA.
Zoals eerder beschreven in deze thesis, is er een associatie tussen vrij-
komst van troponine en HoogT2. HoogT2 zou mogelijk patiënten met een 
hogere ziekteactiviteit kunnen identificeren, die kwetsbaar zouden kunnen zijn 
voor nadelige progressie van ziekte. De bijkomende observaties door andere 
onderzoekers dat HoogT2 geassocieerd was met “non-sustained” ventriculaire 
tachycardiën, gaven aanleiding tot de vraag of HoogT2 mogelijk een waar-
devolle voorspeller zou kunnen zijn van nadelige medische gebeurtenissen, 
en met name van PHD. Dit wordt verder onderzocht in Hoofdstuk 6. Belang-
rijk is dat studies met HoogT2 en systematische klinische follow-up ontbreken. 
Daarom wilden wij de eerste “pilot” data vergaren over HoogT2 en PHD risi-
costratificatie. Om inzicht te krijgen in de potentiële klinische impact van 
HoogT2, onderzochten wij of patiënten met HoogT2 vaker een intermediair of 
hoog risico hadden op PHD afgaande op de ESC en ACC/AHA risicomodellen. 
We toonden aan dat HCM patiënten met HoogT2 een hogere kans hadden op 
een intermediair of hoog risico op PHD, met daarbij een geschat PHD risico dat 
1.5 keer zo hoog was als bij patiënten zonder HoogT2. Een belangrijke bijko-
mende bevinding was dat HoogT2 niet alleen was geassocieerd met variabelen 
uit de bestaande risicomodellen, maar ook met andere markers van nadelige 
ziekteprogressie (zoals uitgebreide LGA, LV massa en ejectiefractie). Dit zijn 
aanwijzingen voor het potentieel dat HoogT2 heeft voor verdere verfijning van 
de bestaande risicostratificatiemodellen. Dit onderstreept de noodzaak voor 
follow-up studies bij HCM aangaande HoogT2 en het risico op PHD.
In Hoofdstuk 7 onderzochten we mogelijke voorspellers van uitgebreide 
LGA ten behoeve van een doelmatiger gebruik van MRI in het kader van PHD 
risicostratificatie bij patiënten met HCM. Gezien de lage incidentie van <1% per 
jaar, blijft het voorspellen van PHD een grote uitdaging. Helaas komt PHD nog 
steeds voor in de veel grotere groep HCM patiënten met een laag of interme-
diair risico, voor wie het nog onduidelijk is of een implanteerbare cardiover-
ter-defibillator (ICD) aangewezen is. Recent hebben experts gesuggereerd om 
uitgebreide LGA mee te nemen in de besluitvorming voor deze categorie HCM 
patiënten. Uitgebreide LGA wordt slechts in ongeveer 10% van deze patiënten 
gezien. In deze context zou een strategie, die gebaseerd is op gemakkelijk te 
verkrijgen karakteristieken en die de voorafkans op uitgebreide LGA veran-
dert, kosteneffectiever zijn dan een strategie van routinematige MRI’s. Eerder 
zijn klinische variabelen en biomarkers gecorreleerd aan LGA. In deze context 
beschrijven wij onze studie in 98 HCM patiënten met laag tot intermediair 
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risico over de identificatie van voorspellers van uitgebreide LGA onder routi-
nematig verzamelde klinische variabelen en een breed panel van biomarkers. 
Wij vonden dat een set van drie klinische variabelen een hoge discriminerende 
waarde had, die significant kon worden verbeterd met toevoeging van hs-cTnT. 
Een strategie op basis van hs-cTnT alleen liet ook opvallende resultaten zien. 
Zelfs zonder rekening te houden met de klinische variabelen, kon op basis van 
alleen een hs-cTnT concentratie beneden de optimale afkapwaarde bij de helft 
van onze studiepopulatie uitgebreide LGA worden uitgesloten. Deze bevin-
dingen zijn de eerste ondersteuning voor de hypothese dat hs-cTnT een poort-
functie kan hebben bij de besluitvorming voor het maken van een MRI voor 
PHD risicostratificatie.
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geweest voor mijn promotie! Ik geniet elke dag van jou, Kasper en Hanna en 
kijk ernaar uit om dat mijn hele leven te blijven doen.
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